DOWN
SYNDROME A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Down Syndrome: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83654-X 1. Down Syndrome-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on Down syndrome. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON DOWN SYNDROME ................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Down Syndrome ......................................................................... 14 E-Journals: PubMed Central ....................................................................................................... 81 The National Library of Medicine: PubMed ................................................................................ 82 CHAPTER 2. NUTRITION AND DOWN SYNDROME........................................................................ 213 Overview.................................................................................................................................... 213 Finding Nutrition Studies on Down Syndrome ........................................................................ 213 Federal Resources on Nutrition ................................................................................................. 217 Additional Web Resources ......................................................................................................... 217 CHAPTER 3. ALTERNATIVE MEDICINE AND DOWN SYNDROME ................................................. 219 Overview.................................................................................................................................... 219 National Center for Complementary and Alternative Medicine................................................ 219 Additional Web Resources ......................................................................................................... 225 General References ..................................................................................................................... 226 CHAPTER 4. DISSERTATIONS ON DOWN SYNDROME ................................................................... 227 Overview.................................................................................................................................... 227 Dissertations on Down Syndrome ............................................................................................. 227 Keeping Current ........................................................................................................................ 234 CHAPTER 5. CLINICAL TRIALS AND DOWN SYNDROME .............................................................. 235 Overview.................................................................................................................................... 235 Recent Trials on Down Syndrome ............................................................................................. 235 Keeping Current on Clinical Trials ........................................................................................... 237 CHAPTER 6. PATENTS ON DOWN SYNDROME .............................................................................. 239 Overview.................................................................................................................................... 239 Patents on Down Syndrome ...................................................................................................... 239 Patent Applications on Down Syndrome .................................................................................. 248 Keeping Current ........................................................................................................................ 250 CHAPTER 7. BOOKS ON DOWN SYNDROME .................................................................................. 251 Overview.................................................................................................................................... 251 Book Summaries: Federal Agencies............................................................................................ 251 Book Summaries: Online Booksellers......................................................................................... 253 The National Library of Medicine Book Index ........................................................................... 260 Chapters on Down Syndrome .................................................................................................... 261 Directories.................................................................................................................................. 267 CHAPTER 8. MULTIMEDIA ON DOWN SYNDROME ....................................................................... 269 Overview.................................................................................................................................... 269 Video Recordings ....................................................................................................................... 269 Bibliography: Multimedia on Down Syndrome......................................................................... 270 CHAPTER 9. PERIODICALS AND NEWS ON DOWN SYNDROME .................................................... 271 Overview.................................................................................................................................... 271 News Services and Press Releases.............................................................................................. 271 Newsletters on Down Syndrome ............................................................................................... 277 Newsletter Articles .................................................................................................................... 278 Academic Periodicals covering Down Syndrome....................................................................... 279 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 283 Overview.................................................................................................................................... 283 NIH Guidelines.......................................................................................................................... 283 NIH Databases........................................................................................................................... 285
viii Contents
Other Commercial Databases..................................................................................................... 288 The Genome Project and Down Syndrome ................................................................................ 288 APPENDIX B. PATIENT RESOURCES ............................................................................................... 293 Overview.................................................................................................................................... 293 Patient Guideline Sources.......................................................................................................... 293 Associations and Down Syndrome ............................................................................................ 302 Finding Associations.................................................................................................................. 312 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 315 Overview.................................................................................................................................... 315 Preparation................................................................................................................................. 315 Finding a Local Medical Library................................................................................................ 315 Medical Libraries in the U.S. and Canada ................................................................................. 315 ONLINE GLOSSARIES................................................................................................................ 321 Online Dictionary Directories ................................................................................................... 323 DOWN SYNDROME DICTIONARY ........................................................................................ 325 INDEX .............................................................................................................................................. 407
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with Down syndrome is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about Down syndrome, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to Down syndrome, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on Down syndrome. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to Down syndrome, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on Down syndrome. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON DOWN SYNDROME Overview In this chapter, we will show you how to locate peer-reviewed references and studies on Down syndrome.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and Down syndrome, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “Down syndrome” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Apo E Genotypes and Risk of Dementia in Down Syndrome Source: American Journal of Medical Genetics (Neuropsychiatric Genetics). 88: 344-347. 1999. Summary: This journal article examines the relationship between apolipoprotein E (apoE) genotype and risk of dementia in people with Down syndrome (DS). ApoE genotyping was completed for 45 individuals with DS (20 with and 25 without dementia), and the results were combined with data from other studies in a metaanalysis. The meta-analysis revealed an estimated odds ratio for dementia of 2.74 for apoE4 carriers compared with apoE3/3, similar to that observed in late-onset Alzheimer's disease (AD). Also similar to the pattern seen for late-onset AD, the apoE2 allele was associated with decreased dementia risk in DS (odds ratio for apoE2/2 plus
4
Down Syndrome
apoE2/3 = 0.37). The findings suggest that apoE genotypes are associated with similar risk effects in DS dementia and late-onset AD. 1 table, 22 references. (AA-M). •
Aging and Dementia Among Adults With Mental Retardation and Down Syndrome Source: Topics in Geriatric Rehabilitation. 13(3): 49-64. March 1998. Summary: This journal article reviews the literature on aging and dementia among people with mental retardation (MR) and Down's syndrome (DS). It reviews the epidemiology of Alzheimer's disease (AD) in the general population, AD neuropathology, and estimates of the risk of AD among adults with MR and DS. It explores factors complicating the diagnosis of dementia in people with MR, including the lack of standard assessment protocols for people with MR, limited communication skills in many people with MR, presence of other medical conditions that may mimic dementia, and difficulties in distinguishing AD from pseudodementia and in recognizing subtle signs of early AD. This article focuses on the association between AD and DS, methodological issues in research with the DS population, possible explanations for the discrepancy between the neuropathologic and clinical profiles of AD in the older DS population, and challenges in differentiating between dementia and developmental aging in DS. The article concludes with a discussion of the implications for future research and clinical practice. 109 references.
•
Earlier Onset of Alzheimer's Disease in Men With Down Syndrome Source: Neurology. 50: 991-995. April 1998. Summary: This journal article describes a study of sex differences in the age of onset and risk of Alzheimer's disease (AD) in adults with Down syndrome (DS), and the possible influence of apolipoprotein E (apoE) gene status on the association between sex and AD risk. The participants were 111 people with cytogenetically confirmed DS (61 men and 50 women, aged 34 to 71 years), identified through the New York State Developmental Disabilities system. The presence of AD was determined through interviews with caregivers and a review of medical records. ApoE genotyping was performed without knowledge of the participant's medical history or clinical diagnosis. The results revealed that both male gender and the presence of an apoE4 allele were associated with an earlier onset of AD. Men with DS were three times more likely than women to develop AD. Participants with the apoE4/4 or apoE3/4 gene status were four times more likely than those with the apoE3/3 gene status to develop AD. No participant with the apoE2 allele developed AD. There was no evidence of an interaction between sex and apoE gene status in risk of AD. The findings suggest that the higher risk of AD in men may be related to differences in hormone function between men and women with DS that are distinct from those in the general population. 2 figures, 3 tables, 35 references. (AA-M).
•
Down Syndrome and Aging: Implications for Rehabilitation Source: Topics in Geriatric Rehabilitation. 13(4): 39-51. June 1998. Summary: This journal article discusses the medical and rehabilitation needs of aging people with Down syndrome (DS). The article focuses on musculoskeletal and other medical problems, but includes information about people with DS who develop Alzheimer's disease (AD). Some research suggests that most or all people with DS will develop AD as they age, but other investigators have challenged this assumption. It is difficult to assess individuals with DS for signs of dementia because diagnostic tools appropriate for determining the presence of AD in DS have not yet been developed. Some studies have found a discrepancy between neuropathological and clinical signs of
Studies
5
AD in people with DS. Moreover, many studies of people with DS have not collected data on a longitudinal basis, which is important to document functional decline in DS. Investigators suggest that the decline in function used to define dementia in DS may be caused by other conditions which are common in DS, including hypothyroidism, sleep apnea, visual and auditory deficits, atlantoaxial instability, and other orthopedic problems. Furthermore, diagnostic tools and criteria appropriate for determining the presence of AD in DS have not been developed. The authors conclude that rehabilitation professionals can help improve our understanding of the aging process in DS by documenting longitudinal changes in function in this population. 60 references. •
Down Syndrome and Incidence of Alzheimer's Disease. [Letter] Source: American Family Physician. 57(7): 1498. April 1, 1998. Summary: This letter to the editor disputes claims in an earlier article that nearly all people with Down syndrome will eventually develop Alzheimer's disease (AD). The author emphasizes that although AD pathology may develop in virtually all brains of people with Down syndrome over age 35 years, the clinical appearance of AD is considerably less frequent. He argues that many cases of suspected AD may actually be due to such conditions as depression, adjustment disorder, or hypothyroidism. He urges clinicians to take a careful history and explore both common illnesses and those more specific to Down syndrome, to rule out potentially reversible causes of dementia. 4 references.
•
Alzheimer-Like Visual Deficits in Down Syndrome Source: Alzheimer Disease and Associated Disorders. 11(2): 88-98. 1997. Summary: This journal article describes a study of visual deficits in Down syndrome (DS). The purpose was to determine whether the pattern of visual impairments seen in Alzheimer's disease (AD) also occurs in Down's syndrome (DS). Participants were 22 adults with DS and 18 adults with mental retardation (MR) of non-DS etiology who were assessed at the Neurology Clinic and Eye Clinic of the Eunice Kennedy Shriver Center for Mental Retardation in Boston, Massachusetts. The DS group consisted of 5 women and 17 men with a mean age of 45.5 years. The MR group was matched to the DS group on the basis of gender ratio and age range. All participants were tested for visual acuity, color discrimination, stereoacuity, and contrast sensitivity function while wearing their own best optical correction. The DS group made more tritanomalous (blue-deficient) errors on the test of color vision than predicted by chance, but not more of other types of hue discrimination errors. The DS group also had higher stereo acuity thresholds than the MR group, and reduced contrast sensitivity across the frequency range. Taken together, the visual deficits observed in the DS group are similar to those seen in AD. Because visual performance was not associated with age, the authors suggest that AD-like visual deficits in DS may present prior to and independent of ageassociated dementia. 2 tables, 59 references.
•
Prospective Study of the Prevalence of Alzheimer-Type Dementia in Institutionalized Individuals With Down Syndrome Source: American Journal on Mental Retardation. 101(4): 400-412. 1997. Summary: This journal article describes a prospective study of the prevalence of Alzheimer's disease (AD) in institutionalized people with Down syndrome. Participants were 307 residents of 3 Dutch institutions for people with mental retardation; their mean age was 38.4 years (range 9.8 to 72 years). The residents were followed over a period of 5
6
Down Syndrome
to 10 years. They were assessed each year with the Early Signs of Dementia Checklist, twice a year with the Social Skills Inventory for the Mentally Retarded, and at least once with electroencephalography (EEG). Postmortem neuropathologic examinations were performed when possible. During followup, 56 of the 307 residents (18 percent) developed symptoms of dementia. The mean age of onset of dementia was 56 years. The prevalence increased from 11 percent at ages 40-49 years to 66 percent at ages 50-59, 77 percent at ages 60-69, and 100 percent at age 70 years and older. Of the 13 residents with a clinical diagnosis of dementia who underwent postmortem neuropathological examination, all showed changes consistent with a severe form of AD. The authors conclude that use of a dementia checklist, a cognitive skills inventory, and EEG can reliably detect AD at an early stage. 3 tables, 46 references. •
Young Adults With Down Syndrome as Caregivers for the Elderly With Dementia: An Intergenerational Project Source: Journal of Gerontological Social Work. 26(3-4): 159-170. 1996. Summary: This journal article describes an intergenerational program in which young adults with Down's syndrome were trained to work with older people with Alzheimer's disease and other dementias attending Melabev, an adult day-care program in Jerusalem, Israel. The project evolved from a belief that young adults with Down's syndrome have several characteristics required of dementia caregivers: patience, friendliness, warmth, the ability to tolerate repetition and routine, and a tendency to show affection freely. Students with Down's syndrome received training in independent living, social, and general vocational skills; and then proceeded to a field placement at Melabev and other community sites serving older people with dementia. At Melabev, the students were trained to assist dementia patients in sitting, getting in and out of cars, and putting on and taking off outer clothing; and to help staff by preparing for daily activities, buying and preparing food, washing dishes, and cleaning up at the end of the day. The program was considered beneficial for the students, Melabev staff, and dementia patients, although some problems related to the nature of Down's syndrome were encountered. The article discusses these benefits and problems, and offers suggestions for replication and further study. 22 references.
•
Parallels Between Down Syndrome Dementia and Alzheimer's Disease Source: Progress in Clinical and Biological Research. 379:77-102. 1992. Summary: This article identifies common issues, particularly in relation to cognitive changes and risk factors for disease, whose investigation can be used both in the study of Alzheimer's disease (AD) and dementia in Down Syndrome (DS). Discussions include the following: the age-related changes of cognition in normal aging and DS, the relationship between age-related change and dementia, a cognitive profile of dementia in AD and DS, and the risk factors for development of dementia. The article reveals that the risk factors for dementia development in DS are similar to those of AD; that DS patients with dementia appear to show a significant decline in memory ability just like that found in AD patients, that pathological evidence suggests that aging and AD are on a continuum with one another as well as with DS, and that genetic explanations exist in dementia development for both DS and AD. Commonalities between these two diseases suggest that the dementia in DS may be a good model for AD. 7 figures, 54 references.
Studies
•
7
Alzheimer's Disease and Down Syndrome: A Review and Implications for Adult Services Source: Education and Training of the Mentally Retarded. 21(2): 144-150. June 1986. Summary: This article discusses how neurological changes associated with Alzheimer's disease consistently have been documented in individuals with Down's Syndrome who are 35 years of age and older. A genetic relationship has been suggested between Down's Syndrome and Alzheimer's disease. In this journal article, the diagnosis of Alzheimer's disease and its progressive behavioral impact on persons with Down's syndrome is discussed.Reports of behavioral changes due to Alzheimer's disease in people with Down's syndrome are inconsistent. Assessment is difficult due to the low levels of mental functioning among people with Down's syndrome. Alzheimer's disease in persons with Down's syndrome may impact on community placement facilities and group homes. Agencies providing such services should anticipate that symptoms of Alzheimer's may increase as their clients with Down's syndrome age. 32 references. (AA-M).
•
Expressive Vocabulary in Young Children With Down Syndrome: From Research to Treatment Source: Infant-Toddler Intervention: The Transdisciplinary Journal. 9(1): 87-100. March 1999. Contact: Available from Singular Publishing Group, Inc. Journals Department, 401 West 'A' Street, Suite 325, San Diego, CA 92101-7904. (800) 521-8545. Fax (619) 563-9008. Email:
[email protected]. Website: www.singpub.com. Summary: This article reports on a study of expressive vocabulary development in a population of 130 children with Down syndrome (age range 1 to 5 years). The authors discuss findings in the areas of vocabulary growth, gender differences, signed and spoken vocabulary, referential and grammatical vocabulary, multiword combinations, and morphosyntactic structures. Although there was continuous growth in expressive referential vocabulary from birth through 5 years, age 5 was found to be an important developmental marker for multiword combinations and grammatical vocabulary. By the age of 3 years, children with Down syndrome understand grammatical concepts such as possession and time concepts such as past events, but are not able to use the grammatical markers that represent these concepts until at least age 5. All 5 year olds in the study had begun to use multiword utterances, 77 percent were using plurals, 78 percent were using the possessive marker. Verb tense markers such as ing and ed were beginning to emerge, but were used by fewer than half of the children. The authors stress that early treatment using Total Communication is needed to facilitate expressive vocabulary development during the first 3 years. The authors discuss treatment applications for early intervention, and then intervention for the birth to age 5 period. 8 tables. 25 references.
•
Gestures and Words in Early Development of Children with Down Syndrome Source: JSLHR. Journal of Speech, Language, and Hearing Research. 41(5): 1125-1135. October 1998. Contact: Available from American Speech-Language-Hearing Association (ASHA). Product Sales, 10801 Rockville Pike, Rockville, MD 20852. (888) 498-6699. TTY (301) 8970157. Website: www.asha.org.
8
Down Syndrome
Summary: This article reports on a study that investigated the development of language and communication in children with Down syndrome (DS). More specifically, the aim was to examine the relations among verbal comprehension, verbal production, and gesture production in the very early stages of development. Forty children (age range 10 to 49 months) with DS and 40 children with normal development (age range 8 to 17 months) participated in this study. The communicative and linguistic development of children with DS was measured by administering the Italian version of the MacArthur Communicative Development Inventory (the children with DS were from two Italian health centers). The children with DS were severely delayed in reaching the developmental stages when compared with normally developing children. In such children, a dissociation emerged between verbal comprehension and production, in favor of comprehension, whereas a synchronous development was found between vocal lexical comprehension and gestural production. The individual differences previously reported in these children are also evident in all domains examined. There were no significant differences between children with DS and typically developing controls matched for lexical comprehension on verbal production. However, the two groups differed significantly in gestural development, suggesting a gesture advantage in children with DS compared with controls matched for word comprehension. The authors discuss some possible reasons for this dissociative profile. (AA). 3 figures. 4 tables. 54 References. •
Down Syndrome: A Multidisciplinary Perspective Source: Journal of the American Academy of Audiology. 6(1): 39-46. January 1995. Summary: Trisomy 21 (Down syndrome), a genetic disorder resulting from a chromosomal abnormality, is one of the most common forms of mental disability in the U.S. This article stresses the importance of a multidisciplinary team in the provision of services to individuals with Down syndrome so that prevention of further disabilities, improved outcomes of medical interventions, and appropriate habilitative and educational planning may follow. The authors focus on the role of the audiologist in this multidisciplinary approach. They stress that audiologic and communication interventions should be established at the earliest possible time to maximize an individual's development potential. Specific topics covered include genetic considerations, outer and middle ear anomalies, inner ear and retrocochlear anomalies, hearing loss, audiologic considerations, and language and speech planning. 2 tables. 31 references. (AA-M).
•
On the Nature of Language Impairment in Down Syndrome Source: Topics in Language Disorders. 13(3): 20-35. May 1993. Summary: This article reports on a study of the responses of a group of adults with Down syndrome to a language elicitation test. The responses are compared with the responses from a group of adults with retardation of unknown origin. In light of evidence for different patterns of language acquisition in the two groups, they discuss the possible nature and source of the biological constraints on language learning in Down syndrome and consider the implications of biologically imposed limits on language acquisition for clinical intervention. They focus on those responses that provide evidence of mastery of the auxiliary verb system. The article is from a special issue on maximizing communication competence in adults with mental retardation. 3 tables. 41 references. (AA-M).
Studies
•
9
Down Syndrome: An Otolaryngologic Perspective Source: Journal of Otolaryngology. 21(6): 394-397. December 1992. Summary: This article examines the association between Down syndrome and various pathological entities related to the head and neck. The authors stress that the otolaryngological manifestations of Down syndrome often masquerade as common and seemingly trivial conditions. Behind this facade lies a broad spectrum of disease that can impair functioning and jeopardize survival. Topics include ear pathology, including the incidence of otitis media, middle ear effusion, hearing loss, and anatomic abnormalities of the auditory canal and eustachian tube; and the diagnosis, pathology, treatment, and complications of sleep apnea. The authors note that altered anatomy coupled with diminished intelligence and an increased propensity for infection in this population complicate diagnosis. They reiterate the need for early diagnosis and treatment so that the potential of this patient group is fulfilled. 1 table. 18 references. (AA-M).
•
Prevalence of IgA-Antigliadin Antibodies and IgA-Antiendomysium Antibodies Related to Celiac Disease in Children with Down Syndrome Source: Pediatrics. 101(2): 272-275. February 1998. Contact: Available from American Academy of Pediatrics. P.O. Box 927, Elk Grove Village, IL 60009-0927. Summary: This article reports on a study undertaken to investigate the prevalence of celiac disease in children and adolescents with Down syndrome. Forty-three children and adolescents with Down syndrome were screened for IgA-antigliadin antibodies (AGA) and IgA-antiendomysium antibodies (EMA). Patients found to be positive for either type of antibodies were investigated further with intestinal biopsy. None of the 43 patients had known celiac disease at entry into the study; 37 percent (16 patients) were found to have AGA levels above normal, and 16 percent (7 patients) were found EMA positive. Of the 15 patients who underwent biopsy, 8 manifested villous atrophy (the hallmark of celiac disease). Villous atrophy was present in all 7 of the EMA positive patients, whereas the villi were normal in 7 of the 13 AGA positive patients who underwent biopsy. The authors conclude that EMA is a good immunologic marker for use in screening for celiac disease, and screening is justified in patients with Down syndrome. 2 figures. 27 references. (AA-M).
•
Stimulated Parotid Salivary Flow Rate in Patients with Down Syndrome Source: SCD. Special Care in Dentistry. 22(1): 41-44. January-February 2002. Contact: Available from Special Care Dentistry. 211 East Chicago Avenue, Chicago, IL 60611. (312) 440-2660. Summary: Saliva is essential for oral defense against infections. Decreased salivary secretion may result in increased dental caries (cavities), oral mucosal changes, an altered sense of taste, difficulty in swallowing, and oral pain. This article reports on a study that documented the parotid gland saliva secretion at different ages in a group of subjects with Down syndrome. Saliva was collected from 39 patients aged 11 to 62 years old, by means of a parotid salivary gland cup and under standardized conditions of stimulated secretion. The rate of salivary secretion in the entire group of patients with Down syndrome was lower than that of healthy controls and lower in the older study group compared with the younger group. Institutionalized subjects or those living in hostel-like apartments had a lower secretion rate than those living at home. In analyses of the four factors (Down syndrome, hypothyroidism, institutionalization, and age),
10 Down Syndrome
Down syndrome was found to be the only variable significantly related to flow. These findings indicate that stimulated parotid salivary hypofunction in Down syndrome subjects is mainly related to their genetic disorder. 2 tables. 30 references. •
Severe Impairment of Secretory Ig Production in Parotid Saliva of Down Syndrome Individuals Source: Journal of Dental Research. 81(5): 308-312. May 2002. Contact: Available from International Association for Dental Research. Subscription Department, 1619 Duke Street, Alexandria, VA 22314. (703) 548-0066. Fax (703) 548-1883. Summary: Infections associated with Down Syndrome (DS) are prevalent in the mucosal-gastrointestinal and respiratory systems, for reasons that are uncertain. This article reports on a study undertaken to assess the levels of parotid salivary immunoglobulins (Ig) in a group of DS individuals as a possible factor in the susceptibility of mucosal surfaces to infections. The study included 29 DS and 10 agematched and sex-matched healthy individuals. The secretion rates of IgA and IgG were diminished by 83 percent and 75 percent, respectively, in the DS population, whereas the secretion rate of IgM was not statistically significantly lower. Analysis of the data suggests that DS individuals are immunodeficient in the humoral mucosal immune response. This may explain, in part, the high incidence of recurrent infections in target organs of the secretory immune system in DS subjects. 3 figures. 1 table. 34 references.
•
Prevalence of Numeric Anomalies in the Permanent Dentition of Patients with Down Syndrome Source: SCD. Special Care in Dentistry. 21(2): 75-78. March-April 2001. Contact: Available from Special Care Dentistry. 211 East Chicago Avenue, Chicago, IL 60611. (312) 440-2660. Summary: This article reports on a study undertaken to evaluate the prevalence of numeric anomalies in the permanent dentition (teeth) of patients with Down syndrome by means of panoramic radiographs. The sample consisted of panoramic radiographs (x rays) from 70 subjects. The authors examined the radiographs to detect hypodontia (less than the normal number of teeth, which is 32) as well as supernumerary teeth (any tooth in addition to the normal number). Results confirm the high prevalence of hypodontia among patients with Down syndrome (60 percent) mostly with mild expression. The teeth most often missing were the upper lateral incisors, usually bilaterally (both sides), followed by the lower second premolars and upper second premolars. Supernumerary teeth were seen in 6 percent of the subjects, and the concomitant occurrence of hypodontia and supernumerary teeth occurred in one patient. The authors note that the clinical relevance of the early recognition of hypodontia and supernumerary teeth in any patient requires adequate treatment planning, for example, the maintenance of deciduous (temporary or primary) teeth or an early orthodontic intervention. 2 figures. 4 tables. 18 references.
•
Treating the Patient with Down Syndrome Source: Journal of Contemporary Dental Practice. 2(4). November 15, 2001. Contact: Available from Journal of Contemporary Dental Practice, an online journal. Website: www.thejcdp.com.
Studies 11
Summary: There are large numbers of individuals with Down syndrome living and working in the general community, thus it is likely that general dental practitioners will encounter patients from this group. This continuing education course is designed for general dentists and hygienists. The course materials cover the physical characteristics of patients with Down syndrome and the relationship of these characteristics to general dental care. The author discusses the prevalence of dental disease in this population, as well as techniques for effective patient management. Home care issues are also addressed. The purpose of the course is to enable dentists and hygienists to feel comfortable in treating most patients with Down syndrome within the general dental practice. The materials include a list of objectives and a posttest with which readers can obtain continuing education credit. The program is designed to be completed online. 9 figures. •
Periodontopathic Bacteria in Children with Down Syndrome Source: Journal of Periodontology. 71(2): 249-255. February 2000. Contact: Available from American Academy of Periodontology. Suite 800, 737 North Michigan Avenue, Chicago, IL 60611-2690. (312) 573-3220. Fax (312) 573-3225. Summary: Individuals with Down syndrome (DS) often develop severe early onset periodontal diseases. This article reports on a study that examined the prevalence of periodontopathic bacteria in DS children to determine if specific pathogens are acquired in their childhood. The subjects were 60 DS children (2 to 13 years old, five in each age bracket) and 60 age matched controls. Ten pathogens were surveyed in subgingival plaque samples using a polymerase chain reaction. Periodontal status was evaluated by probing depth, bleeding on probing, and gingival index. No significant difference in periodontal status was observed between the DS and control groups, however, all of the pathogens were detected with greater frequency in the DS children. A cluster analysis of the microbial profiles of the DS subjects showed that gingivitis severity was associated with increased varieties of the harboring pathogens and the distribution of Porphyromonas gingivalis. The authors conclude that these results suggest that various periodontopathogens can colonize in the very early childhood of DS patients and the maturation of subgingival components, including P. gingivalis, plays an important role in the initiation of gingival inflammation. 2 figures. 2 tables. 29 references.
•
Prevalence of Tooth Transposition, Third Molar Agenesis, and Maxillary Canine Impaction in Individuals with Down Syndrome Source: Angle Orthodontist. 70(4): 290-296. August 2000. Contact: Available from Allen Marketing and Management. P.O. Box 1897, Lawrence, KS 66044-8897. (785) 843-1235. Fax (785) 843-1274. Summary: Alterations in the size, morphology (shape) and number of teeth are among the many inherited disorders that have been reported in individuals with Down syndrome. By contrast, third molar agenesis (lack of development) and tooth transposition have been largely ignored and the prevalence of canine impaction has not been reported. This article reports on a study undertaken to quantify the occurrence of these anomalies in a group of individuals with Down syndrome, using standardized records, which included a clinical examination, dental cases, and a panoramic radiograph (x ray). The results saw a notably high prevalence of third molar agenesis (74 percent of individuals older than 14 years), canine impaction (15 percent), and maxillary canine and first premolar transposition (15 percent), compared to published figures from random population samples. The authors stress that these anomalies should not be
12 Down Syndrome
seen as separate, independent entities, but as associated phenomena. The slow rate of cell growth and a consequent reduced cell number that characterize this syndrome may be responsible for the underdevelopment of the upper jaw, the delayed dental development, the reduction in teeth number and size, and the altered path of canine eruption. 3 figures. 1 table. 43 references. •
Significance of Oral Health in Persons With Down Syndrome: A Literature Review Source: Developmental Medicine and Child Neurology. 41(4): 275-283. April 1999. Summary: Down syndrome (DS) is an autosomal chromosomal anomaly that affects approximately 1 in 700 to 800 live births. Many of the medical and physiological characteristics of DS have direct consequences for the oral health of subjects affected with DS. There are also indirect consequences for the quality of life of persons with DS and their caregivers. This article provides an overview of the literature concerning the orofacial problems confronting patients with DS and reviews the different treatment options available. Topics include anatomical consideration, mastication (chewing) and swallowing, dental disease, bruxism, and dental trauma (patients with DS may be more prone to falls). Systemic dysfunction (such as immunological deficiency) in this population may predispose to oral disease, which may in turn aggravate systemic disease. The authors emphasize that regular reviews, preferably by a specialist team, should be undertaken to identify and prevent both functional problems and disease processes. These patients should be seen at least every 6 months, but more regularly should specific problems arise. These regular reviews should have the following aims: early introduction to the dental environment in order to facilitate subsequent preventive intervention, diagnosis and, if possible, to allow appliance therapy; early neuromuscular stimulation of oral proprioception essential for full development of orofacial function in the infant; education of caregivers with regard to nutrition, taking into account chewing function, food texture, caries prevention, and fluoride administration; and institution of a personalized oral hygiene regimen for the prevention of periodontal disease, taking into account the motor capacity of the patients and aiming for autonomy of care. 3 figures. 108 references.
•
Neutrophil Chemotaxis in Down Syndrome and Normal Children to Actinobacillus Actinomycetemcomitans Source: Journal of Clinical Pediatric Dentistry. 22(2): 141-146. Winter 1998. Contact: Available from Journal of Clinical Pediatric Dentistry. P.O. Box 830259, Birmingham, AL 35283-0259. Summary: During the last decade a lot of attention has been diverted to the study of Actinobacillus actinomycetemcomitans (Aa) as the principal microorganism in the pathogenesis of periodontal disease. Because of the defective body defenses, there is an increased likelihood of periodontal disease among patients with Down syndrome. The authors of this article attempt to correlate the relationship between the gingival and periodontal health status to the isolation of Aa from the subgingival plaque in children with Down syndrome. They compare this to the neutrophil chemotactic activity in normal subjects. The authors observed a strong observation between the occurrence of Aa as well as significant differences between the normal and Down syndrome subjects in neutrophil defense activity. Thus the higher prevalence of periodontitis diagnosed in children with Down syndrome seems to be more related to the impaired host defense mechanism rather than to the occurrence of specific periodontal pathogens. 3 figures. 2 tables. 52 references. (AA-M).
Studies 13
•
Dental Care for the Patient with Down Syndrome Source: Down Syndrome Research and Practice. 5(3): 111-116. 1998. Contact: Down Syndrome Educational Trust. Subscriptions, DownsEd, The Sarah Duffen Centre, Belmont Street, Southsea, Hampshire, P05 1NA, England. +44 (0) 1705 824261. Fax: +44 (0) 1705 824265. E-mail:
[email protected]. Website: www.downsnet.org/dsrp. Also available from Down Syndrome: Health Issues. Website: www.ds-health.com/dental.htm. Summary: This article reports on a clinical and literature review of the special dental considerations unique to individuals with Down syndrome. The author is both a dentist and parent of a child with Down syndrome. The author discusses the physical and orofacial characteristics of Down syndrome, including the teeth, gingiva, tongue, palate, and occlusion. Incidences of dental decay and periodontal disease are discussed as are recommendations for treating these diseases in persons with Down syndrome. The author notes that most, if not all, persons with Down syndrome have some type of occlusal disharmony; orthodontic therapy is discussed. The author also discusses medical problems associated with Down syndrome, the social and emotional factors involved in dental treatment, techniques to help children with Down syndrome become cooperative dental patients, how to choose the right dentist for a child with Down syndrome, how parents can communicate effectively with the dental staff, proper home care, and the prevention of dental disease (including the most recent dental products). The author concludes that dental care for the patient with Down syndrome can be achieved in the general practitioner's office in most instances with minor adaptations. Although this population has some unique dental care needs, few patients require special facilities in order to receive dental treatment. 24 references.
•
Concomitant Occurrence of Hypodontia and Supernumerary Teeth in a Patient with Down Syndrome Source: SCD. Special Care in Dentistry. 17(2): 54-57. March-April 1997. Summary: This article reports the case of a patient with Down syndrome in whom concomitant hypodontia and supernumeraries are present. Concomitant hypodontia and supernumerary teeth are relatively rare, and this is the first case reported in a patient with Down syndrome. The article first describes Down syndrome, including its epidemiology, general and facial features, and dental and oral anomalies. The case report of a 12 1/2 year old Caucasian girl with Down syndrome and mild mental retardation is then presented. Her main dental complaint was that a new tooth had recently 'appeared in the roof of her mouth.' An evaluation of the radiographs showed missing maxillary right and left second premolars and also a mandibular right second premolar. The maxillary left and mandibular left, and right second molars were developing normally, but the maxillary right second molar appeared peg-shaped. The authors note that a conservative approach to management will be pursued, with the accent on oral hygiene reinforcement and prevention. 3 figures. 32 references. (AA-M).
•
Down Syndrome: A Review of the Literature Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics. 84(3): 279-285. September 1997. Summary: This article reviews the literature on Down syndrome, focusing on various systemic and oral anomalies, clinical manifestations, and recommendations for the dental management of persons with Down syndrome. From the time Down syndrome
14 Down Syndrome
was diagnosed by phenotype, to the present when karyotyping distinguishes chromosomal subgroups, increasingly sophisticated tests and treatments have influenced the lives of Down syndrome patients. Medical advances, special educational programs, and increasing social acceptance of disabled people in the community have resulted in current trends of normalization and deinstitutionalization of these patients. The author emphasizes that once a dentist is familiar with a patient's medical history and takes needed precautions, patients with Down syndrome can be treated routinely in a dental office. 39 references. (AA-M). •
Oligodontia: A Radiographic Comparison of Subjects with Down Syndrome and Normal Subjects Source: SCD. Special Care in Dentistry. 17(5): 137-141. September-October 1997. Summary: This article reports on a study in which panoramic radiographs and clinical records were used to investigate developmentally absent permanent teeth in 98 subjects with Down syndrome (trisomy-21). This retrospective study was based on the records and panoramic radiographs of subjects from approximately five years of age (the age at which mineralization of the permanent tooth germ could be identified) to their current age. The time period covered by records ranged from 6 to 28 years. The majority of subjects with Down syndrome (63 percent) exhibited oligodontia (missing teeth), and many subjects were missing two or more teeth (53 percent). The most frequently absent teeth were the lower lateral incisors (23.3 percent), the upper second premolars (18.2 percent), the upper lateral incisors (16.5 percent), and the lower second premolars (15.3 percent). In general, the distribution of the developmentally absent teeth was similar for teeth in homologous positions on either side of the midline or between the maxilla and the mandible. The only significant exceptions to this pattern were seen with the central incisors and the second molar. This study's findings suggest a high risk of oligodontia in subjects with Down syndrome. 3 figures. 2 tables. 13 references. (AA-M).
•
Toxic Shock and Down Syndromes in a Dental Patient: A Case Report and Review of the Literature Source: Special Care in Dentistry. 14(6): 246-251. November-December 1994. Summary: In this article, the authors first present a literature review of toxic shock syndrome (TSS), including epidemiology, etiology, signs, symptoms and management, and its relationship to infection susceptibility in the Down syndrome patient. The authors then present a case of a Down syndrome patient with TSS, focusing on the role of odontogenic infection. They report the patient's medical history, social history, and dental history. They conclude with a discussion of the management of the dental patient with a TSS history. 3 figures. 2 tables. 42 references. (AA-M).
Federally Funded Research on Down Syndrome The U.S. Government supports a variety of research studies relating to Down syndrome. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable 2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies 15
database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to Down syndrome. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore Down syndrome. The following is typical of the type of information found when searching the CRISP database for Down syndrome: •
Project Title: 10TH INTERNATIONAL MEETING CHROMOSOME 21 & DOWN SYNDROME Principal Investigator & Institution: Yarowsky, Paul J. Scientist; Pharmacol & Exper Therapeutics; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2002; Project Start 26-SEP-2002; Project End 29-SEP-2002 Summary: (provided by applicant): The objective of the 10th International Meeting of Chromosome 21 & Down Syndrome is to bring together investigators from the international community with a broad spectrum of research interests to discuss the current state of knowledge regarding Down syndrome and human chromosome 21. Topics for discussion are designed to encompass all relevant areas of biology, molecular biology, and medicine, including functional genomics and neurobiology. Invited speakers will present an overview highlighting topical issues. These introductions will be followed by platform presentations from submitted abstracts. The organizers anticipate a small but highly interactive meeting to facilitate the exchange of the latest ideas between senior and junior scientists, including postdoctoral fellows. Following the sequencing of chromosome 21, researchers are putting the results of these molecular analyses into biological context. This can best be done with a multidisciplinary group of researchers including those specializing in the mental retardation and cognitive deficits of Down syndrome, the neurobiology of Down syndrome, congenital heart defects, immune deficits, leukemia, craniofacial abnormalities, communicative and digestive disorders, and premature aging, as well as genomic research, transgenic mouse construction and analysis, and mouse behavioral studies. It is anticipated that this conference will foster interaction across disciplines, help to focus and redirect research efforts for maximal use of developing data, and establish new collaborations and avenues of investigation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A CLINICAL TRIAL OF DONEPEZIL FOR DOWN SYNDROME Principal Investigator & Institution: Kishnani, Priya S. Assistant Professor; Pediatrics; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: (Adapted from the applicant's abstract): The primary hypotheses of the proposed project is that administration of Donepezil to young adults with Down syndrome (DS) will improve adaptive functioning and expressive language as measured by a change from baseline to endpoint at 24 weeks of therapy. DS is the most common genetic cause of mental retardation worldwide. Cognitive and functional deficits, of variable degree, are seen in all subjects with DS and currently there is no
16 Down Syndrome
approved treatment for these domains. An impaired cholinergic system, which persists throughout the lifespan, has been detected early in life in individuals with DS. This cholinergic deficit is believed to underlie many of the cognitive and functional impairments in DS. A therapy that increases the bioavailability of acetylcholine could produce improvements in cognition and consequently, adaptation in DS. Alzheimer's disease (AD) is a model for this effect. Donepezil Hydrochloride, an FDA-approved second generation cholinesterase inhibitor, is currently the most widely-used medication for the pharmacotherapy of cognitive and functional deficits in AD. A previous open label study of DS adults found Donepezil to be well tolerated with improvement in expressive language and adaptive domains. Rationale for its use in young DS individuals is to enhance availability of acetylcholine because of its key role in learning and not to treat symptoms of AD in DS. The proposed study is a single Center, randomized 24-week double-blind, placebo-controlled study with a subsequent 24-week open treatment and six-week washout phases. Sixty individuals with DS will participate, and half will receive drug during the first 24 weeks. The primary endpoints are the adaptive behavior composite score of the Vineland Adaptive Behavior Scales (VABS) and expressive language subtests of the Clinical Evaluation of Language Fundamentals (CELF-3) comparing the treated group to the control group after the 24 weeks of blinded treatment. A number of secondary aims will investigate effects of treatment of specific components of cognition, i.e., memory and mood. Safety and tolerability will also be evaluated. As DS individuals are now living longer, improving their quality of life and maximizing their developmental potential are of paramount importance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: A GENETIC ANALYSIS OF MINIBRAIN KINASE IN C. ELEGANS Principal Investigator & Institution: Raich, William B. Ctr for Neurobiology Behavior; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-SEP-2001 Summary: The goal of this research proposal is to identify molecular pathways involving minibrain kinase (mnbK), both in normal neuronal function and in the cognitive defects of Down syndrome. Studies of partial trisomy of chromosome 21 suggest that a considerable portion of the Down syndrome phenotype result from a 2Mb region at the 21g22.2 region; mnbK localizes to this genomic region. Overexpression of mnbK in mice causes severe defects in learning and memory, strongly implicating mnbK in the cognitive defects of Down syndrome. Currently, the substrates and regulators of mnbK are unknown. To elucidate this pathway, the Caenorhabditis elegans mnbK homologues mbk-1 and mbk-2, will be investigated. I propose to characterize the expression and subcellular localization of the mbk gene products, generate null alleles via chemical mutagenesis coupled with population PCR, and simulate the Down condition by overexpressing the wildtype and activated gene products. As a tool for determing the focus of MBK activity, the tetracycline-dependent transactivator system will be adapted to C. elegans, a system that permits temporally and spatially regulated gene expression. Candidate genes will be tested to determine if they belong to a mbk pathway, and pilot suppressor and/or enhancer screens will be performed to identify upstream and downstream components in an unbiased manner. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 17
•
Project Title: A STIMULUS CONTROL ANALYSIS OF ATTENDING Principal Investigator & Institution: Serna, Richard W. Associate Professor; Eunice Kennedy Shriver Center; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, MA 01655 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2005 Summary: In typically-developing children, initially slow, one-at-a-time word learning is followed by an apparent "explosion" in their lexicon. One estimate suggests that children are learning up to nine new words a day through slow and deliberate effort (e.g., McLean, 1993). Yet word learning is a foundational component of human development, necessary for advanced linguistic functions (e.g. syntactic operations) and contributing to complex representation skills (for instance, categorization; Bowerman, 1988). Yet word learning is a foundational component of human development, necessary for advanced linguistic; Bowerman, 1998). To the extent that a cognitive disability interferes with cord learning, progress in these domains will be correspondingly limited. It is therefore essential to explore in detail the nature of lexical impairments in mental retardation. The existence of difficulties in lexical acquisition among individuals with severe mental retardation raises important questions. When rapid vocabulary expansion occurs, what linguistic/cognitive processes support that learning? When it does not occur, what skills are deficient or absent? A phenomenon called fast mapping may be of greatest potential relevance for rapid vocabulary expansion. Fast mapping refers to a "quick, initial, partial understanding of a 'new' word's meaning" derived from the context of word use )Rice, 1989, p.152). Fast mapping has been argued to facilitate the vocabulary expansion. This proposed role has received empirical confirmation in typical youngsters and children with Down Syndrome )Mervis & Bertrand, 1994, 1995). Yet evidence from children with atypical cognition/language has recently challenged the universality of this relation. My own studies (Wilkinson & Green, 1997) have added to preliminary evidence of selective deficits in fast mapping among individuals with severe mental retardation, Williams Syndrome, or specific language purpose of vocabulary expansion. These recent findings oblige a more systematic analysis of the precise role of the principle in learning outcomes in mental retardation. Is fast mapping at risk in individuals with severe mental retardation, potentially limiting their vocabulary expansion? I propose a five-year study of vocabulary expansion and delay, focusing specifically on rapid expansion of an extant, but limited, vocabulary. This study will implement methods developed by the applicant (Wilkinson & Green, 199) that for the first time enable systematic analysis of unresolved questions of lexical expansion in severe mental retardation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ADAPT NEURODEGENERATION
78
IN
OXIDANT
STRESS,
AGING
AND
Principal Investigator & Institution: Davies, Kelvin J. Gerontology; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, CA 90033 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2005 Summary: We are interested in a possible link between oxidative stress, aging and neurodegenerative diseases. In recent studies of adaptation to oxidative stress we have identified several previously unknown genes (in addition to confirming the overexpression of several known genes) that appear to provide stress protection in isolated hamster cells in culture. These "adapt" genes include: adapt15, adapt33, adapt66, adapt73, adapt78, and adapt 116. Although our studies indicate that full
18 Down Syndrome
adaptation depends upon both transcription and translation, it is not clear which genes are actually required. Although each of these newly discovered genes is worthy of detailed study, adapt78 whose mRNA levels increase more than 50 fold in adaptation, in particular stands out. In screening studies employing autopsy samples from human brains, we have now found that the human homologue of adapt78 exhibits extremely high levels of expression in brain autopsy samples from Alzheimer's disease patients, and low levels of expression in brain samples encompassing the substantia nigra from patients who died with Parkinson's disease. Recently, it has become clear that our adapt78 is identical to (or at least highly homologous with) the simultaneously independently discovered Down syndrome critical region 1 (DSCR1) gene of chromosome 21. Furthermore, two different isoforms of both adapt78 and DSCR1 are differentially expressed; corresponding to differentially spliced forms of exons 1-5, 6, 7 and exons 4-5, 6, 7. We propose to now carefully study expression of both isoforms of the human adapt78 gene in different brain regions, using the more sensitive techniques of RT-PCR and in situ hybridization. We plan to study adapt78 expression as a function of age, in brain autopsy samples from otherwise healthy individuals, since adapt78 expression may well vary with age. We will perform detailed studies of brain samples from Alzheimer's disease patients, Parkinson's disease patients, and Down syndrome patients in order to carefully determine both qualitative and quantitative differences in expression of both isoforms of adapt78 mRNA. Localization of adapt78 mRNA expression by cell type will also be studied. We also will synthesize and characterize the (1-5, 6, 7 and 4-5, 6, 7) Adapt78 proteins and generate antibodies to them in order to study expression of the actual proteins in all cell and brain samples. In cell culture studies, with PC-12 cells, we will test the hypothesis that inducible overexpression of adapt78 may confer an oxidative stress resistance phenotype. We will also test the ability of inducible adapt78 overexpressing cells to overcome the lethal oxidizing effects of glutathione deficiency, caused by expression of antisense message to gamma glutamylcysteine synthetase. These studies will allow us to begin to investigate our hypothesis that aging, and perhaps certain neurodegenerative diseases, involving defects in the expression of adapt78 and other adaptive genes required to cope with the deleterious effects of oxidative stress. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ADULT MOUSE MODEL FOR DOWN SYNDROME Principal Investigator & Institution: Davisson, Muriel; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001 Summary: The long term goal of this Project is to define the genetic and biological bases for abnormalities seen in individuals with Down syndrome (DS; Trisomy 21, Ts21), using genetically defined and genetically manipulated mouse model systems. The Down syndrome region of human Chromosome (Chr) 21 is conserved in at least three mouse chromosomes Chr 10, 16, and 17- with the largest segment in Chr 16. My research group has produced a mouse strain that carries segmental trisomy [Ts(1716)65Dn] for most of the region of mouse Chr 16 that is homologous with the Down syndrome region of human Chr 21 genes at dosage imbalance in this model by combining Ts65Dn with transgenes containing genes from the region of human Chr 21 that is conserved in mouse Chr 10; (2) study the effects of individual candidate genes in the Ts65DN segment by combining in mouse Chr 10; (2) study the effects of individual candidate genes in the Ts65Dn segment by combining it with targeted mutations for the singleminded (Sim2) and minibrain (Dyrk) homologs of Drosophila genes, which are
Studies 19
important in central nervous system development and glycolysis; (3) analyze the behavior and pathology of the combining mice produced and (4) carry out neurological and electrophysiologic studies on the combination mice produced. The evaluation of neural function will include in vitro recording from fresh brain slices to assess synaptic transmission and plasticity. In vivo procedures, such as electrocorticograms and quantification of tremor activity also will be used. These assessments will be complemented by the analysis of hippocampal place cell activity and dendritic morphology of a limited number of strains. This research will provide not only a better understanding of the role of single genes in the Down syndrome phenotype but also a more complete adult mouse model for testing therapeutic intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AGE-RELATED CHANGES IN TS65DN MOUSE FOREBRAIN & LEARNING Principal Investigator & Institution: Hyde, Lynn A. Pediatrics; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, CO 800450508 Timing: Fiscal Year 2001; Project Start 01-NOV-2000 Summary: Ts65Dn mice are a model of Down syndrome and may be useful as a model Alzheimer's disease as well. Alzheimer's patients lose basal forebrain cholinergic (BFC) neurons and cholinergic function. Similarly, Ts65Dn mice lose BFC neuronal markers earlier than control littermates, but the functional effects of this loss has not been examined. This proposal will examine the functional effects of premature loss of BFC neurons in Ts65Dn mice on learning tasks that depend on the BFC system and two areas it innervates, the hippocampus and prefrontal cortex. To this end, learning will be assessed in tasks that have been shown to be dependent on BFC function (delayed nonmatch and match to sample, radial arm maze spatial working memory, and passive avoidance), the hippocampus (spatial, but not non-spatial, radial arm maze) and/or prefrontal cortex (behavioral flexibility). Further, we will relate learning in these tasks to BFC neuronal number and function at 3 ages that span the progression of BFC loss in Ts65Dn mice. Importantly, this proposal will determine if the cholinergic cell loss parallels the learning deficits. Data from this study may aid in understanding of the role that the loss of cholinergic neurons and function may play in dementia seen in Alzheimer's disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ALTERNATIVE SPLICING OF THE DROSOPHILA DSCAM PREMRNA Principal Investigator & Institution: Graveley, Brenton; Genetics & Developmntl Biology; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, CT 060302806 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2007 Summary: (provided by applicant): The long-term goals of this proposal are to understand how the alternative splicing of the Drosophila Down syndrome cell adhesion molecule (Dscam) gene is regulated and to determine the mechanism by which Dscam alternative splicing is mutually exclusive. The Dscam gene encodes an axon guidance receptor that plays an important role in neural development and is the most extensively alternatively spliced gene known to date. The Dscam gene contains 115 exons, 95 of which are alternatively spliced. The alternative exons are organized into 4 distinct clusters containing 12, 48, 33 and 2 mutually exclusive exons each. Because the
20 Down Syndrome
exons within each cluster are alternatively spliced in a mutually exclusive manner, it is possible that 38,016 different Dscam isoforms can be expressed. It has been proposed that each Dscam isoform might interact with a different set of axon guidance cues and that the collection of Dscam isoforms expressed by a cell will be directly involved in guiding neurons to different addresses. It is therefore likely that individual neurons must in some way be programmed to splice the Dscam pre-mRNA in specific ways. Thus understanding the mechanisms regulating Dscam alternative splicing will provide insight into the genetic program that specifies neural wiring. This proposal is aimed at understanding the mechanisms involved in regulating the alternative splicing of the Dscam exon 4 cluster which contains 12 mutually exclusive exons. First, we will identify RNA sequences involved in the regulation of Dscam alternative splicing and the proteins that bind to these elements. Second, we will determine the mechanism involved in the developmental regulation of exon 4.2 alternative splicing. Third, we will determine the mechanism by which the SR protein B52 and the general splicing factor dU2AF modulate exon 4.4 alternative splicing. Finally, we will determine the mechanistic basis by which alternative splicing of the Dscam exon 4 cluster is mutually exclusive. Together, these experiments will provide significant insight into the mechanisms involved in regulating alternative splicing, the mechanism responsible for mutually exclusive alternative splicing, and the genetic program that determines the specificity of neural wiring in Drosophila. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALZHEIMER'S DISEASE IN DOWN SYNDROME: ANTIOXIDANT TRIAL Principal Investigator & Institution: Lott, Ira T. Pediatrics; University of California Irvine Campus Dr Irvine, CA 92697 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): The objective of this pilot clinical trial is to obtain information on the tolerability, safety, and efficacy of a high potency combinatorial supplement in the treatment of Alzheimer disease (AD) in Down syndrome (DS). Individuals with DS have an increased incidence of AD and evidence of oxidative stress in brain. The DS population is an excellent candidate for antioxidant intervention. The trial will conform to a double-blind, placebo-controlled, and repeated analysis of variance design. The supplement will consist two cellular antioxidants (vitamins E 900 IU/day and C 200 mg/day) and a mitochondrial antioxidant (alpha-lipoic acid 600 mg/day). The clinical diagnosis of AD in DS will be made by the investigators utilizing their previous experience with DSM-IV criteria for dementia in DS. There are three specific aims: 1) to determine whether cognitive measures are improved by antioxidant supplementation. Outcome measures have been shown to have reliability and validity for DS. They comprise three informant scales (Dementia Rating Scale for Persons with Mental Retardation, Neuropsychology Behavior and Affect Profile, Vineland Adaptive Scales) and three direct assessments (Severe Impairment Battery, Brief Praxis Test, and the FULD-Object/Memory Test-modified); 2) to determine whether plasma biomarkers of lipid oxidative damage (malondialdehyde, isoprostanes), protein oxidative damage (carbonyl group formation), levels of beta-amyloid, and vitamin E levels will be altered in subjects receiving the diet; and 3) to determine the safety and tolerability of the antioxidant supplementation utilizing checklists for adverse events, clinical chemistries, and measures of medication compliance. All study measures will be obtained at baseline and at 6-month intervals for a total of 24 months of treatment. All study patients will be on an acetylcholinesterase inhibitor. Power analysis configured on the primary outcome
Studies 21
measures supports a study group of 30 treated and 30 placebo randomized patients. Database management will facilitate analysis of the 24-month observations. The data from this study is intended to provide information relevant to the indications for a multicenter definitive clinical trial of antioxidants in DS. Since the process resulting in AD in DS is age dependent across the lifespan, a positive result from this pilot trial may have implications for utilizing high potency combinatorial antioxidants at earlier age epochs in DS. The pilot trial should also contribute information as to the possible role of antioxidants in the treatment or prevention of AD in the general population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANALYSIS AND CONTROL OF CHROMOSOME MOVEMENT Principal Investigator & Institution: Nicklas, R B. Zoology; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-JAN-1976; Project End 30-NOV-2005 Summary: (Verbatim from the applicant's abstract): The goal is to understand precise chromosome movement and the accurate distribution of chromosomes to the daughter cells in mitosis and meiosis. Errors in distribution can lead to cancer and to Down syndrome and other chromosome disorders in humans. How cells avoid errors is the subject of this project. Mechanical tension from mitotic forces is the key. Early in mitosis, chromosomes move to a position quite precisely midway between the spindle poles. The movement is powered by motile kinetochores (the structures that attach the chromosome to spindle microtubules). Kinetochores switch between pulling and an inactive, 'neutral' state. The switch may be regulated by tension, which will be tested directly by pushing on chromosomes with a micromanipulation needle to relax the tension and allow switching to occur. The motors dynein and CENP-E are present at kinetochores when chromosomes begin to move but are later lost from the chromosomes. The possible uses for such transitory kinetochore motors will be tested. The common errors in chromosome distribution are of two sorts, and tension is involved in avoiding both of them. Avoiding errors of the first sort depends on an anchorage of chromosomes to the spindle that is sensitive to tension. The possibility that the poles are the sensitive site will be tested by micromanipulation. Errors of the second sort are avoided by a checkpoint that detects errors and delays the completion of mitosis. Tension-sensitive kinetochore protein phosphorylation may be the signal to the checkpoint. Tension certainly causes kinetochore dephosphorylation, but the effect may be direct (deformation of some component) or indirect (tension increases the number of microtubules, which may lead to dephosphorylation). This ambiguity will be resolved by creating a situation in which tension can be manipulated yet does not increase the number of microtubules. The effect of tension on the structure of the kinetochore and its components will be explored by combining micromanipulation to vary the tension force with electron microscopy to view the consequences. Kinetochores will be reconstructed by threedimensional tomography. The ultimate goal is to understand how tension, by altering structure, can lead to chemical changes such as dephosphorylation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANALYSIS OF DSCAM BINDING PROPERTIES Principal Investigator & Institution: Flanagan, John J. Biological Chemistry; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2002; Project Start 30-SEP-2002
22 Down Syndrome
Summary: (provided by applicant): Down syndrome is molecularly characterized by a trisomy of chromosome 21, which results phenotypically in malformations of the neuroanatomy and malfunctions in neurochemistry. The founding member of the Down Syndrome Cell Adhesion Molecule (Dscam) family was isolated through a direct screen of a region of chromosome 21. Recently, a new member of the Dscam family, Dsam-1, was identified in Drosophila and statistically exists in over 30,000 isoforms due to alternative splicing of four variable exons. It was shown to be necessary for proper development of the Drosophila central nervous system,and was identified as an axon guidance receptor. Following the discovery of Dscam-1, three new members of the family have been identified in Drosophila. Since the Dscam molecules belong to the immunoglobulin (Ig) superfamily of cell adhesion molecules, they have the potential to act as homo/heterophilic receptors. To identify the molecular function of Dscam-1 and its paralogues, stable cell lines will be constructed expressing one of the four family members. These cell lines will be tested for homo/heterophilic cell adhesion using a standard cell adhesion assay. Briefly, cells will be incubated in suspension either with cells expressing the same Dscam receptor or a different one. The cells will be differentially labeled with lipophilic dyes and checked for aggregation using confocal microscopy. Dscam receptors may also interact in cis (on the same cell surface). This will be tested through transient transfection of one receptor into a stable line expressing another. Co-immunoprecipitation experiments will be done to identify interactions between the two receptors. All possible combinations will be tested. These experiments will begin to elucidate the specificity of the Dscam receptors for each other and their role in axon guidance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AXON GIUDANCE AND TARGETING IN DROSOPHILA Principal Investigator & Institution: Zipursky, S L. Professor; Biological Chemistry; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (provided by applicant): Dscam is an axon guidance receptor that is required for the formation of neuronal connections in the Drosophila nervous system. Dscam loss-of-function phenotypes have been characterized in detail for an embryonic nerve called Bolwig's nerve (BN). Phenotypic studies of Dscam mutants suggest that Dscam protein is critical for mediating a short-range interaction between BN and an intermediate target. Dscam also is required for the specification of other connections in the developing embryo. Dscam protein contains 10 Ig repeats, 6 fibronectin type III repeats, a single transmembrane segment and a cytoplasmic tail with multiple binding sites for the Dock adapter protein, a signaling component connecting Dscam to actin cytoskeletal regulators. Alternative splicing of Dscam may lead to more than 38,000 forms of the receptor. These receptors share the same domain structure, but differ in amino acid sequence in 4 different domains. Three of the Ig domains and the transmembrane domain are variable. This variability reflects the use of alternative exons. In this proposal, the specific form of Dscam expressed in BN will be determined using RT-PCR. Transgene rescue experiments will be used to verify that this form is functional in BN. Transgenes containing different variable domains will be tested for function by targeted expression in BN. Additional experiments will be directed towards determining the pattern of expression of Dscam isoforms in the developing embryo and the developing eye imaginal disc using both in situ hybridization and RT-PCR techniques. These studies will form the foundation for determining whether different
Studies 23
Dscam isoforms contribute to a molecular code for axon guidance and targeting. As Drosophila Dscam is structurally related to a human gene implicated in Down Syndrome, the studies described in this grant may provide insights into the abnormalities in brain development in Down Syndrome patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BEHAVIORAL ANALYSIS OF A MOUSE MODEL OF DOWN SYNDROME Principal Investigator & Institution: Crnic, Linda S.; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001 Summary: 6The Ts65Dn mouse model of Down syndrome has demonstrated as behavioral phenotype consistent with aspects of the human phenotype of DS. The aims of this proposal are first to continue to determine the behavioral phenotype of this interesting model and second to begin to determine the mechanisms by which overexpressed genes produce the neural and behavioral phenotype. Because DS is a complex disorder, no one brain region is responsible for the cognitive phenotype. Similarly, in this Ts65Dn model, multiple brain regions are implicated by the findings to date, namely the prefrontal cortex, hippocampus, cerebellum and perhaps amygdala. Understanding how deficits in these multiple regions interact to produce the DS phenotype will require a thorough exploration of the behavioral phenotype. We will use contextual and cued fear conditioning, skilled reaching, chaining behavior, reference and working memory, delayed and alternation and a range of eyeblink conditioning paradigms. Our approaches in this aim have from the start been guided by the research and theorizing of our colleagues (Pennington and Nadel) on Project 8. In the new grant period, we have designed experiments in parallel, and in future will be able to make use of their findings with humans to design tests for the animal models. In addition, hypothesis about neural systems involved in DS that derive from the human work can be tested in animals. The hypothesis to be tested regarding neural involvement in DS is that basal forebrain and medial septal cholinergic neurons are involved in the prefrontal and hippocampal deficits in this mouse model. This will be testing by manipulating these cholinergic systems with a well-established prenatal choline supplementation and examining number and size of cholinergic neurons and dendritic spins on hippocampal and cortical neurons. The role of the over production of interferon receptors in the cholinergic phenotype will be tested by crossing the Ts65Dn mice with knockout mice for these receptors to normalize their copy number. In addition, we will make use of transgenic and knockout mice produced by other projects that can be used to determine the role of other individual genes and gene regions in the cognitive phenotype of DS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CEREBRAL GLUCOSE METABOLISM IN DOWN SYNDROME Principal Investigator & Institution: Haier, Richard J. Professor; Pediatrics; University of California Irvine Campus Dr Irvine, CA 92697 Timing: Fiscal Year 2001; Project Start 20-JUL-1999; Project End 30-JUN-2004 Summary: This project will use PET to determine the location and sequence of cerebral glucose metabolic changes as dementia develops in adults with Down Syndrome (DS). Based on the sequencing of brain lesions found in Alzheimer's Disease (AD) and a model proposed by Braak and Braak (1997), we hypothesize that: 1) as dementia begins in DS, the earliest brain changes will be glucose metabolic rate (GMR) decreases in basal
24 Down Syndrome
neocortex or temporal- entorhinal cortical areas and 2) as dementia increases, hippocampal formation areas will show the greatest GMR decreases before frontal and occipital cortex decreases occur. We will examine 20 older non-demented DS patients already entered into the DS Core of the UCI Alzheimer's Disease Research Center and now at risk for dementia based on age (over 35 years old) and impairment scores. Each will receive a PET/FDG scan and neuropsychological assessment once a year for up to five years. A comparison group of mild probable AD patients (n=20) already entered into the Clinical Core also will be studied for five years as will a group of age and sex matched normal controls (n=15). All PET scans will be done with a simple cognitive activation (the Continuous Performance Test of attention) with groups matched on performance. PET and co-registered MRI data will be analyzed using regions-of-interest, SPM96, and other morphing and multivariate techniques. The analyses will include group comparisons of GMR over time in selected brain areas using accelerated growth curve techniques, determining functional relationships among brain areas selected a priori within groups using correlations, and person by person analyses to examine idiographic GMR patterns. We will also compare GMR in ApoE4- defined subgroups of the DS and AD subjects. This project will be unique in combining functional brain imaging using cognitive activation and a 5 year longitudinal design in DS and AD adults as dementia develops. These data will provide important information for the timing of treatment interventions and may aid in early detection of dementia and the classification of DS subtypes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COGNITIVE FUNCTION IN AUTISM Principal Investigator & Institution: Ozonoff, Sally; Associate Professor; University of Utah 200 S University St Salt Lake City, UT 84112 Timing: Fiscal Year 2001 Summary: Project II focuses on cognitive variables that may be part of the extended phenotype present in first-degree relatives of individuals with autism. Specifically, this project will focus on the executive function abilities of family members of autistic probands. Initial cognitive studies of parents and siblings focused on general impairments (e.g., mental retardation, learning disabilities), providing mixed evidence for a cognitive endophenotype. More recent investigations focusing on specific cognitive impairments that may aggregate in the families of autistic probands have been more promising, however. Project II concentrates on the integrity of one specific set of neuropsychological processes, executive functions, in family members of autistic probands. To examine whether executive deficits are stratified as a function of proband intellectual level, performance of parents/siblings of non-retarded autistic individuals will be compared with parents/siblings of children with learning disabilities (matched on IQ to autistic probands), while parents/siblings of mentally retarded autistic children will be compared to parents/siblings of probands with Down Syndrome (again matched on IQ to autistic subjects). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: COGNITIVE STRENGTHS AND WEAKNESSES IN DOWNS SYNDROME Principal Investigator & Institution: Fidler, Deborah J. Human Develmt & Family Studies; Colorado State University Fort Collins, CO 80523 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2005
Studies 25
Summary: (Provided by Applicant): For individuals with Down syndrome, the most common genetic mental retardation syndrome, research is converging on a cognitive profile consisting of poor verbal working memory and relatively stronger visuo-spatial processing. The implications of this research point to changes in the way children with Down syndrome are taught. Yet this information has remained relatively under-utilized by practitioners, possibly because the visuo-spatial processing relative strength remains poorly understood. In this application, the investigator proposes to: in Specific Aim 1, describe the strengths and weaknesses within the visuo-spatial relative strength in Down syndrome; and in Specific Aim 2, explore the relationship between performance on domains within visuo-spatial processing and other domains of processing (i.e. verbal working memory, auditory processing, expressive vocabulary, reading/decoding, logic). In subsequent research endeavors, the investigator also plans to identify strategies for improving auditory-dependent outcomes in Down syndrome (such as language acquisition) through the relative strength in visuo-spatial processing. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COGNITIVE-BRAIN PHENOTYPING OF ATYPICAL CHINESE CHILDREN Principal Investigator & Institution: Karmiloff-Smith, Annette; U of L University College London University College London London, Timing: Fiscal Year 2003; Project Start 28-SEP-2003; Project End 28-FEB-2005 Summary: (provided by applicant): The present proposal describes a series of planning activities to develop an international collaborative program of research on cognitive and brain phenotypes of mentally retarded Chinese children with genetic disorders. Specifically, an international team of medical, psychological, genetic, and computational researchers from P.R. China, the United Kingdom, the United States, and Canada will collaborate to study Chinese children with Fragile-X syndrome (FXS), Williams syndrome (WS), and Down syndrome (DS). The specific aims of the present research planning proposal are:(1) To assess the existing research infrastructure at the Chinese institution (Zhejiang University) for conducting the proposed research activities, (2) To enhance the research capacities of our Chinese research team through workshops and short-term training; (3) To conduct pilot studies that (a) test the feasibility of a computer-assisted 3D photography-based system for identifying a large population of mentally retarded children whose facial dysmorphology may suggest FXS, WS or DS and verify such identifications by genetic tests, (b) translate, adapt, and pilot-test procedures developed by the researchers in UK, US, and Canada to assess children with genetic disorders in terms of their abilities in the areas of language, executive function, and faces and visual-spatial information processing, and compare the Chinese children's cognitive profiles with the existing profiles of affected Western children; (c) use eventrelated potential techniques to examine the neuro-physiological correlates of a small group of the Chinese children with WS, FXS, and DS when they process language and face-spatial information, and compare the results with those obtained with the existing samples of affected Western children. Based on the outcome of 1,2, and 3, the international interdisciplinary team will develop a R01 research proposal that will systematically examine cognitive and brain functions or dysfunctions of Chinese children with Williams, Fragile-X, and Down syndromes from infancy to middle childhood. Our long-term goal is to chart the developmental trajectories of cognitive and brain development in children with genetic disorders, to understand the interaction between genetic abnormality and neuro-cognitive development in different socio-
26 Down Syndrome
cultural contexts, and to provide information for the creation of syndrome-specific and, if necessary, culture-specific intervention programs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--LANGUAGE AND COGNITION Principal Investigator & Institution: Reilly, Judy S. Professor; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2001; Project Start 16-SEP-1985; Project End 31-JUL-2006 Summary: The primary function of Core C is to chart the developmental trajectories through adolescence of language, discourse, attention, spatial cognition, memory and executive function in both normally developing and experimental populations. The Core organization allows us to maximize the efficiency of testing and ensure the smooth flow of information regarding children's testing between the Projects and Cores. It also serves to enhance the consistency, reliability and validity of data collection across Center populations. Core C will have primary responsibility for testing and tracking all normally developing subjects. The experimental populations are those identified with the Population Projects, and include children with early and late brain damage, Language Impairment, Williams Syndrome, and Down Syndrome, and Down Syndrome. These will be tested in close collaboration with Core C on two sub-batteries: A) Longitudinal, off-line: Language, Discourse, Spatial Cognition, Memory, Executive Function; B) Cross-sectional, on-line: Language, Attention and Spatial Cognition. The first sub-battery includes measures to assess later language development, specifically metalinguistic and discourse abilities. By assessing linguistic performance in isolation and in discourse, we address issues of linguistic knowledge versus performance. Using the CHILDES system, Core C will transcribe and code all elicited spoken and written language data. The Attention and Spatial Cognition, Memory and Executive Function Battery includes measures to assess various levels of non-linguistic processing: visual and auditory attention; hemispatial neglect, spatial cognition, verbal and spatial memory, and executive function. These data will permit us to identify association and dissociations within and across the domains of linguistic and non- linguistic cognition. The on-line tasks of Testing Battery B are directly yoked to the neuro-imaging studies (FMRI) and the the ERP studies. The studies outlined in Core C build on our previous research and introduce new lines of inquiry that will inform our understanding of later development in both normal and atypical populations. This new core will centralize our resources and provide a clearly-defined forum for the discussion and investigation of cross-population and investigation of cross-population hypotheses with respect to the development and integration of these basic cognitive systems. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--TISSUE CULTURE AND MONOCLONAL ANTIBODIES Principal Investigator & Institution: Michaelis, Mary L. Professor; University of Kansas Lawrence Lawrence, KS 66045 Timing: Fiscal Year 2001; Project Start 01-AUG-1991; Project End 30-JUN-2006 Summary: Investigations into the cellular and molecular mechanisms that lead to abnormalities associated with developmental disabilities and mental retardation are increasingly being carried out with in vitro model systems such as cell cultures, including cells transfected with foreign genes and cells derived from transgenic and knockout mice. Advances in understanding the mechanisms for the biochemical pathology of diseases that lead to mental retardation, such as Down syndrome or the
Studies 27
mucopolysaccharidoses, have been critically dependent upon the development of techniques for studying the altered cellular and biochemical milieu in isolated cell culture systems. In addition, state-of- the-art research in developmental biology frequently requires that investigators develop unique biological reagents such as polyclonal and monoclonal antibodies, various types of nucleotide probes, and constructs for transfection of foreign genes into cells. The Tissue Culture/Monoclonal Antibodies Laboratory (TCMAC) has facilitated the research of several of the Kansas MRDDRC investigators by providing core facilities and services that enable them to develop, maintain, and characterize numerous cellular model systems for exploring aspects of normal cell growth, signaling pathways that regulate cell viability, and effects of exogenous agents that enhance or disrupt cell growth. The TCMAC Laboratory takes great pride in the many enhancements that have been made in the facility during the past grant period as these improvements enable the lab to provide the highest level of support for MRDDRC investigators. The facility has also successfully developed unique polyclonal and monoclonal antibodies that served the needs of individual investigators. The antibody work done for Robert Palazzo has provided an excellent tool in his efforts to identify critical proteins in the centrosome and monitor changes during the cell cycle. The series of antibodies developed for Elias Michaelis have led to important discoveries regarding protein expression and localization in response to chronic ethanol exposure. Antibodies developed by the facility during the past grant period are currently being utilized at other universities in collaborative studies, and a major company has expressed interested in marketing some of those highly specific and valuable tools so they will be available to scientists on an international level. As the TCMAC looks to the future and means of enhancing the Center's focus on biobehavioral processes, the Core will play an expanding role in studies involving gene transfections, growth of ES cells, and other techniques required to produce transgenic or knockout mice. The TCMAC has been and continues to be a relatively small core, but it has played an extremely important role in attracting new, highly productive scientists to the Center itself and encouraging them to apply their talents to new, highly productive scientists to the Center itself and encouraging them to apply their talents to question related to developmental disabilities. For example, the TCMAC was instrumental in the attracting Rick Dobrowsky, Doug Ruden and Robert Palazzo to the MRDDRC shortly after they joined to KU faculty. This core is likely to continue in this role as the University hires new faculty members in the areas of molecular genetics, bioinformatics and developmental neurobiology. The goal of the TCMAC has been and will continue to be the provision of unique bioreagents, skilled technical support, and state-of-the-art equipment to facilitate and enhance the research of MRDDRC investigators who study molecular events leading to developmental disabilities. The TCMAC will continue to facilitate MRDDRC research at The University of Kansas by: (1) Maintaining a centralized facility that provides a cost-effective alternative to purchase of expensive equipment and services by MRDDRC investigators. (2) Producing and characterizing unique monoclonal/polyclonal antibodies and maintaining hybridoma cell lines for projects requiring a consistent supply of antibodies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORE--TRANSGENIC MOUSE Principal Investigator & Institution: Brennan, Miles B.; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001
28 Down Syndrome
Summary: The identification of a large fraction of the genes on chromosome 21q by Investigators of this PPG has lead to a number of specific, compelling hypothesis about how trisomy of single genes, and also how trisomy of functionally related sets of genes from chromosome 21q may contribute to aspects of the Down syndrome phenotype. Now we can test these genes singly and in the context of the recently developed moused Ts65Dn model of Down syndrome: with these development it has become possible to test these gene by either "adding" or "subtracting" one or more of these genes from the complement of genes trisomic in Ts65Dn, and assaying for the enhancement or amelioration of Down syndrome-like phenotypes in mutant mice. The purpose of this Core is to coordinate and centralize the production of single gene transgenics and single gene knockout mutants. Our target genes will be those identified by Investigators of this PPG as strong candidates for involvement in the Down syndrome phenotype. Not only will it be more efficient to have one transgenic facility, it will also facilitate standardization of the genetic background and initial analyses of mutant phenotypes. We will produce 5 "over-expressing" transgenic lines per year. In the first years of the grant, these will include over expression of CBS (cystathione beta synthase), RED1 (an RNA editase), GAPBA ( a transcription factor), DS-CAM (a cell adhesion molecule), and CHD-1 (a novel protein expressed in brain). We will make 2 knockouts per year from the region trisomic in Ts65Dn. In the first year, these will include Glur5 (a glutamate receptor subunit) and Gart (a protein with three activities of de novo purine synthesis). The mice produced in this Core will be analyzed both by the collaborating Investigators of the PPG as well as by the Behavior Screening Core (Dr. Crnic). While our initial approach to "over-expression" transgenics is the standard oocyte injection protocol (Hogan et al, 1991) which we have used successfully for Gart and Rfc transgenics, we are cognizant of the artefacts frequently encountered with this approach, e.g. altered transcriptional patterns and insertion site mutations (e.g. Burgess et al, 1995; Perry, et al, 1995). Accordingly, we are investigating the use of the recently developed Cre/lox system (Sauer, 1994) to target single copies of the transgenes to specific sites in the mouse genome, known to be transcriptionally permissive and non-mutagenic (Lasko et al, 1996). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CORTICAL SURFACE AREA & THICKNESS IN HEALTH AND DISEASE Principal Investigator & Institution: Barta, Patrick E. Associate Professor; Psychiatry and Behavioral Scis; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-JAN-2000; Project End 31-DEC-2004 Summary: We propose to explore the neurobiological basis of Down syndrome, schizophrenia, and bipolar disorders using novel methods for measuring cortical neuroanatomy. We will develop and validate methods for measuring surface area, thickness, and thickness distribution of cortical structures, and use these methods in four subject groups: healthy individuals, and patients with Down syndrome, schizophrenia and bipolar disorder. We hypothesize that surface area and thickness measures will be more informative that conventional volume measures, and that patients with Down syndrome will have global cortical deficits. We believe that specific cortical regions will be affected in schizophrenia (heteromodal cortex) and bipolar disorder (entorhinal cortex). Although we focus here on three diseases, we believe that the methods that we will develop would be useful to researchers studying other diseases too. We plan to make our soDware (written in the JAVA language and thus
Studies 29
portable to most popular computers including C's, Mac's and Unix-based systems) available on the laboratory's web site. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CYSTATHIONINE B SYNTHASE AND ARA C THERAPY FOR LEUKEMIA Principal Investigator & Institution: Taub, Jeffrey W. Pediatrics; Wayne State University 656 W. Kirby Detroit, MI 48202 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2006 Summary: The goal of this project is to better understand the biology of acute myeloid leukemia (AML) in Down syndrome (DS) children related to the association of the chromosome 21-localized gene, cystathionine-beta- synthase (CBS) and response to cytosine arabinoside (ara-C)-based therapy. Childhood AML has the worst prognosis of all major childhood cancers with five year relative survival rates of approximately 37%. In contrast, DS children with AML represent an unique group of leukemia patients in view of having significantly higher event-free survival (EFS) rates (70-100% with relapse rates < 15%) compared to non-DS children when treated with ara-C-based protocols. Thus, identifying the biological basis for the extremely high cure rates of DS AML patients can have very important implications and potentially can lead to improvements in AML therapy for all patients. Our previous results have begun to shed light on the underlying mechanisms responsible for the striking increased EFS in DS AML patients. Our results demonstrating i) significantly increased CBS transcript levels in DS myeloblasts and a correlation with in vitro ara-C sensitivity and ara-CTP generation, ii) dramatic increased in ara-C metabolism to ara-CTP in vitro in leukemia cell lines transfected with the CBS cDNA, associated with increased in vitro and in vivo ara-C sensitivity, and iii) significant differences in frequency of the 844ins68 CBS gene polymorphism in DS myeloblasts, provide compelling evidence of an integral relationship between CBS gene expression and ara-C metabolism. This mechanisms is likely a major factor that accounts for the increased chemotherapy sensitivity and high cure rates of pediatric DS AML patients. This study will continue to examine over novel hypothesis and laboratory observations which bridge basic research (e.g., understanding the transcriptional regulation of CBS, determining the relation of CBS mutations/polymorphisms and ara-C metabolism) and apply this work to translational studies using clinical leukemia samples. These findings may ultimately be applied clinically to improve the treatment and cure of AML. The specific aims of the study are: 1) To characterize the transcriptional regulation of the CBS gene in leukemia cell lines and clinical leukemia samples; 2) To develop CBS-transfected AML cell models and to determine the mechanistic basis for the effects of CBS on ara-C metabolism and sensitivity; 3) To determine the relationships between CBS gene expression and ara-C sensitivities in patient myeloblasts with wild-type CBS and with the T833C, G919A, 844ins68 CBS gene variants. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DEFINITION AND DEVELOPMENT OF THE PHENOTYPE IN AUTISM Principal Investigator & Institution: Rogers, Sally J. Professor of Psychiatry; Psychiatry; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, CO 800450508 Timing: Fiscal Year 2001; Project Start 01-JUN-1997; Project End 31-MAY-2002
30 Down Syndrome
Summary: The overall goal of this Program Project is to define more clearly what is both familial and specific in the autism phenotype at three levels of analysis "brain, neuropsychology, and behavior" through a series of converging tests. The Program Project is designed to provide a rigorous set of converging tests of five competing neuropsychological explanations of autism: 1) a basic sensory deficit measured by means of magnetoencephalograph (MEG), 2) a praxis deficit, 3) an affective deficit, 4) an inter-subjectivity deficit, and 5) a deficit in executive functions. The converging tests of the latter four, higher level deficit/s are 1) Does the candidate deficits/appear early in the development of children with autism? (0003) 2) Is the deficit/s specific to autism? (Projects 0002 and 003) 3) Are sib pairs concordant for autism also concordant for the deficit/s? (Project 0002) 4) Is the deficit/s pervasive in the sense that it is part of the familial phenotype? (Project 0002) and 5) Is the deficit/s correlated with the brain phenotype, either at a structural (measured by MRI scans) or functional (measured by MEG) level? To permit this set of converging tests, we are studying the same behaviors and neuropsychological constructs in all the samples across Projects. The samples to be studied are 1) 25 multiplex families with idiopathic autism and 25 Down syndrome control families (Project 0002) 2) 40 adults with idiopathic autism, 40 adults with FXS, 40 adults with developmental disabilities (DD) but neither autism nor FXS, and 40 CA and 30 MA controls (Project 0001); and 3) 25 very young children with idiopathic autism, 25 MA and CA controls with DDs but neither autism nor FXS and 25 typically developing MA controls (Project 0003). In collaboration with Jeanette Holden, we will also test the hypothesis that lowered maternal serum dopamine betahydroxylase (DBH), secondary to allelic differences at the DBH locus, provides a uterine environment which is part of the etiology of autism and autistic features in both idiopathic autism and Fragile X syndrome (FXS). GRNT P01HD354680001 Autism is a devastating developmental disorder with an incidence of approximately 1 in 1,000 live birth. While strongly genetically determined, specific abnormalities remain to be determined, and the clinical picture is sufficiently diffuse to implicate pathology in multiple neural systems. Central to the syndrome is impaired social interaction, a severely restricted range of interests, and abnormalities of attention (a hyper-attentiveness), sensation (usually hyperreactivity). We propose to utilize magnetoencephalographic (MEG) sensory evoked field (EF) data, EEG evoked potential (EP) data, and MRI anatomical data to specifically address early cortical processing of sensory information. We will study 1) 40 high functioning (IQ>50) autistic adults, 2) 40 IQ and age matched FraX patients, 3) 40 age matched MR subjects, and 4) 40 age matched normal adults. We will specifically: 1) Using MEG and EEG, we will quantify reactivity of primary auditory and somatosensory cortex to stimuli of varying intensity; 2) By localizing and quantifying very high frequency (VHF) MEG activity (600 Hz) from primary somato-sensory cortex we will directly measure cortical GABA-ergic inhibitory interneurone activity, which we hypothesize will be deficient in autistic subjects (and correlated with cortical hyperreactivity); 3) Using an MEG auditory EF based goodness of fit metric, we will quantify the ability of autistic subjects to shirt attention from one hemisphere to the other during a binaural auditory oddball task; 4) Using the amplitude of the 100 msec latency auditory EF (termed M100) as a function of auditory interstimulus interval (ISI) we will calculate tau (t), the time constant of the decay of the echoic memory trace, generated in Heschl's gyri. We hypothesize this will be prolonged in autistic subjects, relative to normals, Fra-X or MR groups; 5) Using the EEG EP based metric termed mis-match negativity (MMN) we hypothesize that autistic subjects will demonstrate evidence of an accentuated pre-attentive, automatic cortical feature detection processes; 6) Using and MEG EF metric of auditory cortex MEG alpha suppression during a tonal memory task, we hypothesize that autistic subjects will demonstrate evidence of greater alpha suppression than normals, supporting enhanced should term auditory memory storage,
Studies 31
scanning and retrieval; 7) using high resolution MR images of the brain we will quantify volume and relate MEG EF sources to specific cortical areas to determined is MEG and EEG based functional abnormalities are related to observed anatomical deficits in the cortex generating those signals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHILDREN
DEVELOPMENTAL
PROFILES
OF
WILLIAMS
SYNDROME
Principal Investigator & Institution: Bellugi, Ursula; Research Professor; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2001; Project Start 16-SEP-1985; Project End 31-JUL-2006 Summary: William's syndrome (WMS) is a genetically based syndrome that results in a cognitive profile of peaks and valleys of cognitive abilities in the mature state. We investigate the development of this unusual profile in WMS Children in order to provide clues to alternative theories of language, cognition, and brain organization. Contrasting Development of Language and General Cognition in WMS. Importantly, in the development of first words, WMS and Down syndrome (DNS) children are equally delayed, and it is only as grammar emerges that WMS appear to show an increasing advantage over DNS. We will examine both on- line and off-line measures focusing and dissociations between language and other domains, as well as the development of discourse functions. a) The Intersection of Language and Affect in Discourse. We investigate hyperaffectivity and language in developing WMS children, which may set them apart from other Center populations. b) The Dissociation between Language and Spatial Representation in WMS. Because of their severe spatial cognitive deficit, WMS children provide a special opportunity to probe potential between language and spatial representations. Contrasting Development: The Dissociation between Space and Face Processing in WMS. WMS results in a highly specific impairment in spatial construction. In contrast, face processing shows strength across paradigms. Thus, WMS children provide a powerful vehicle for investigating the developmental separability of functions within the visual domain. Brain Organization in the Developing Child with WMS. We will examine the hypothesis that developmental aspects of language and spatial functions in WMS may be mediated by neural systems that differ in major ways from those in normal populations. We also hypothesize that there may be differential dysfunction in the dorsal as opposed to the ventral stream of visual processing in WMS, addressed vial electrophysiological and functional MRI studies. Comparison of the profiles of developing WMS Children and other Center populations can provide insights into issues of the genetic bases of higher cortical functions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIFFERENTIAL GENE EXPRESSION IN DOWN SYNDROME PLACENTAE Principal Investigator & Institution: Gross, Susan J.; Montefiore Medical Center (Bronx, Ny) Bronx, NY 104672490 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 30-APR-2004 Summary: Pregnant woman are offered multiple marker serum testing for fetal Down syndrome (DS) in the second trimester as routine standard of care. However, serum markers are only a screening tool and not a diagnostic test. Thus, when patients are screen positive, they are offered amniocentesis to confirm the suspicion of fetal DS. These serum markers are nonspecific for DS and, as a result, this test is burdened with a
32 Down Syndrome
significant false positive and false negative rate. Consequently, the vast majority of patients with a positive test will undergo amniocentesis with the real possibility of fetal loss for an unaffected pregnancy. Our hypothesis is that microarray technology available at our center can by used to isolate differentially expressed genes from DS placentae. Our proposed strategy is to apply this high-throughput method of gene expression analysis to identify gene expression changes in placentae from pregnancies affected with Down syndrome, followed by characterization of these genes and their gene products. These findings will form the basis of a subsequent grant submission that will be directed towards the ultimate goal of our placental research program identification and development of specific protein assays for fetal Down syndrome. The specific aim of this current submission is to determine qualitative or quantitative differences in gene expression between DS and normal placentae using microarray chip technology, which will allow for the screening of thousands of genes at once. Differential expression revealed in the microarray studies will be confirmed by Northern blot analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIGITAL VIDEO ANALYSIS SYSTEM FOR HOME CAGE BEHAVIOR Principal Investigator & Institution: Liang, Yiqing; Clever Systems, Inc. 1334 Stokley Way Vienna, VA 22182 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2003 Summary: There is a critical need for automated phenotyping of mutant mouse models that have grown out of recent advances in molecular biology. We propose to meet this need by developing a system for automated scoring of mouse behavior from video records of undisturbed mice in the home cage. Phase I funding resulted in excellent progress on identifying, tracking, and scoring mouse behavior, resulting in 93.5% accuracy in identifying five postures. Phase II funding is requested to extend this system to the entire behavioral repertoire of the mouse in the home cage and refine the algorithms used to identify, track and score mouse behavior with the aim of producing a marketable prototype product. Algorithms for segmenting mouse, tracking its position, identify its posture and behaviors will be developed. The validity of the results will be determined using comparison with human scoring of behavior. The sensitivity of the system will be explored by comparing the results of the prototype systems' analysis of mouse models of Down syndrome, glutaric acidemia (knock- out model) and over expression of purine metabolism genes (GART transgemic) with existing data from other forms of behavioral analysis. The proposed system will produce a major advance in the analysis of behavior and in the ability of investigators to detect novel phenotypes in genetically altered animals. The system will not only provide quantitative data on mouse behavior throughout the daily cycle, but will present the investigator with video clips of novel behaviors that it cannot identify, thus allowing the investigator to see abnormalities in behavior. The system will be efficient enough to be realized with readily available video and computer hardware. The team assembled for this project consists of computer scientists, experts in mathematical modeling, and an expert in mouse behavior has worked well together in Phase 1 and is uniquely prepared to succeed with this project. PROPOSED COMMERCIAL APPLICATION: This proposed research will not only create enormous benefits for the neuroscience and behavior research community including medical research institutes, universities, pharmaceutical companies, and hospitals and clinics who are conducting behavior study and analysis. But also find applications in the entire area of biology will be interested in the system to help them conduct research in such areas as genetic research, cancel research, HIV
Studies 33
research, etc. It can be applied to human-computer interface and surveillance and monitoring areas. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DOWN SYNDROME NEUROGENESIS AND COGNITION--GENES AND FUNCTION Principal Investigator & Institution: Korenberg, Julie R. Professor; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001 Summary: Down Syndrome (DS) is the major recognized cause of genetic mental retardation (MR) and affects the welfare of more than 300,000 individuals in the United States Alone. The brains of individuals with DS, although not grossly abnormal at birth, develop microcephaly with decreased size of the prefrontal cortex and cerebellar vermis, and show characteristic subtle abnormalities that include regression and distortion of the dendritic tree and spines, defective lamination of the cortex, and abnormal synapses. The ultimate goal of the research described in this proposal is to began to define the cause of these defects by elucidating the pathways between genes and cognition in Down syndrome and providing models in which to ameliorate them. In the past 5 years, a powerful arrays of tolls has been developed including chromosome 21 genes, the DS phenotypic map, and mouse models of DS. As a first step in identifying a subset of genes that are critical for the neuroanatomic and functional defects of DS, a consensus region for a part of DS mental retardation was generated by this component, and a dense contiguous array of clones covering more than 4 Mb of two critical regions was constructed, one homologous to MMU16 and the other to MMU10. We have isolated and characterized human and mouse gene homologs from these regions that are expressed in the human brain. These genes include DS-CAM, encoding a novel member of neural cell adhesion molecules, responsible for morphogenesis and function of the vertebrate brain. Expressed specifically in the nervous system, it occupies 10-15% of the entire candidate region, and it is a strong candidate for some subtle structural and cognitive defects of DS; PEP19, a peptide expressed only in the post-natal cerebellum and retina; CHD1, highly expressed in fetal brain and brown fat; hPWP2, a yeast homolog responsible for cell separation;TMEM, a large, ubiquitous transmembrane protein. We propose four aims: I. To characterize chromosome 21 gene expression in the brains of Down syndrome and controls during pre and post-natal development using Northerns, tissue in situ hybridization and immunocytochemistry. Genes will include DS-CAM, CHD1, hPWP2, PEP-19 and TMEM-1. II. To characterize mouse gene expression of human 21 homologues in normal, Ts65Dn and Cre-Lox mice with the appropriate duplications, using immunohistochemistry and tissue in situ hybridization. III. To construct transgenic and knockout mice using chromosome 21 genes expressed in the human brain. IV. To analyze transgenic and knockout mice in Aim III for general and neuroanatomy, gene expression and behavior. These models will provide clues to brain morphogenesis and cognition in DS and in normal developments as well as providing models in which to test strategies for treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DOWN SYNDROME, MITOCHONDRIAL DNA AND OXIDATIVE STRESS Principal Investigator & Institution: Sinha, Santosh K.; Brain Insights, Inc. 17595 Harvard Ave, Ste C-173 Irvine, CA 92612
34 Down Syndrome
Timing: Fiscal Year 2001; Project Start 10-JUL-2000; Project End 30-JUN-2005 Summary: (Verbatim from the Applicant's Abstract) Human chromosome 21 (HC21) harbors genes which is believed to be associated with a number of neurological diseases, including amyotrophic lateral sclerosis (ALS 1), familial Alzheimer disease (FAD), and Down syndrome (DS). Among these, DS constitutes the most common disease resulting from partial or total trisomy of HC21. DS is characterized by a number of pathological consequences the most important of which result in precocious aging often accompanied by signs of Alzheimer disease (AD). Several early observations indicated that a small HC21 segment (Down syndrome critical region or DSCR) containing a restricted number of genetic elements may be responsible for most of the Down symptoms. Other regions of HC21 and even some genes present on heterologous diploid chromosomes may also contribute to the complex phenotype of DS either through compensatory or additive interactions. This is presumed to be especially true for genes which code for antioxidant enzymes and which are dispersed throughout the nuclear genome. This has particular relevance in view of the fact that trisomy of HC21 leads to an overexpression of at least two enzymes which are implicated in the production and metabolism of reactive oxygen species (ROS), viz., superoxide dismutase (SOD I) and carbonyl reductase (CBR). In the absence of compensatory support from other antioxidant genes located on heterologous chromosomes (such as glutathione peroxidase and catalase genes), trisomy of HC21 may lead to an accumulation of highly reactive hydroxyl radicals which could severely damage the functional integrity of the cell. One important consequence of such a situation would be lesions in mitochondrial DNA that is especially vulnerable to oxidative injury. The major goals of the present project are to (A) examine the interactions between some of the the key genes of trisomic CH21 and other chromosomal genes, and (B) to verify if antioxidants such as coenzyme Q, vitamin E and ascorbic acid, individually or in combination, could play a positive role in at least partially restoring the normal functioning of trisomic HC21 cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SEGREGATION
DROSOPHILA
GENES
AFFECTING
CHROMOSOME
Principal Investigator & Institution: Goldberg, Michael L. Professor; Molecular Biology and Genetics; Cornell University Ithaca Office of Sponsored Programs Ithaca, NY 14853 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 31-MAR-2005 Summary: (Applicant's Abstract): Mistakes in chromosome segregation during meiosis or mitosis can lead to spontaneous abortion or to abnormalities such as Down syndrome, They have also been implicated in the genetic progressions leading to cancer and aging. Our laboratory studies several genes in Drosophila that are required for proper chromosome segregation. We believe that this organism offers important advantages in genetics, genomics and cytology that provide unique opportunities to investigate chromosome behavior and cell cycle progression during cell division. We first focused on an evolutionarily conserved gene called zwlO. Mutations in zwlO not only disrupt chromosome segregation, but they also prevent the operation of the spindle assembly checkpoint that regulates anaphase onset. The ZW1O protein displays an unusual, dynamic pattern of localization during the cell cycle, moving between chromosomal kinetochores and kinetochore microtubules. We found that this pattern is influenced by bipolar tension across individual chromosomes. We also discovered that ZW1O is part of a large protein complex, one of whose activities is to target the molecular motor dynein to the kinetochore. The first specific aim describes further
Studies 35
investigations on ZW1O.We will use real-time video microscopy to characterize the distribution of a ZW1O-GFP fusion protein during the cell cycle. We will determine which domains of ZW1O are required for various aspects of its intracellular distribution and function. We will analyze double mutant combinations to position ZW1O in the biochemical pathways underlying the spindle checkpoint and other aspects of anaphase onset. We will also test whether all aspects of the zw10 mutant phenotype, including its effects on the spindle checkpoint, are caused by the absence of dynein at the kinetochore. The second specific aim is to characterize biochemically and genetically the large complex of which ZW1O is a part. Preliminary efforts to purify the complex by affinity chromatography have been promising. We will use several techniques to verify the association of candidate proteins with ZW1O. We will then identify these proteins by mass spectrometry, and will determine whether they are subject to post-translational modification. Our ultimate goal is to obtain antibodies against these proteins, as well as mutations in the genes encoding them. The third specific aim will exploit our identification in the previous funding period of a set of new mutations that cause precocious sister chromatid separation, aneuploidy, or metaphase arrest in Drosophila. We will study the phenotypes associated with these mutations in more detail, clone selected mutant genes, and then investigate the intracellular location of the corresponding gene products. Because we are focusing on genes not previously known to function in any aspect of mitosis, we believe the genetic and antibody reagents obtained by the proposed studies will provide a broadened and unique view of the events occurring at anaphase onset. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DYRK TRANSGENIC MICE AS A MODEL FOR DOWN SYNDROME Principal Investigator & Institution: D'arcangelo, Gabriella; Pediatrics; Baylor College of Medicine 1 Baylor Plaza Houston, TX 77030 Timing: Fiscal Year 2001; Project Start 01-APR-2000; Project End 31-MAR-2003 Summary: (adapted from applicant's abstract) Down Syndrome is the most common genetic disease associated with mental retardation, affecting about 1 in every 800 live births. The syndrome results from triplication of chromosome 21 or a segment of it, and it includes facial abnormalities, heart disease, increased frequency of leukemia, earlyonset Alzheimer's disease and mental retardation. The latter is associated with decreased neuronal number and reduced complexity of neuronal processes in many regions of the brain. The entire spectrum of Down Syndrome abnormalities likely results from overexpression of several genes located in a critical region on chromosome 21q22.2, and it is thus a complex trait. However, individual aspects of the syndrome may be attributable to one or few genes. Recently, the human homologue of Drosophila minibrain, also known as Dyrk, has been mapped to the Down Syndrome critical region. Mutant minibrain flies have a reduced number of brain cells, suggesting that the mutated gene encodes a protein involved in neurogenesis. Mammalian Dyrks are dual specificity protein kinases with extensinve similarities to Drosophila Minibrain and to the yeast Yak1 protein kinase involved in cell division. Injection of a YAC containing genomic sequences including the Dyrk gene in transgenic mice causes altered neurogenesis and cognitive impairment, suggesting that Dyrk is involved in the brain abnormalities associated with Down Syndrome. To understand whether Dyrk plays a role in the developmental neuropathology underlying the mental retardation aspect of Down Syndrome, the investigators plan to first analyze in detail the normal pattern of expressionand activity of Dyrk in the developing mouse brain. Second, they will create transgenic mice that transiently and specifically express elevated levels of Dyrk in the
36 Down Syndrome
proliferative zone of the developing brain. Finally, they will analyze in detail the brains of these mice to ascertain whether reduction in the number of neuronal cells, or other defects reminiscent of Down Syndrome, have occurred as a result of Dyrk overexpression in the brain during the period of neurogenesis. Their transgenic mice may serve as a novel animal model to investigate the molecular basis of mental retardation in Down Syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EARLY DEVELOPMENT: WILLIAMS OR DOWN SYNDROME CHILDREN Principal Investigator & Institution: Mervis, Carolyn B. Distinguished University Scholar and Pro; Psychological and Brain Sciences; University of Louisville University of Louisville Louisville, KY 40292 Timing: Fiscal Year 2001; Project Start 01-MAR-1993; Project End 31-MAY-2004 Summary: The general objective of the proposed research is to delineate the developmental relations between language and cognition. The research will focus on early linguistic and cognitive development by three groups of children: children with William syndrome, children with Down syndrome, and normally developing children. Previous researchers have argued that children with Williams syndrome have language skills that exceed their cognitive skills, whereas children with Down syndrome have cognitive skills that are more advanced than their language skills; in general, normally developing children have equivalent levels of linguistic and cognitive skills. Because of the differences in the general nature of the relations between language and cognition for the three populations, inclusion of all three in a single study provides a unique opportunity to investigate the universality or non-universality of specific relations among language and cognition. The proposed research consists of a five year longitudinal study with supplemental studies conducted at specific points in development. Both observational and experimental methodologies will be used. There are four specific objectives. First, a series of general and specific relations between language and cognition will be examined. Second, the reference of children's earliest words will be explored, using observational, quasi- experimental, and experimental procedures. Third, the development and use of lexical operating principles by children with mental retardation will be considered. Finally, general issues of development by children with Williams syndrome and Down syndrome will be addressed. The research will have implications both for theoretical models of the relation between language and cognition and for the design of early cognitive and language intervention for children with developmental disabilities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EPIDEMIOLOGY OF DOWN SYNDROME--LEUKEMIA & DOWN SYNDROME Principal Investigator & Institution: Ross, Julie A. Associate Professor; None; University of Minnesota Twin Cities 200 Oak Street Se Minneapolis, MN 554552070 Timing: Fiscal Year 2001; Project Start 25-SEP-1997; Project End 30-JUN-2004 Summary: The environmental aetiology of Down syndrome (DS) is largely unknown. DS children are at nearly a 20-fold increased risk of developing leukemia compared to children in the general population. Trisomy 21 is also one of the most common acquired cytogenetic abnormalities in childhood leukemia. Thus, constitutional trisomy 21 may represent a first genetic event in the development of leukemia. Since only 1% of DS
Studies 37
children ever develop leukemia, subsequent environmental exposures could be responsible for frank leukemia in this population. The proposed investigation will include: 1) children with DS, under the age of 19, diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), identified through the CCG; 2) children with DS, under the age of 19, frequency-matched by geographic region, age, and race to DS-leukemia cases; and 3) random-digit dialing (RDD) selected regional controls. The proposed case-control studies will include parental interviews, collection of cytogenetic and morphologic data, and medical record validation. In the first casecontrol study (DS-leukemia compared to DS without leukemia) the plan is to determine whether children with DS and leukemia share similar risk factors reported to be associated with childhood ALL and/or AML including maternal alcohol exposure during pregnancy, specific parental occupational exposures, maternal history of prior fetal loss, preconceptional and in utero exposure to X rays. Other potential risk factors will also be explored that may be unique to this case group, including childhood medical exposures, frequency of exposure to infections, vitamin supplementation, and maternal diet during pregnancy. In the second case-control study (DS compared to normal population), the plan is to investigate potential risk factors for DS, as epidemiologic investigations concerning the environmental aetiology of DS are limited. Specifically, the following risk factors, based on previous study findings, will be addressed: parental occupations and occupational exposures, parental smoking and alcohol use, prior use of specific contraceptives, family history of Alzheimer's disease, and parental preconception exposure to x-rays. The proposed study would utilize resources available through the CCG and would include: 1) 152 DS-leukemia cases diagnosed over a five-year period from 1/1/97 through 12/31/01 by the CCG; 2) 304 frequency-matched DS controls; and 3) 304 frequency matched RDD controls. It is claimed that each case-control study has adequate statistical power to address the hypotheses being explored. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EPIDEMIOLOGY OF MENOPAUSE AND DEMENTIA IN DOWN SYNDROME Principal Investigator & Institution: Schupf, Nicole; Institute for Basic Res in Dev Disabil Developmental Disabilities New York, NY 10314 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-MAR-2003 Summary: An epidemiologic study is proposed to test the hypothesis that reductions in estrogen, indicated by onset of menopause, are associated with onset of Alzheimer's disease (AD) in women with Down syndrome (DS). We further hypothesize that this association will be stronger in women who are genetically susceptible to AD because they carry the apolipoprotein E (apoE) epsilon4 allele. Prior studies in the general population suggest that declines in estrogen levels following menopause play an important role in the etiology AD and that the presence of the apoE epsilon4 allele is associated with earlier age at onset and increased risk of AD. The relationships between onset of menopause, apoE and onset of AD are difficult to study in women in the general population because of the extended time period between menopause and onset of AD. In contrast, women with DS have a very high risk of AD, with an average age at onset of AD between 50-55 years, 10-15 years earlier than in the general population. Thus, women with DS experience onset of AD more closely in time to onset of menopause than is typical in the general population, providing a unique cohort in which to study the relationship between menopause and AD. We hypothesize that earlier age at menopause will be associated with earlier age at onset of AD. We propose
38 Down Syndrome
a 5-year longitudinal study of incident dementia in 350 women with DS, 45-52 years of age, followed at 18 month intervals. We will ascertain age a menopause by chart review, as menstrual cycles are regularly charted in nursing notes. We will supplement this measure with assays of reproductive hormones at each assessment. We will assess declines in cognitive and adaptive competence indicative of AD using a uniform neuropsychological test battery and neurological examination of those suspected to be affected and a sample of those not suspected, with ascertainment of other medical or psychiatric conditions that might cause dementia. We will use standardized criteria for dementia and the differential diagnosis of AD. We will determine DS karyotypes and apoE genotypes. The results of this study will provide important information about the role of estrogen in the etiology of AD and the optimal strategy for the development of clinical trials of hormone replacement therapy in women with DS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ERP/MRP INDICES OF EARLY DEVELOPMENT IN INFANTS W/DS Principal Investigator & Institution: Hill Karrer, Jennifer; R L Smith Mental Retard Center; University of Kansas Medical Center Msn 1039 Kansas City, KS 66160 Timing: Fiscal Year 2001; Project Start 15-MAR-2000; Project End 28-FEB-2005 Summary: During the first 12 months of development in human infancy, the emergence of cognitive and the emergence of motor skills are interconnected. These skills are subsequently applied to most domains of development, including language. Thus, cognitive and motor skills to be achieved during early infancy serve as an essential based for developmental outcome. However, cognitive, linguistic and gross motor domains express the fewest and least consistent gains actualized through early intervention for individuals with Down syndrome (DS) (Connolly et al., 1993; Gibson and Harris, 1988; Piper et al., 1986). It is the working hypothesis of this project that most phenotypic expressions of DS are first actualized as atypical cognitive and motor development during the first year of life. Accordingly, this research project will investigate brain-behavior relationships during cognition and movement among infants with DS that are 1 to 12months of age. Neural measures of attention, stimulus encoding, learning, memory and movement preparation will be recorded in both cross-sectional and longitudinal studies. Results will, for the first time, provide new knowledge concerning brain-behavior relationships during early cognitive and motor development. A group of infants without known risk of developmental difficulties (matched on age, sex and SES) will serve as a comparison group to provide sensitive examination of neurobehavioral expressions in the dysfunction of the nervous system due to DS genetic status. Moreover, characterization and evaluation of the impact of Trisomy-21 upon cognitive and motor functions will be observed before confounding impacts of language impairments are manifested in the development of an individual with DS. At the conclusion of the 5-year project, application of brain-behavior measures in establishing developmental trajectories of cognitive and motor skills will provide new and sensitive methodologies to assess developmental status and, accordingly, the effectiveness of early intervention Thereafter, application of such techniques may provide the foundation for subsequent specialization and refinement of early intervention, particularly with respect to cognitive and motor abilities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 39
•
Project Title: SYNDROME
EXERCISE
ADHERENCE
AMONG
ADULTS
WITH
DOWN
Principal Investigator & Institution: Heller, Tamar; University of Illinois at Chicago 1737 West Polk Street Chicago, IL 60612 Timing: Fiscal Year 2001 Summary: Project aims are a) to test the efficacy of a physical exercise program for adults with Down syndrome and b) to test the applicability of the transtheoretical model and social cognitive theory for predicting long- term adherence to enhanced physical activity in this population. It will also test the effects of a health promotion program on their physiological, adaptive behavior, and psychosocial outcomes. The design includes three randomized groups (n=36 per group): control and two intervention groups. Both intervention groups will received a 12-week center-based group exercise and education program offered at the Institute on Disability and Human Development's Center on Health Promotions for Persons with Disabilities. Only one of the intervention groups will receive the caregiver education programs. The project objectives are the following: 1. Test the efficacy of the exercise and education program for older adults with Down syndrome immediately following the program and in four six month intervals after the program is completed. The Exercise program is geared to increase cardiorespiratory fitness, muscle strength, and endurance. The education program for the adults with Down syndrome aims to increase knowledge of exercise benefits and to increase perceived exercise self-efficacy. 2. Assess the long-term benefits of a caregiver (family or vocational and residential staff) education training program geared to help caregivers support adherence to an exercise program. Outcomes assessed to four six month intervals following the program includes exercise adherence, physiological functioning, adaptive functioning, and psychosocial functions of the adult with Down syndrome. 3. Determine predictor variables associated with exercise adherence in the short and longer term (immediately after the training and in four six month intervals after the training)> Predictor variables include level of disability, age, type of residence, and exercise decisional balance (balance of perceived gains and losses and exercise self-efficacy of the adult with Down syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EXPLORING HIPPOCAMPAL FUNCTION IN DOWNS SYNDROME Principal Investigator & Institution: Stedron, Jennifer M. Psychology; University of Denver Box 101562 Denver, CO 80208 Timing: Fiscal Year 2002; Project Start 08-JAN-2002 Summary: (provided by applicant): The proposed research is designed to assess hippocampal function, as characterized by a computational theory of the hippocampus, in children with Down syndrome (DS). The tasks used to assess function are motivated by the hypothesis that the hippocampus is best distinguished as a fast encoder of conjunctive stimuli. This fast, conjunctive theory is supported by both behavioral evidence and a neural network model that incorporates known properties of hippocampal neuroanatomy and physiology. It is hypothesized that a new, hippocampal version of the Eyeblink Classical Conditioning Task (HECC) designed for the proposed studies, will isolate hippocampal function in accordance with the theory and thus is well-suited to assess children with DS. While both toddlers and adolescents with DS and DS mouse models have shown deficits in various tasks thought to tap hippocampal function, these results may be misleading because past tasks also heavily recruit other brain areas that may be impaired in DS, such as the prefrontal cortex or
40 Down Syndrome
areas related to expressive language. Thus, the HECC will provide more conclusive evidence concerning hippocampal function in this population. It is hypothesized that children with DS and a control group will perform similarly on a delay version of the Eyeblink Classical Conditioning Task (DECC) that taps cerebellar function, but will show performance differences on the HECC. In addition, an analysis of the hypothesized performance deficits will be conducted through a neural network model that incorporates neuroanatomical and physiological abnormalities known to be present in DS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FAMILIAL PHENOTYPE IN AUTISM Principal Investigator & Institution: Landa, Rebecca; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, CO 800450508 Timing: Fiscal Year 2001 Summary: The overall goal of this project is to test both what is familial and what is specific about the idiopathic autism phenotype (IAP) at two levels of analysis: the symptom and neuropsychological levels. Previous research has identified social and/or language abnormalities in non-autistic first- degree relatives of probands with autism, which is referred to her as the Familial Autism Phenotype (FAP). This Project builds on that previous work and will specify in more detail the nature of the language abnormality in the FAP. However, neither the full range of symptoms nor all the underlying neuropsychological deficits founds in the IAP have been tested in nonautistic relatives, so that both the boundaries of the FAP and its similarity to the IAP remain unclear. It is also unclear which aspects of the FAP and the IAP are specific to autism and not found in other, even closely related developmental disabilities. This project will attempt to close these gaps in existing knowledge by comparing first degree relatives of autistic sib pairs with 1) first degree relatives of Down syndrome (DS) children, 2) females with fragile X syndrome (FXS) from Project III. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FAMILY EFFECTS ON SOCIAL OUTCOMES FOR CHILDREN WITH MR Principal Investigator & Institution: Floyd, Frank J. Professor of Psychology; Psychology; Georgia State University University Plaza Atlanta, GA 30303 Timing: Fiscal Year 2001; Project Start 24-SEP-1998; Project End 31-MAY-2003 Summary: Children with mental retardation experience social rejection and isolation; however, there is little information about how families can facilitate their children's social competence and social participation out of the home. This investigation will examine family facilitation of social outcomes in two groups of school age children with mild and moderate mental retardation: a representative sample who do not have Down syndrome (n=60), and a group of children with Down syndrome (n=60). Two comparison groups of school age children also will be evaluated: families of children with learning disabilities (n=60) who are at high risk for social rejection and families of typically developing children (n=60). Three forms of family facilitation will be investigated: indirect facilitation through family interactions that either teach and promote social competencies or lead to social deficiencies, coping assistance strategies to help children manage social problems and direct facilitation through active orchestration of children's social activities. The study will evaluate mothers and fathers and siblings roles in family facilitation using in-home observations and semi-structured
Studies 41
interviews with families. Social competence for the target child will be comprehensively evaluated with observations and parent, teacher, and child reports of social behaviors and adjustment at home and at school. Multiple informants will report on social participation and peer relationships and the children's social-cognitive functioning will be directly assessed. The investigation will employ an overlapping cohort design to evaluate longitudinal changes in family facilitation processes, children's social outcomes, and the associations among these factors. Initial assessments will be conducted when the children are 8 to 10 years old, and all children will be followed through age 11. The families will complete yearly follow-up sessions for 2 to 3 years, and the children's social behaviors and experiences at school will be assessed at 6 month intervals. Hierarchical linear modeling will be used to evaluate linear and non-linear growth trends at the individual and group level, and will examine group differences in both the slope and the shape of changes across time. The analyses will examine hypotheses regarding three general mechanisms which propose that a) the quality of family interactions will influence children's social skills and behavioral adjustment, which in turn will influence their social outcomes; b) both family interactions and family assistance in coping with social rejection will influence the children's social-cognitive functioning; and c) direct efforts by families to arrange and monitor peer activities will be important techniques to promote social participation and acquisition of social skills for children who have disabilities. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FAMILY DIMENSIONS
EXPERIENCE
OF
GENETIC
TESTING:
ETHICAL
Principal Investigator & Institution: Vanriper, Marcia L. None; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-AUG-2003 Summary: (from applicant's description) Genetic testing is becoming more widely applied. Nurses will be offering, reporting results, and interpreting genetic tests to families; in addition they will be caring for families dealing with the complex personal, social, and ethical issues associated with genetic testing. There is little research available to guide practice in this area. The candidate proposes a study combining qualitative and quantitative methods to explore how families define, manage, and reason about the ethical issues that emerge during four different types of genetic testing (triple marker screening for Down syndrome, carrier testing for cystic fibrosis, mutation analysis for Huntington disease [HD], and BRCA1 testing for cancer risk). The Family Management Style (FMS) Model will guide the study. There are 6 specific aims. Numbers 1 and 2 are related to family member's definition, management, and reasoning about moral issues. Number 3 involves comparison of family members from the same family. Number 4 concerns how responses differ according to the type of test. Number 5 involves description of distinct family management styles of decision-making. Numbers 6 is designed to explore management style and psychological well being of the tested family member. Participants will be members of 40 families (10 from each of the four types of testing). Inclusion criteria include having undergone one of the 4 selected genetic tests or being a family member of such a person. The term family is defined and members are self identified. Families will only be studied if both the tested member and at least one other family member agree to participate. An interview guide will be developed based on the FMS model, the literature on genetic testing, clinical experience of the investigator, and Rest's work on moral judgement. The Defining Issues Test (DIT) will be used to assess patterns of moral reasoning. The tested family member also will
42 Down Syndrome
complete Ryff's measure of psychologica well being, and the POMS to measure psychological distress. Data will be analyzed following guidelines and techniques of Knafl and Ayers, Knafl and Webster, Miles and Huberman, and Patton. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FEASIBILITY OF PRENATAL SCREENING FOR SLO SYNDROME Principal Investigator & Institution: Haddow, James E. Vice President and Medical Director; Foundation for Blood Research Box 190, 69 Rte 1 Scarborough, ME 04070 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2004 Summary: This study aims to evaluate the efficacy of routinely identifying Smith-LemliOpitz Syndrome (SLOS) prenatally. This serious inherited metabolic disorder (birth prevalence 1:20,000) is characterized by moderate to severe mental retardation and congenital anomalies. Two circumstances now make it possible to carry out the proposed intervention trial. First, the cause of SLOS is now known to be a defect in the conversion of 7-dehydrocholesterol to cholesterol. This discovery makes it possible to confirm the diagnosis biochemically by measuring cholesterol precursors in the serum of affected individuals and in amniotic fluid. Secondly, the array of maternal serum analytes currently measured routinely to screen for Down syndrome in 2,000,000 U.S. pregnancies annually includes unconjugated estriol (uE3). This analyte requires cholesterol as a precursor, and its concentration in maternal serum is lower when the fetus has SLOS. The major barrier to identifying SLOS prenatally is the absence of sound screening methodology that takes into account the detection rate, the false positive rate, and the prevalence. The investigators have developed a model, based on actual data from SLOS pregnancies, and propose to test it in 1,000,000 pregnancies in which maternal serum uE3 (and other) measurements are currently being done routinely. The screening false positive rate is projected to be 0.2 percent, the detection rate 57 percent, and the odds of being affected given a positive result 1:70. These rates all compare favorably with routine prenatal screening tests. Diagnostic testing in amniotic fluid is highly reliable and will correctly identify the affected and unaffected pregnancies. In the proposed trial, the investigators will introduce this SLOS model into several major U.S. prenatal screening centers, and develop informational materials for both physicians and patients. Diagnostic testing will be provided by participating expert laboratories. It will also be possible, for the first time, to determine whether SLOS diagnostic studies can be carried out in maternal urine, rather than amniotic fluid, thereby avoiding invasive procedures. The study will also aid in refining prevalence estimates by race and ethnicity, and will determine whether several rare disorders in the cholesterol biosynthetic pathway would be detectable. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FUNCTION OF MAMMALIAN SINGLE MINDED GENES, SIM1 AND SIM2 Principal Investigator & Institution: Fan, Chen-Ming; Carnegie Institution of Washington, Dc 1530 P St Nw Washington, DC 20005 Timing: Fiscal Year 2001; Project Start 01-MAY-1998; Project End 30-APR-2003 Summary: (adapted from investigator's abstract): The goal of this proposal is to investigate the function of mammalian Sim1 and Sim2 genes using transgenic mouse models. Sim1 and Sim2 are homologues of the Drosophila sim (singleminded) gene. In the fly, sim plays essential roles in the development of the central nervous system. Preliminary studies of the mouse Sim genes strongly suggest evolutionarily conserved
Studies 43
functions. The SIM proteins contain conserved sequence motif termed the PAS domain, which is hared by several environmental sensor proteins such as the Dioxin receptor, the Hypoxia Inducible Factor, the Drosophila circadian rhythm regulator Per, and the B. subtilis sporulation regulator KinA. This information strongly indicated that SIMs may also respond to specific environmental signals via their PAS domains. This proposal includes the following aims: 1) documenting the expression patterns of Sim1 and Sim2 in detail; 2) establishing mouse models lacking Sim1 and Sim2 gene function by homologous recombination and characterizing mutant phenotypes in order to assess the normal function of these genes, and 3) identifying possible small molecule ligands that modulate the function of Sim1 and Sim2. Importantly, the mouse Sim2 gene is located in the syntenic human Down syndrome critical region. Furthermore, mutant mice lacking Sim1 display neurological disorders that may relate to multiple sclerosis. Exploration and identification of possible small ligands that regulate Sim1 and Sim2 function will be the first step towards developing methods to alter their gene activities in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE ISOLATION AND FUNCTIONAL ANALYSIS OF 21Q11-21 RELATING TO DOWN SYNDROME Principal Investigator & Institution: Kao, Fa-Ten; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001 Summary: The overall aim of this sub-project focuses on gene isolation and molecular analysis of the proximal half of the long arm of human chromosome 21 including 21q1121, a region under-exploited but associated with mental retardation of individuals with Down Syndrome. The specific objectives are: (1) Isolation, characterization and sequencing of unique sequence microclones from microdissection libraries constructed specifically for the 21q11-21 region; (2) Homology analysis between the unique copy microclones and know genes or cDNAs; (3) refined regional mapping of microclones within 21q11-21; (4) comparative mapping between 21q11-21 and the mouse genome; (5)methylation analysis of 21q11-21; (6) chromatin condensation analysis of 21q11-21 during interphase; (7) isolation and characterization of CDNAS from 21q11-21; (8) gene expression analysis using demetylation strategies; (9) study of the genomic structure and organization of 21q11-21 relating to its function and regulation; (1) analysis of genes and cDNAs identified in 21q11-21 for possible involvement in cognitive-neural developmental deficits in mental retardation. Promising progress towards most of these objectives have already been made to demonstrate that the 21q11-21 region indeed have genes which may be important to Down syndrome. These studies also showed that 21q11-21 has unique structures which may be crucial to the regulation of the genes residing in this region. Thus, gene isolation and better understanding of the regulation and expression of 21q11-21 should be important to the unraveling of the etiology of mental retardation in Down syndrome and for possible early intervention of this devastating pathology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENES FOR KERATOCONUS AND OCULAR FEATURES IN TRISOMY 21 Principal Investigator & Institution: Bergwerk, Katherine L.; Cedars-Sinai Medical Center Box 48750, 8700 Beverly Blvd Los Angeles, CA 90048 Timing: Fiscal Year 2001; Project Start 01-SEP-2000; Project End 31-AUG-2005
44 Down Syndrome
Summary: This application for a Mentored Patient-Oriented Clinical Scientist Development Award (K23) seeks support for Katherine Bergwerk, MD, a staff ophthalmologist at Cedars-Sinai Medical Center (CSMC), who recently completed a Clinical fellowship in Ophthalmic Genetics at CSMC and U.C.L.A.'s Jules Stein Eye institute. Under the mentorship of Julie R. Korenberg, MD, PhD, and Yaron S. Rabinowitz, MD, Dr. Bergwerk will pursue investigation of gene loci for keratoconus and other ocular abnormalities in patients with partial trisomies and tetrasomies of chromosome 21. Identifying a gene for keratoconus may allow for early detection of the disease and may enable medical therapy to be developed to retard its progression. This will obviate the need for the current therapy of multiple complex contact lens fittings or corneal transplantation surgery. Keratoconus is a major cause of visual disability and one of the leading causes for penetrating keratoplasty in the United States. In the process of completing comprehensive ocular examinations on these rare patients for keratoconus, attempts will be made to make genotype-phenotype correlations of other eye abnormalities in patients with Down syndrome. Dr. Rabinowitz is a prominent researcher in the field of ophthalmic genetics, who has established a candidate region for a keratoconus gene locus. This region is a 5.4 centimorgan (cM) region which is 11 cM distal to the centromere on the long arm of chromosome 21 (see appendix A). Review of the literature suggests that keratoconus may occur as much as 300 Xs more commonly in Down syndrome patients than in the general population. Dr. Korenberg is a renowned molecular geneticist who has served on the Human Genome Project for defining genes on Chromosome 21. Her unique population of partial trisomy Down syndrome patients are the ideal group to use in refining a gene locus for keratoconus and to make genotype- phenotype correlations of ocular features of Down syndrome. Under Dr. Rabinowitz and Dr. Korenberg's mentorship and with institutional support from the Divisions of Medical Genetics and Ophthalmology at CSMC, Dr. Bergwerk will further her training in clinical genetic research, and enhance her skills in clinical and molecular genetics. Dr. Bergwerk aspires to achieve her goal of becoming an independent investigator who is capable of solving clinical problems in a research laboratory. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENES, ANEUPLOIDY AND MAMMALIAN DEVELOPMENT Principal Investigator & Institution: Gearhart, John D. Professor; Gynecology and Obstetrics; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-APR-1989; Project End 30-JUN-2004 Summary: Down Syndrome is the most common known genetic cause of mental retardation. The major goal of this program is to understand the genetic and biologic bases of mental retardation in Down Syndrome. Building on the increasing large body of information on Down Syndrome, from the genetics to the clinical features, this program utilizes recombinant DNA technology, comparative genetics, and animal models in attempts to identify and characterize the genes involved in the Syndrome, particularly those producing the neurobiological and cognitive deficits. Also, utilizing some of the animal models, neuropharmacological interventions are proposed in attempts to ameliorate the learning and memory deficits that have been demonstrated in these animals. These animal-based efforts will ultimately lead to therapies for the neurobiological and cognitive deficits characteristic of Down Syndrome. Finally, we propose a new study combining cytogenetic, molecular and epidemiological approaches to address factors that may predispose to non-dysfunction of chromosome 21 and the genetic basis of the phenotypic consequences of an additional chromosome 21.
Studies 45
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC MODIFIERS OF ALZHEIMER'S DISEASE ANIMAL MODELS Principal Investigator & Institution: Lamb, Bruce T. Assistant Professor; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001 Summary: Alzheimer's disease (AD), the most common cause of dementia in the elderly, is now the fourth major cause of death in the developed world after heart disease, cancer and stroke. AD is strongly influenced by genetics, with current estimates suggesting that greater than 40% of all AD cases are familial (FAD). Genetic investigations have demonstrated that AD is a heterogeneous disorder with several known etiologies including: dosage imbalance for chromosome 21 as occurs in Down syndrome (DS); mutations in the amyloid precursor protein (APP) gene on chromosome 21, the presenilin-1 (PS-1) gene on chromosome 14 and the presenilin-2 (PS-2) gene on chromosome 1 in autosomal dominant early-onset FAD; and inheritance of distinct alpha-2 microglobulin and apolipoprotein E (ApoE) gene alleles on chromosome 12 and 19, respectively, as significant genetic risk factors for late-onset FAD. Additional genetic risk factors for AD are certain to exist. A pathologic hallmark in the brains of individuals with AD is deposits of the beta- amyloid (Abeta) peptide in the parenchyma of amygdala, hippocampus and neocortex. One of the major difficulties in studying the mechanism(s) of Abeta deposition and its impact on AD-related neuropathology, behavior and physiology is the paucity of accurate animal models. To establish an accurate genetic model for AD, we have focused on introducing entire genomic copies of either wild-type (wt) or mutant human APP and PS-1 genes carried on yeast artificial chromosomes (YACs) into the mouse germline and have recently demonstrated that a threshold into the molecular and mechanisms of the disease. The specific aims of the current proposal are to examine the effect of specific human AD genetic risk factors, namely dosage imbalance for genes on chromosome 21 (in the Ts65Dn mouse model of DS) and the various ApoE alleles (in ApoE knock-in mice), across the lifespan of APP YAC transgenic mice on: 1) Localization and timing of Abeta deposition and other structural neuropathology. 2) Learning and memory deficits characteristic of individuals with AD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC RISK FACTORS FOR HYPERHOMOCYSTEINEMIA Principal Investigator & Institution: Gravel, Roy A. Professor of Cell Biology & Anatomy And; University of Calgary 2500 University Dr Nw Calgary, Timing: Fiscal Year 2002; Project Start 01-AUG-1997; Project End 30-NOV-2006 Summary: (provided by applicant): It is now well established that elevated total plasma homocysteine is an independent risk factor for cardiovascular disease and that low folate shows association with increased risk for having a child with neural tube defects. Extrapolating from the central role played by a polymorphism of MTHFR in this process, we set out to clone genes and identify polymorphisms to determine if other genes involved in the metabolism of homocysteine would show such associations. A major outcome was the discovery of a novel enzyme methionine synthase reductase (gene and enzyme symbol, MTRR) required for the activation of cobalamin-dependent methionine synthase (MS). Through these experiments we detected a polymorphism, 66A>G (122M), present at a remarkable - aboutO.5 frequency, that appears to be
46 Down Syndrome
associated with premature coronary artery disease, neural tube defects and Down syndrome. Significant progress included identification of mutations in severely affected patients with MTRR deficiency, modeling the 122M variant in the orthologous E. coli flavodoxin, and development of a mouse model of MTRR deficiency (founder heterozygotes confirmed). We hypothesize that the association of the 122M polymorphism with disease derives from structural and functional disturbances in the variant enzyme with impact on biochemical homeostasis and development. Accordingly, we propose the following specific aims to characterize the mechanism and physiological role of this novel enzyme and polymorphism: (1) Determine the biochemical impact of the 122M mutation in E. coil flavodoxin and humanMTRR. These studies will include biochemical characterization of 122 and M22 MTRR; assessment of FMN binding and domain interactions by 122M flavodoxin; and comparative crystal structure of 122M flavodoxin. (2) Characterize the phenotype of homozygous and heterozygous MTRR knock-out mice to gain understanding of the impact of severe and mild MTRR deficiency on physiology and development. We will examine the expression patterns of MS and MTRR during embryogenesis and in adult tissues by in-situ hybridization, Western blot and tissue immuno-fluorescence; evaluate levels of folate and methionine cycle metabolites in heterozygous and homozygous mutant mice, characterize the general pathology and behavioral phenotype of affected mice; evaluate vascular pathology and function; and explore nutrition-based treatment of homozygous mutant mice. In summary, our study will give a biochemical and physiological face to the impact of 122M on enzyme function, development and disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS OF TURNER SYNDROME--COGNITIVE/PHYSICAL ASPECTS Principal Investigator & Institution: Zinn, Andrew R. Assistant Professor of Internal Medicine; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2001; Project Start 01-MAR-1997; Project End 31-JUL-2002 Summary: Turner syndrome is a human genetic disorder involving females who lack all or part of one X chromosome. The principle features are short stature, infertility, and anatomic abnormalities that include webbed neck, congenital heart disease, and renal and skeletal malformations. Selected neurocognitive deficits, including impaired visualspatial abilities, are also characteristic of Turner syndrome, but global developmental delay is uncommon. As a relatively common genetic disorder with well-defined manifestations, Turner syndrome presents the opportunity to investigate genetic factors that influence female physical and cognitive development There is potentially informative genetic and phenotypic variation among Turner syndrome subjects with partial X deletions (partial monosomy X). Careful clinical and molecular characterization of these unusual subjects who represent "experiments of nature" could link individual Turner syndrome phenotypic features to specific X chromosome regions. Similar studies are in progress for Down syndrome and other chromosome disorders. Turner syndrome is an excellent model for such phenotype mapping studies because of its prevalence, the well-characterized phenotype, and the wealth of molecular resources available for the X chromosome. The disorder is also a model for studying genetic aspects of cognition because of the selective nature of neurocognitive deficits and the relative sparing of verbal abilities. This study will examine approximately 80 partial monosomy X subjects. Each subject will have a thorough clinical evaluation and extensive neurocognitive testing to determine the presence or absence of specific Turner
Studies 47
syndrome phenotypic features. Cell lines will be established and used for molecular studies to precisely define the subjects' X deletions. The goal of this study is to define critical regions of the X chromosome for neurocognitive deficits and physical features associated with Turner syndrome. Phenotype mapping of X deletions will be helpful for genetic counseling and for predicting which girls with Turner syndrome are at high risk for learning difficulties; these children and their parents might benefit from extra social, psychological, and educational support. The collection of cell lines will also provide a valuable resource for future studies aimed at identifying specific Turner syndrome genes. Characterization of these genes would provide insight into the pathophysiology of Turner syndrome as well as processes of normal physical and cognitive development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS, MORTALITY AND DEMENTIA IN DOWN SYNDROME Principal Investigator & Institution: Zigman, Warren B. Reasearch Scientist; Institute for Basic Res in Dev Disabil Developmental Disabilities New York, NY 10314 Timing: Fiscal Year 2001; Project Start 16-FEB-1999; Project End 31-JAN-2004 Summary: Down syndrome, one of the most common genetic causes of mental retardation associated with genetic factors, occurs in approximately 1.2 per 1000 live births, is typically caused by a nondisjunction of the 21st chromosome during meiosis resulting in a complete trisomy genotype, although atypical forms occur occasionally. Adults with Down syndrome have benefited from the advances in public health practices that have resulted in a dramatic extension in life expectancy. However, Down syndrome is still characterized by increased mortality rates during later stages of life. Causes of higher mortality rates later in life may be due to a number of factors, two of which are an increased risk for Alzheimer~s disease and an apparent tendency toward premature aging. Aging processes among adults with Down syndrome have been of interest for over 100 years because of the occurrence of the signs and symptoms of Alzheimer~s disease in the population. Indeed, brain tissue of virtually all adults with Down syndrome over 35 to 40 years of age displays significant accumulations of amyloid plaques, historically considered to be a hallmark of Alzheimer's disease neuropathology presumably due to the triplication and over expression of the gene for beta-amyloid precursor protein located on chromosome 21. The genotypic and phenotypic characteristics of the "oldest old" (i.e., 65 and older) adult population with mental retardation due to Down syndrome will be compared to those of their younger peers (also with Down syndrome) in order to identify genetic risk factors associated with survival and the cognitive declines associated with dementia of the Alzheimer~stype. We have been able to identify a group of 100 people with Down syndrome 65 years of age or older. Investigation of this unique group of individualist will allow us to characterize the phenotype of the ~oldest old~ with Down syndrome and identify genetic and health status factors that are associated with extended survival and successful aging on one hand and the development of DAT on the other. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GONADAL PEPTIDE EFFECT ON FEMALE REPRODUCTION-ACTIVINS Principal Investigator & Institution: Lin, Yu-Wai P.; Barry University 11300 Ne 2Nd Ave Miami, FL 33161 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2007
48 Down Syndrome
Summary: Folliculogenesis in vertebrates involves the developmental progression from a small primordial follicleto a large preovulatory follicle containing a fully competent oocyte arrested at the second meiotic metaphase by the time of ovulation. This entire process is regulated and coordinated by endocrine hormones such as the pituitary gonadotropins, and locally modulated by steroids and factors (inhibin/activin) acting in an autocrine/paracrine manner. The molecular nature of these factors is only now being elucidated. Gonadal peptides such as inhibin and activin are currently being recognized not only as regulators of the pituitary gonadotropins secretion, but also as multifunctional modulators in the ovary and in the utero-placental unit. In addition to their normal reproductive roles, inhibins and activins have been implicated in gonadal oncogenesis and pathologies of the reproductive system. In this regard, high levels of inhibin B are associated with granulosa cell carcinoma, and high levels of inhibin A are correlated with pre-eclampsia and Down syndrome during pregnancy. The understanding of the relationship of several gonadal peptides to the signals for gonadal function still has many unanswered questions. This proposal is designed to elucidate the molecular mechanisms underlying the expression and the paracrine and autocrine biological activities of inhibin/activin A and B. Although the different inhibin/activin isoforms (A and B) appear to have similar effects in the pituitary, there is also precedent suggesting that they may have distinct physiological roles in different tissues. The availability of recombinant inhibin/activin A and B now gives the possibility to assess the functions of the various inhibin/activin isoforms. In order to implement the above objectives, the following projects will be carried out:: a) Isolation and cloning of the inhibin/activin subunits (alpha,betaA,and betaB) from ovarian tissue, b) Antibodies against the inhibin/activin subunits will be generated to carry out western blot analysis, c) Expression of inhibin/activin subunits during follicle development and during the process of gonadotropic stimulation of oocyte maturation, d) Paracrine (local effect at neighboring cells) and autocrine (local effect in the same cells) biological activities (on steroidogenesis and oocyte maturation) of inhibin/activin A and B will be assessed using in vitro ovarian follicle cultures, to test the hypothesis that the various forms of the gonadal peptides may have distinct physiological roles in the ovary. The proposed research will furnish critically needed information about the molecular dynamics and actions of the inhibin/activin in the ovary. Understanding the physiology of inhibins and activins and the interplay of major endocrine and paracrine mechanisms involved in the ovary is essential to decipher the process of gonadal differentiation in both normal and disease conditions, and may ultimately help in the diagnosis and treatment of reproductive dysfunction in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GRAMMATICAL /INTELLIGIBILITY INTERVENTION--DOWN SYNDROME Principal Investigator & Institution: Camarata, Stephen M. Professor of Hearing and Speech Sciences; Psychology & Human Development; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2004 Summary: (provided by applicant): Children with Down syndrome often display speech-intelligibility and grammatical deficits beyond what would be predicted based upon general cognitive levels. The purpose of the proposed study is two-fold. First, recast intervention techniques that have proven effective in other populations with speech-intelligibility and grammatical deficits will be piloted in children with Down syndrome. Second, mismatched negativity (MMN) and N1 will be measured using ERP
Studies 49
techniques and oral motor functioning as potential predictors of growth during intervention. A total of 12 children will be included in a multiple baseline, multiple probe design during the two year project. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMPACTS OF PARENTING ADOLESCENTS & ADULTS WITH AUTISM Principal Investigator & Institution: Seltzer, Marsha M. Waisman Ctr/Mr & Human Devlmt; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 01-FEB-1990; Project End 31-AUG-2005 Summary: This application seeks five years of support to continue the investigators' dual site research involving the impacts of life long parenting for adolescent and adult sons or daughters with mental retardation (MR). The focus of the work shifts in this application to a new population, as a sample of 400 families of adolescents and adults with autism will be studied. The proposed investigation will address four central issues: (1) the manifestation of symptoms of autism among adolescents and adults (both crosssectionally and longitudinally, (2) the effects of the behavioral, communicative, and social functioning of persons with autism on parental well-being (again cross-sectionally and longitudinally), (3) the antecedents and consequences of placement of the person with autism, and (4) the impact of differential diagnostic groups on family well-being. The fourth aim, families of persons with autism will be compared with two previously collected samples of families: one with a son or daughter with Down syndrome, and one with a son or daughter with schizophrenia. These samples, and the data relating to them, are available from previous or ongoing funded work by the current investigative group. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: LANGUAGE DEVELOPMENT IN DOWN SYNDROME CHILDREN Principal Investigator & Institution: Chapman, Robin S. Professor; Waisman Ctr/Mr & Human Devlmt; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 01-JUL-1987; Project End 31-DEC-2003 Summary: Children and adolescents with Down syndrome (DS) are reported, variously, to have language skills above (vocabulary comprehension) and below (expressive syntax) their nonverbal mental age; cross-sectional evidence suggests that the deficits increase with age. The goals of the present work are to determine, through longitudinal study, whether the gaps between the cognitive level of children with DS and their expressive and receptive language levels widen with age and to identify acquisition processes associated with variation in language skill with DS children. This competing continuation proposal extends the period of longitudinal study of 5 DS children and adolescents aged 5 to 21 years from two to six years and the number of DS observation points from two to four. It permits a definitive longitudinal test of the cumulative deficit hypothesis and, in doing so, permits an empirical test for an elaborated theory of language production development (Child Talk) that would not be possible in normally developing children, whose cognitive and language skills do not ordinarily diverge widely. Computer analyses of the free speech transcripts will permit a detailed longitudinal description of changes in the syntax, semantics, and pragmatics of spoken language in children with DS over the six year period. Hierarchical linear modeling will be used to evaluate between-s predictors of rates of growth in the language variables. In
50 Down Syndrome
addition, new studies of DS children's ability to narrate and recall novel events, to "fast map" novel word meaning from event and story contexts, and to benefit from prior discourse use of words and sentence structure in utterance formulation will be conducted, elaborating the experimental investigations of narration, vocabulary acquisition, and prior discourse priming on the basis of outcomes in the current grant period. Experimental tasks evaluating comprehension strategies will be added. Performance on all tasks will be compared to three groups of normally developing children statistically matched for 1) nonverbal mental age and SES; 2) language comprehension and SES; and.3) language production and SES. Within the DS group, experimental task performance will be analyzed for variation as a function of cognitive, comprehension, and production skills in a test of the Child Talk model. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LINGUISTIC COMMUNICATION AND MENTAL RETARDATION Principal Investigator & Institution: Abbeduto, Leonard J. Professor; Waisman Ctr/Mr & Human Devlmt; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 01-SEP-1987; Project End 30-JUN-2003 Summary: This project will investigate the development of discourse in adolescents who have mental retardation due to Down syndrome (DS) or fragile X syndrome (FXS). Each syndrome is characterized by impairments in the domains of behavioral functioning that support discourse development (e.g., cognition, receptive language) and, thus, individuals with either syndrome are likely to find discourse to be especially challenging. There are also differences in the behavioral phenotypes of DS and FXS, which may lead to different profiles of discourse problems. There are few data on the discourse skills of individuals with DS or FXS and fewer data still on discourse problems that may be specific to one syndrome or the other. The need for such data is especially acute during the adolescent years. During adolescence, preparation begins for adult roles that demand expertise in discourse. This project will examine discourse in adolescents with DS and adolescents with FXS from a model in which discourse is seen to emerge from the collorative activity of people working toward a common goal. This project has three specific aims. This first is to determine (a) whether discourse development is more severely disrupted in these adolescents than expected from their levels of functioning in domains that support discourse development (i.e., cognition, linguistic ability) and (b) whether it is disrupted differently in the two syndromes. The second aim is to (a) identify the ways in which developments of nonverbal cognition, language, social cognition, speech, and hearing contribute to the ability of these adolescents to collaborate effectively and (b) determine whether these domains make different contributions to discourse for DS and FXS. The third aim is to determine what syndrome-specific impairments (i.e. psychopathology and auditory memory problems) contribute to discourse collaboration. Five studies will address these aims. In each, participants will engage in a referential task that is designed to highlight differences between the syndromes. Comparisons with younger, typically developing children will determine the extent to which discourse development is disrupted in each syndrome. Measures will be taken of domains in which there are syndrome-shared impairments. Hierarchial multiple regression will be used to examine the contributions of these domains to the discourse collaboration of the DS and FXS groups. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 51
•
Project Title: LONGITUDINAL LANGUAGE Principal Investigator & Institution: Hart, Betty; University of Kansas Lawrence Lawrence, KS 66045 Timing: Fiscal Year 2001 Summary: The proposed research will examine the contribution of fewer declarative sentences and less frequent conversation to delays in expressive language among children with Down syndrome. Data from more than 10 years of longitudinal observations of communicative development in children with retardation being reared at home will be compare to data from 21/2 years of methodologically-identical observations of typically-developing children learning to talk. Each declarative sentence will be located in each child's data and coded for initiator, turns, shared topic, different and mutual vocabulary, and parent behaviors that may be facilitate learning to converse. The results of the two studies will be the basis for proposing interventions to remediate the deficit in MLU (mean length of utterance) that leads the language skills of children with Down syndrome to lag behind measures of their cognitive functioning. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF LEUKEMOGENESIS IN DOWN SYNDROME Principal Investigator & Institution: Crispino, John D. Ben May Institute; University of Chicago 5801 S Ellis Ave Chicago, IL 60637 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2007 Summary: (provided by applicant): Children with Down syndrome (DS) have a 10-20 fold increased risk of developing leukemia, in particular acute megakaryoblastic leukemia (AMKL). While the genetic lesions that promote leukemia in Down syndrome have been largely undefined, we recently demonstrated that leukemic cells from every DS-AMKL patient examined harbor mutations in the essential hematopoietic transcription factor gene GATA1. In every instance, the mutation involved a small insertion or deletion in GATA1 that resulted in a frame-shift and the introduction of a premature stop codon within the sequences encoding the N-terminal activation domain of GATA-1. These mutations prevent the synthesis of the 50-kD full length GATA-1, but not of a 40-kD isoform initiated further downstream, termed GATA-1s. In this application, we propose to study the mechanism of leukemogenesis in patients with GATA1 mutations. Furthermore, we will seek to identify the cooperating factors that are likely contributed by trisomy 21 in Down syndrome AMKL. Specifically, we plan: 1) To determine the incidence and distribution of GATA1 mutations in a greater number of DS-AMKL samples as well as in DNA from patients with DS pre-leukemia, named Transient Myeloproliferative Disorder; 2) To assess whether loss of GATA-1 in conjunction with the mouse equivalent of trisomy 21 can promote leukemogenesis in mice, and further, whether overexpression of GATA-1s can promote immortalization of GATA-1-deficient megakaryocyte progenitors; and 3) To develop a mouse model of DSAMKL by creating mice that will conditionally express only the 40-kD isoform of GATA-1 and breeding them to mice with the murine equivalent of DS. Separately, we will also cross these novel GATA1 mutant mice into the BXH-2 strain of mice to identify genes that cooperate with the GATA1 mutations in leukemia. These studies will likely increase our understanding of how GATA1 mutations contribute to the initiation or progression of leukemia in Down syndrome and may also lead to the identification of novel leukemia disease genes on chromosome 21. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
52 Down Syndrome
•
Project Title: MEMORY AND COGNITION IN AGING ADULTS WITH DOWN SYNDROME Principal Investigator & Institution: Devenny, Darlynne A.; Institute for Basic Res in Dev Disabil Developmental Disabilities New York, NY 10314 Timing: Fiscal Year 2001; Project Start 15-JUN-1998; Project End 31-MAY-2003 Summary: Adults with Down syndrome (DS) experience changes in functioning associated with normal aging precociously, and they are at higher risk for developing Alzheimer's disease than their peers with other forms of mental retardation (MR). The first aim of the proposed project is to characterize specific changes in memory and cognitive processing that occur during normal aging and to identify individual differences in vulnerability to early onset of age-associated changes in adults with DS. This project will focus on the study of working and episodic memory, two systems known to be sensitive to aging processes. Each of the components of a model of working memory (central executive function, visuospatial sketchpad, phonlogical loop; Baddeley, 1986) will be tested with multiple converging measures. The second aim is to distinguish the patterns of change in performance on tests of memory and cognition that are associated with normal aging from changes associated with early dementia of the Alzheimer type. The third aim is to describe the natural history of dementia in adults with MR. Individual performance on tests of memory and cognition will be related to mental status and caregiver informant-based scales of adaptive behavior and dementia. Because the test battery spans a broad range of cognitive domains and difficulty, it will be possible to describe the course of decline from early onset through to advanced stages of dementia. By the end of the proposed study those tests that are most sensitive to early declines in functioning will have been identified and their utility as clinical instruments verified with longitudinal measures. By delineating the changes in specific memory and cognitive processes related to individual differences in normal and abnormal aging in adults with DS, this work will contribute to understanding vulnerability to age-related changes, in general. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MODELING DYNAMIC RESOURCES TO SOLVE MOVEMENT PROBLEMS Principal Investigator & Institution: Ulrich, Beverly D. Kinesiology; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2006 Summary: (provided by applicant): The long-term goal of the work proposed here is to understand the production and change over time in patterns of motor behavior. The studies are informed by a dynamic systems perspective and expand the use of mathematical models that address coordination issues by focusing on the availability of dynamic resources from which humans select control strategies for solving movement problems. Recently such a model has been developed but limited in its validation to normal children and those with cerebral palsy (CP). This proposal addresses the generalizability of this modeling approach by focusing on a population with unique dynamic resources, Down syndrome (DS). It extends previous work by studying behavior across the lifespan in a population whose control problems are poorly understood. Focus is on walking because it emerges relatively early in life, is well practiced over time, complex, changes over the lifespan, is an important functional skill, yet has received limited directed attention by the scientific community. Specific aim #1 is to examine the capacity of the model to explain gait pattern differences in
Studies 53
preadolescent children with DS and typically developing (TD) children as well as their ability to adapt to perturbations. Preadolescence is a time when performance on this task may be expected to be optimal. Comparison will be made between gait kinematics and the model's predicted dynamic gait strategies (i.e., relative stiffness and forcing functions. Specific aim #2 is to extend the application of this model across developmental levels, including new walkers and older walkers. At these levels optimality constraints may be quite different; they represent different levels of practice, as well as differences in the biomechanical and physiological constraints, within the same population. In particular, new walkers will be tested in a longitudinal study design in order to map the emergence of dynamic strategies within participants. Specific aim #3 is to concurrently validate the effectiveness of the model. This will include comparing the model's method for estimating stiffness and forcing to measures developed by other researchers, examining neuromuscular correlates of the model's estimates for stiffness and forcing, and determining if non-linear components in the model are required to minimize the error and maximize generalizability of the model. These studies have wide-ranging implications for a.) understanding the emergence of control strategies, b.) understanding general processes of change, and c.) impacting on clinical practice, especially physical and occupational therapy and orthopaedic medicine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODELING PHARMACOLOGICAL TREATMENTS IN THE TS65DN MOUSE Principal Investigator & Institution: Moran, Timothy H. Professor; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001 Summary: The development of mouse models of Down Syndrome, with appropriate gene expression to mimic what takes place with a trisomy of human chromosome 21, provides test systems for potential therapeutic interventions aimed at improving cognitive performance. As detailed under Dr. Davisson's Project, the Ts65Dn mouse containing homologs to the majority of the genes on human chromosome 21. This segmental trisomy model has a number of distinct advantages over previous models, not the least of which is survival to adulthood. We and others have demonstrative a cognitive phenotype in the Ts65Dn mouse which has clear similarities to that seen in Down Syndrome. Ts65Dn mice demonstrate performance deficits in tests of learning and memory against a background of relatively intact motor and sensory abilities. Both acetylcholine and glutamate play important roles in learning and memory and are involved in neural organization during development. Alterations of cholinergic and glutamatergic activity in DS have been identified. The proposed experiments will 1) provide a more complete characterization of the development of cholinergic and glutamatergic systems in Ts65Dn mice. This characterization will provide a necessary background for proposed experiments aimed at, 2) assessing whether strategies aimed at blocking cholinergic degradation with the acetyl cholinesterase at, 2) assessing whether strategies aimed at blocking cholinergic degradation with the acetyl cholinesterase inhibitor donepezil or producing a development increase in cholinergic function with prenatal choline can improve performance in the Ts65Dn mouse, 3) assessing whether developmental treatment with piracetan alone, or piracetam combined with prenatal choline administration, improves performance in the Ts65Dn, and 4) assessing wheth4r developmental treatment with the neuroprotective agent acetyl-L-carnitine prevents cholinergic degeneration and results in improved cognitive
54 Down Syndrome
performance in the Ts65Dn mouse. In these studies, we will assess performance in the Morris water maze and a cued and contextual conditioning paradigm. We will also monitor activity over the 24 hour cycle and in elevated plus maze paradigm. Behavioral assessments will be followed up by appropriate neurobiological analyses to determine whether the neurochemical systems impacted by these treatments respond similar in Ts65Dn and control mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODULATION OF GLUTAMATE SYNAPSES IN NEONATAL CORTEX Principal Investigator & Institution: Friedlander, Michael J. Professor and Chair; Neurobiology; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2001; Project Start 14-JUN-2000; Project End 31-MAY-2005 Summary: Altered structural integrity of cortical synapses has been demonstrated in a variety of forms of mental retardation, including those attributable to chromosomal abnormalities (e.g., Down Syndrome, Fragile X, Angelman Syndrome, Praeder-Willi Syndrome, William's Syndrome), prenatal exposure to teratogens (e.g., ethanol) and severe neonatal seizures. Most of these structural defects are at synapses located on dendritic spines, sites of glutamatergic input, and they can occur in humans and animal models. The efficiency, distribution, and structure of these glutamatergic cortical synapses undergo substantial modulation by experience, neural activity, and other neurotransmitters such as serotonin during normal development. (Interference with normal glutamatergic synaptic transmission can lead to seizures, neurotoxicity, and development of abnormal cortical architecture). This program project is a multi-faceted inquiry into (1) the initial molecular assembly of the cortical glutamate synapse (Project I); (2) its capacity for transferring behaviorally relevant signals during development (Project II); and (3) its modulating during postnatal development by (i) two neighboring cell types-subcortical white matter neurons and astrocytes, (ii) the modulators, serotonin (5-HT) and nitric oxide, and (iii) the 5-HT and glutamate neurotransmitter transporters (Projects III, IV, and V). A Developmental Neurobiology Imaging Core (Core B) and an Administration/Project Development Core (Core A) Neurobiology Imaging Core (Core B) and an Administration/Project Development Core (Core A) will provide critical services and will promote synergy among projects. By learning the molecular components of these synapses, their functional properties in a physiological context, and the mechanisms of their modification by intrinsic gating pathway in the normal neonate, this project will provide a substantial new basis for understanding the sensitivity of developing glutamate synapses to the convergent processes that compromise synaptic structure and function in MR. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR BASIS FOR HYPOPLASTIC HEART SYNDROMES Principal Investigator & Institution: Olson, Eric N. Professor; Molecular Biology; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: Congenital heart defects account for the largest number of birth defects in humans. Many heart defects can be attributed to abnormalities in specific steps in cardiac development, particularly in the formation and function of the ventricular chambers and in the neural crest-derived components of the heart. While the
Studies 55
embryologic events involved in heart development have been carefully documented, little is known of the underlying mechanisms and molecules that control cardiac myogenesis and morphogenesis. The overall goal of this project is to elucidate the molecular mechanisms involved in specification and development of the ventricular chambers and the cardiac neural crest and to identify the genes responsible for defects in these cardiac compartments in three human chambers and the cardiac neural crest and to identify the genes responsible for defects in these cardiac compartments in three human syndromes associated with congenital heart disease: hypoplastic left heart syndrome, Down syndrome, and DiGeorge syndrome. Recently, the Olson lab found that two novel bHLH transcription factors, referred to as dHAND and eHAND, are expressed in specific subsets of ventricular precursor cells and in the cardiac neural crest and that mouse mutants lacking dHAND fail to form a right ventricle specification and cardiac neural crest and that mouse mutants lacking dHAND fail to form a right ventricle or cardiac neural crest derivatives. The discovery of these molecules provides a molecular entry point into the mechanisms for ventricular specification and cardiac neural crest development and establishes a conceptual framework for the overall SCOR. The SCOR contains four interwoven projects and three cores that encompass basic molecular strategies to understand cardiac development and clinical studies to identify the gens responsible for congenital heart diseases in which the ventricular and neural crest components of the heart are affected. The projects are as follows. 1) E. Olson will define the roles of the HAND family of cardiac basic helix-loop-helix (bHLH) transcription factors in normal and abnormal cardiac development. 2) D. Srivastava will define the downstream target genes regulated by dHAND in the developing heart, with particular attention to a recently discovered gene that is dHAND-dependent and is localized to the minimal chromosomal deletion in DiGeorge syndrome. 3) K. Chien will clone and characterize the gene responsible for hypoplastic left heart syndrome. 4) Korenberg will identify the gene(s) responsible for heart defects in Down syndrome. The possibility that one of the candidate genes, which encodes a novel cell adhesion molecule, called DS-CAM, is a transcriptional target for MEF2 will also be addressed. Each of these projects is interrelated through the creation of novel strains of mouse mutants in which key cardiogenic regulatory genes can be inactivated in a temporaland compartment-specific manner within the developing heart. These studies will provide an in-depth understanding of the basic molecular pathways that regulate heart development and the ways in which these pathways can be disrupted in congenital heart diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR DIVERSITY AND FUNCTION OF THE RECEPTOR DSCAM Principal Investigator & Institution: Schmucker, Dietmar; Dana-Farber Cancer Institute 44 Binney St Boston, MA 02115 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-APR-2007 Summary: (provided by applicant): We have recently identified the Drosophila receptor Dscam and shown that it is essential for the formation of proper connectivity in the fly nervous system. Dscam is a member of the immunoglobulin superfamily and is highly related to the human protein "Down syndrome cell adhesion molecule" (DSCAM). The Drosophila Dscam gene is extraordinarily complex and can generate some 38,000protein isoforms through alternative splicing. The overall goal of our studies is to test the hypothesis that alternative splice isoforms of the Dscam receptor constitute a molecular recognition code for synaptic specificity. We will use genetic and molecular
56 Down Syndrome
approaches to functionally test the importance of neuronal receptor diversity. We propose that the extraordinary molecular diversity of Dscam provides a paradigmatic and genetically accessible case for systematically dissecting the mechanism by which neuronal receptors contribute to synaptic specificity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR GENETIC EPIDEMIOLOGY OF THREE CARDIAC DEFECTS Principal Investigator & Institution: Lauer, Ronald M.; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2001 Summary: (Adapted from the Applicant's Abstract) Congenital heart defects (CHDs) are thought to result from genetic and environmental factors that disturb cardiac embryogenesis. Because families with multiple members affected with atrial septal defects (ASDs) and atrioventricular canal defects (AVCDs) have been described, and the paramembranous ventricular septum is in part completed by the formation of the atrioventricular cushions, this project describes a genetic-epidemiologic study of ASDs, paramembranous ventricular septal defects (VSDs), and AVCDs. Three groups of subjects, each with surgically- or echocardiographically-confirmed diagnoses of ASDs, VSDs or AVCDs have been identified for study at the University of Iowa Hospitals and Clinics, and at Wolfson Children's Hospital in Jacksonville, Florida. A fourth group of older subjects with ASDs and their progeny will be studied at Iowa because of the reported high recurrence of heart disease in the offspring of subjects with ASDs. The strategy proposed calls upon the molecular genetic capacities available at the University of Iowa to carry out genome-wide searches for genetic loci involved in these defects. Several candidate regions have been identified for ASDs, VSDs and AVCDs. In addition, three well-recognized syndromes provide additional candidate regions - Down syndrome, Holt-Oram syndrome and 8p-syndrome. Parent-affected child trios will be genotyped for closely-spaced markers within these regions and linkage disequilibrium analysis will be used to narrow or exclude these candidate intervals. A genome-wide association study of the trios will employ a parsimonious technique in which DNA from cases with the same CHD phenotype will be pooled, and compared to the pooled DNA from their parents. Loci will be identified where the allele frequency distributions in the affected children and their parents are significantly different. When such loci are identified, a finer localization of the chromosomal area will be undertaken using a highdensity set of short tandem repeat polymorphic markers that spans each of the candidate intervals. This study has the potential to identify new candidate loci which are risk factors for the development of congenital heart defects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR MECHANISM OF THE MITOTIC CHECKPOINT Principal Investigator & Institution: Schuyler, Scott C. Molecular and Cellular Biology; Harvard University Holyoke Center 727 Cambridge, MA 02138 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2005 Summary: (provided by applicant): The broad long-term objective is to understand the process of chromosome segregation during eukaryotic cell division. Inaccurate chromosome segregation leads to genetic instability. Down syndrome is the most frequent genetic defect in infants and cancer will kill one American in four. Both are conditions caused by genetic instability and it is possible that lesions in the spindle
Studies 57
checkpoint cause meiotic chromosome loss in Down syndrome and chromosome loss and gain in many tumors. The primary focus within the proposal is the study of the molecular mechanism by which chromosomes signal to stop cell cycle progression in response to mitotic spindle damage in budding yeast. The first specific aim is to identify the components of the complex that inhibit Cdc20p-APC activity in response to spindle damage. The second specific aim is to identify the kinetochore sensor necessary for activating the checkpoint signal complex. To achieve these ends, yeast molecular genetics coupled with classical protein biochemistry shall be employed. When used in combination these methods have been shown to be powerful tools for exploring the molecular roles of protein complexes. The hope is that understanding the molecular mechanism of the spindle checkpoint in budding yeast will help us to understand its role in human disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODEL OF RETARDATION IN DOWNS SYNDROME Principal Investigator & Institution: Gladzicki, Zygmunt; Henry M. Jackson Fdn for the Adv Mil/Med Rockville, MD 20852 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 28-FEB-2004 Summary: (Provided by applicant): Down syndrome (DS) or trisomy 21 (Ts21) is caused by the presence of three copies of chromosome 21, and is the most frequent genetic cause of mental retardation. The Ts65Dn trisomic mouse has recently been developed and is trisomic only for the segment of murine chromosome 16 that is homologous to the segment of human chromosome 21 thought to contribute to mental retardation and vulnerability to Alzheimer disease in DS. This mouse demonstrates abnormal behavior and is impaired in various learning paradigms. We demonstrated that long-term potentiation (LTP) and long- term depression (LTD) decrease and increase respectively in the CAl region of the Ts65Dn mouse of Ts65Dn mouse hippocampus. The objective of this proposal is to find mechanisms that cause the abnormal LTP and LTD. Three specific aims are proposed to test that abnormal LTP and LTD are due to changes in signal transduction pathways mediated by protein kinase A (PKA) and/or protein kinase C (PKC) that would cause posttranslational changes in voltage-dependent Na+, Ca2+ channels and NMDA-, AMPA-glutamate receptors and cause changes in synaptic activity in the hippocampus. Aim#1: Determine PKA pathway activity in Ts65Dn hippocampus in relation to LTP and LTD paradigm. Determine expression of phosphorylated CREB. Aim #2:PKC activity in Ts65Dn hippocampus in relation to LTP and LTD paradigm. Determine expression pattern of PKC isoforms. Aim #3:Determine the expression and posttranslational modification of voltage dependent Na+, Ca2+ channels and NMDA -, AMPA- glutamate receptors using nucleated patch-clamp recording technique and binding studies. The impact of PKC isoforms will be tested in cell lines that permanently over express Na+ channel, Ca2+ channels, NMDA and AMPA receptors. Signal transduction impairments in genetic model of DS will determine important targets for treatment of mental retardation. In addition the outcome of this research will include further understanding of the role of PKA and PKC and voltage-dependent channels and NMDA- and AMPA-receptors in the mechanisms that are behind LTP and LTD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOUSE MODELS OF DOWN SYNDROME Principal Investigator & Institution: Roper, Randall J. Physiology; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218
58 Down Syndrome
Timing: Fiscal Year 2003; Project Start 01-MAR-2003 Summary: (provided by applicant): Trisomy 21 is the most frequent human aneuploidy compatible with survival. It occurs in 1 out of 700 live births causing a constellation of effects known as Down syndrome (DS). Significant efforts to establish the genetic control of the many phenotypes of DS have been made using mouse models. HSA21 is homologous with regions on mouse chromosome 10 (MMU10), MMU16, and MMU17. Extensive investigations have been done with Ts65Dn, a mouse model with segmental trisomy at dosage imbalance for about half of the genes on human chromosome 21 (HSA21). Using Cre-lox chromosome engineering, new models of DS will be made for MMU10 regions of conserved synteny with HSA21 including about 50 homologous genes. Quantitative phenotypes for trisomic (Ts2Rhr) and monosomic (Ms2Rhr) mice will be compared to clinical data for human trisomy and segmental monosomy 21. Additionally, Ts2Rhr/Ts65Dn compound transgenic mice will be used to assess the contribution of the MMU10 region in DS phenotypes. The importance of MMU10 will be verified using analysis of variance (ANOVA) and regression with comparisons between the different DS mouse models. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODELS OF DOWN SYNDROME: PHENOTYPIC MAPPING Principal Investigator & Institution: Epstein, Charles J. Professor of Pediatrics; Pediatrics; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001; Project Start 01-MAR-1995; Project End 30-NOV-2002 Summary: The overall objective of this research program is to discover the mechanisms by which the presence of an extra copy of human chromosome 21 produces the phenotype of Down syndrome (DS). The approach we are using is based on the premise that it will be possible to relate specific components of the trisomic phenotype to the increased expression of genes or sets of genes present on chromosome 21. Our work on this problem has led to the development of several animal models for DS including the full trisomy 16 (Ts16) mouse and, very recently, the new partial trisomy 16 mice, Ts1Cje and Ms1Ts65, which are trisomic from below Sod1 to Mx and from above App to above Sod1, respectively. In addition, we have studied Ts65Dn, another partial trisomy 16 mouse which is trisomic for the region App to Mx. The abnormalities of the Ts1Cje and Ts65Dn, which more faithfully reproduce the genetic imbalance that results in DS than does Ts16, are principally restricted to the nervous system and affect learning and behavior, although Ts65Dn is also male sterile. Ts65Dn, with the larger degree of imbalance, is more abnormal (in spatial learning) than is Ts108Cje. Furthermore, Ts65Dn mice display atrophy of basal forebrain cholinergic neurons (BFCN) which can be reversed by nerve growth factor, but Ts108Cje animals have normal BFCN. To determine the regions of chromosome that are responsible for the learning deficits and neuronal atrophy in the partial trisomy mouse for DS, we shall first compare in detail the behavioral differences among Ts1Cje, Ts65Dn, and Ms1Ts65. We shall then use an approach to phenotypic mapping that is subtractive in nature. It is based on the analysis of the changes in phenotype that result from decreases in the size of or the removal of specific loci from the region of trisomy. We shall analyze the effects of deleting either App or Sod1 on the phenotype of Ts65Dn. Then, starting with Ts65Dn and Ts108Cje, we shall generate two series of partial Ts16 mice with progressive radiation- induced deletions of chromosome 16. The resulting progeny will be assessed with regard to which phenotypic features of partial Ts16 disappear as extra copies of particular regions of the chromosome are no longer present. Regions so identified can then be further
Studies 59
analyzed to identify candidate genes, and the true role of these genes in producing the phenotypic changes of partial trisomy 16 can be established by transgenic and homologous recombination techniques. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER NETWORK OF MATERNAL-FETAL MEDICINE UNITS Principal Investigator & Institution: Carpenter, Marshall W. Associate Professor; Women and Infants Hospital-Rhode Island 101 Dudley St Providence, RI 02905 Timing: Fiscal Year 2001; Project Start 03-APR-2001; Project End 31-MAR-2006 Summary: (provided by applicant): WIH and the Department of Obstetrics and Gynecology at Brown University School of Medicine have the capability to participate actively as a new member of the Cooperative Multicenter Maternal-Fetal Medicine Units Network. WIH operates one of the nation?s larger obstetrical services. All obstetric care is supported by insurance in Rhode Island. Consequently, the State?s ethnic and racial diversity is reflected among both private and clinic patients. Providing care to 74 percent of the State s patients, WIH s demographic and clinical statistics wholly reflect those of Rhode Island. During fiscal year 1999, 9023 deliveries were performed at WIH, 2099 among WIH Clinic and Maternal-Fetal Medicine patients. Of the total WIH deliveries, 174 had ruptured membranes before 35 weeks, 556 delivered prior to 35 weeks, 207 had multi-fetal pregnancies, 179 had gestational or chronic diabetes, 794 had hypertensive disorders in pregnancy, 539 had asthma or other respiratory disease and 163 had cardiac or vascular disease. The academic faculty and private practice community have had a consistently collaborative relationship providing access to the entire obstetrical population for cohort studies. Consequently, WIH is particularly suited for performance of clinical trials. The Maternal-Fetal Medicine Division is composed of six board-certified and one active candidate for the Maternal-Fetal Medicine boards, all of whom will support Network research protocols. The Division also employs two research nurses and a sonographer, all presently supported by NICHD funding, and three additional clinical nurses, all with extensive experience in cohort research. The Division has successfully enlisted patients (53-100 percent enlistment rates) in complex tocolysis trials and exercise, and metabolic and hemodynamic cohort studies with retention rates of 79-93 percent. The Division has maintained strong clinical and investigational relationships with local and regional private obstetricians, reflected in the proportions of private patients in Divisional cohort studies of 54-80 percent. The Division is presently engaged in three multicenter cohort studies funded by NICHD. It was selected by the Network in April 2000 to participate in the Beneficial Effects of Antenatal Magnesium (BEAM) Study to increase patient enlistment in this protocol and is presently beginning to enroll subjects. The Division has been funded as one of five North American sites in an international study of the maternal and perinatal impact of maternal glucose intolerance, the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) Study. The Division is also a participant in the First and Second Trimester Evaluation of Risk (FASTER) Study examining combined biochemical and sonographic first trimester screening for Down syndrome. WIH and the Maternal-Fetal Medicine Division will enlist subjects for all Network protocols and actively participate in proposing, planning and executing Network studies. Local infrastructure available for participation in multicenter clinical trials at WIH include (1) a large patient volume and highly involved full-time and voluntary obstetrical faculty; (2) robust clinical patient, laboratory, anatomic pathology, and pharmacy databases; (3) a strong history of collaboration between Maternal-Fetal Medicine and Neonatology
60 Down Syndrome
Divisions; (4) decades-old perinatal tissue samples and anatomic pathology; and (5) a strong Departmental commitment to outcomes research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MULTICENTER VITAMIN E TRIAL-PERSONS WITH DOWN SYNDROME Principal Investigator & Institution: Dalton, Arthur J.; Institute for Basic Res in Dev Disabil Developmental Disabilities New York, NY 10314 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2005 Summary: (Adapted from the application) There is evidence from a multicenter clinical trial that vitamin E slows the rate of clinical deterioration in individuals with moderately severe Alzheimer s disease (AD). The AD Cooperative Study (ADCS) is now mounting a large study to test the effects of vitamin E in persons at the earliest stage of cognitive deterioration. Older individuals with Down syndrome (DS) are at very high risk for AD. Most individuals with DS develop functional decline and show neuropathological evidence of AD by the sixth decade. The applicants propose an international multicenter randomized double-blind study to determine whether vitamin E supplementation will slow the rate of cognitive/functional decline in individuals with DS. Subjects with DS who are at least 50 years of age will be randomized into two treatment groups: vitamin E 2000 IU plus a multivitamin per day or placebo plus multivitamin. The multivitamin contains vitamin E 15 IU. The treatment period will be three years with evaluation visits every six months. The primary outcome measure will be a three year change score on a cognitive/functional measure that was derived for this purpose from the DYSPRAXIA Scale for Adults with Down Syndrome. Secondary outcome measures will include additional cognitive tests as well as informant-based measures of function and behavior. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NATURE AND DEVELOPMENT OF SPATIAL COGNITION IN AUTISM Principal Investigator & Institution: Ogline, Jamie S. Psychology; University of Denver Box 101562 Denver, CO 80208 Timing: Fiscal Year 2001; Project Start 01-JUN-2001 Summary: The overall goal of the proposed research is to examine the nature and development of spatial cognition in individuals with autism. Although previous research suggests that spatial cognition may be a strength in those with autism, research findings in this area are inconsistent and need further examination. For instance, central coherence theory claims that those with autism have difficulty attending to the gestalt and will focus more on the local parts of a spatial configuration. This theory is inconsistent with the possibility that individuals with autism may have a strength in the spatial domain because many spatial tasks require attention to both the global and local parts of configurations. Another inconsistency is evident between previous findings of executive deficits in autism and the findings that individuals with autism are not impaired on spatial tasks that may require executive processing, such as the WISC block design. The proposed study will attempt to resolve these inconsistencies and add to knowledge about spatial cognition in autism by testing low-functioning children with autism as compared to Down syndrome and normally developing mental age matched control groups using measures of spatial working memory, global/local processing, and a spatial task previously not examined in this population. Broadening knowledge about
Studies 61
spatial cognition in this disorder will allow for a better understanding of development in this disorder and any potential strengths that may exist. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROBEHAVIORAL STUDIES OF LANGUAGE IMPAIRMENT Principal Investigator & Institution: Wulfeck, Beverly; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2001; Project Start 16-SEP-1985; Project End 31-JUL-2006 Summary: A growing body of research is challenging the notion of specific language impairment. Our investigations of language-impaired children (LI) reveal limitations in language, but neurologic abnormalities and deficits in other cognitive domains have also been noted. Further insights require study of non-verbal cognition as well as language, and the neural substrates that subserve them. Because LI can extend into adulthood, we will include adolescents with LI in our studiers. The major aims of this project are: 1. Study basic language processing abilities across a wider age range (7- 16) and examine higher order language to determine how early LI impacts on later language use and literacy. 2. Test for associations and dissociations and differentiate knowledge from processing deficits. 3. Study attention, spatial localization, laterality, visual memory and mental rotation abilities and examine for selective sparing and/or impairment across non-verbal cognitive domains. 4. Test for patterns of association and dissociation between language and cognition. 5. Conduct fMRI and ERP studies of language using paradigms tightly yoked to behavioral measures to examine languagebrain mappings in LI children. 6. Conduct fMRI and ERP studies of spatial cognition and attention using paradigms tightly yoked to behavioral measures to examine for patterns of sparing and impairment in non-verbal cognition. 7. Conduct longitudinal studies of LI to examine developmental trajectories for evidence of differential catching up or continued impairment across language and cognitive domains. 8. Compare LI results to results from children with different etiologies including early focal brain injury (FL), Williams or Down Syndrome, and FL Variants (i.e. bilateral or late onset brain lesions) to further characterize the contrasting behavioral profiles noted in the last funding period and determine whether these are associated with alternative forms of brain organization. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEUROGENESIS IN DISORDERS OF BRAIN DEVELOPMENT Principal Investigator & Institution: Krueger, Bruce K. Physiology; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2001; Project Start 14-JUL-2000; Project End 30-APR-2004 Summary: (adapted from applicant's abstract): The cause of mental retardation in Down syndrome (DS) is not understood but is thought to result, at least in part, from defective brain development during the embryonic period when neurons of the cerebral cortex are being generated. The trisomy 16 (Ts16) mouse shares a common genetic defect with DS and may be useful for studying the mechanisms underlying abnormal embryonic development of the cerebral cortex. Prenatal generation of postmitotic neurons in the Ts16 mouse cortex is delayed and subplate neurons are born concurrently with cortical plate neurons rather than preceding them as in the normal cortex. These abnormalities in the timing of Ts16 neurogenesis may lead to defective connectivity in the mature brain; similar defects during the prenatal development of the human brain may contribute to mental retardation in DS. Proliferation of neuroprogenitor cells
62 Down Syndrome
(neuroblasts) and the decision of daughter cells to leave the cell cycle, which ultimately control the timing of neurogenesis, are regulated by neurotransmitters and growth factors such as glutamate and brain derived neurotrophic factor (BDNF). Ts16 neuroblasts fail to respond to glutamate and BDNF, raising the possibility that this signaling defect may underlie delayed neurogenesis in Ts16. The molecular basis for defects in the regulation of Ts16 neurogenesis will be studied in a) dissociated cell cultures of neuroblasts and b) organotypic slices from Ts16 and littermate euploid cortex. Both of these preparations enable not only the direct application of putative regulators of neurogenesis and of inhibitors of signaling pathways, but also direct measurement of proliferation, cell death and intracellular levels of Ca2+, a key modulator of proliferation, neuronal differentiation and migration. Experiments in organotypic slices will enable these processes to be analyzed in a structurally intact cortex and will allow the behavior of anatomically-distinct populations of neuroblasts and postmitotic neurons to be distinguished. The overall goals of this research project are to identify the signaling defects that lead to abnormal neurogenesis in the Ts16 mouse cerebral cortex and, at the same time, to determine the molecular signaling mechanisms underlying the control of neurogenesis in the normal brain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROPSYCHOLOGICAL BASIS OF THE BROAD AUTISM PHENOTYPE Principal Investigator & Institution: Piven, Joseph; Professor; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant): For over 15 years our research team and others have taken Kanner?s original observations about personality features characteristic of some parents of autistic individuals and developed definitions of, and standardized measures for, a broader autism phenotype. The broad autism phenotype (BAP) is thought to represent the phenotypic expression of the genetic liability to autism in non-autistic relatives of autistic probands, and is defined by characteristics that are milder but qualitatively similar to the defining features of autism. This work has potential importance for 1) teasing apart the gene-behavior relationships in autism, 2) understanding brain-behavior relationships in autism and, 3) providing additional qualitative and quantitative information on the range and nature of the phenotypic expression of autism genes, which may augment our ability to find those genes. While autism and the BAP are defined by particular behavioral characteristics, they are clinically and etiologically heterogeneous, and are the end result of a range of underlying neuropsychological, neural and genetic mechanisms. In this project we propose to examine the relatives of autistic and Down syndrome probands on selected neuropsychological measures of social cognition, central coherence and executive function, three principal cognitive frameworks proposed as theories to explain the neuropsychological basis of autism. These neuropsychological characteristics will be examined in relationship to our clinically-based measures of the BAP, in order to both elucidate the neuropsychological basis of the BAP and to provide efficient, valid and reliable measures for future studies of the BAP. Autism and OS relatives will be compared in these three neuropsychological domains, to a unique sample of individuals with focal brain lesions in the amygdala, orbital-frontal cortex and right somatosensory cortex, drawn from a brain injury registry at the University of Iowa, to provide insights into the neural basis of the behavioral and neuropsychological characteristics of autism and the BAP. Finally, patterns of co-occurrence of these characteristics will be examined
Studies 63
in individuals and families. This study will complement ongoing studies of the same neuropsychological characteristics in autistic probands. This project brings together a unique group of experienced researchers with complementary expertise in familygenetic (Piven) and neuropsychological studies of autism (Happe), and in the neural basis of social cognition (Adolphs), to study the neuropsychological basis of the broad autism phenotype. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROPSYCHOLOGY OF DOWN SYNDROME Principal Investigator & Institution: Pennington, Bruce F.; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001 Summary: In contrast to several other mental retardation syndromes, the neuropsychology of Down Syndrome is relatively unexplored. The proposed research will fills gap in existing knowledge by testing the functional status of three neural systems particularly at risk in DS: the prefrontal cortex, hippocampus, and cerebellum. We will examine these three neuropsychological domains in a cross-sectional study of two age cohorts of individuals with DS (n=36 each) compared to two control groups, 1) younger normally developing children matched on MA, and 2) CA and MA matched children with non-DS mental retardation. Our component will provide a target phenotype for our colleagues working with mouse models, which will help them isolate the specific genetic determinants of the neural bases of this form of mental retardation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NGF SIGNALING NEURODEGENERATION
IN
MODELS
OF
AGE
RELATED
Principal Investigator & Institution: Mobley, William C. Professor, and Chairman; Neurology & Neurological Scis; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2001; Project Start 15-SEP-1998; Project End 31-AUG-2003 Summary: The broad long-term goal is to elucidate the mechanisms responsible for the dysfunction and loss of neurons in degenerative neurological disorders. In Alzheimer's disease (AD) and Down syndrome (DS), age- related degeneration of basal forebrain cholinergic neurons (BFCNs) contributes significantly to dementia. Defining the molecular events leading to BFCN degeneration would significantly advance our understanding of pathogenesis. In studies on the Ts65Dn mouse, a genetic model for DS, we documented age-related degeneration of BFCNs. Nerve growth factor (NGF) is essential to the function of normal BFCNs and recent findings suggest that failed NGF signaling contributes to their degeneration of Ts65Dn. We will test the hypothesis: that a failure in NGF signaling is responsible for the degeneration (i.e. progressive dysfunction) of BFCNs in the Ts65Dn mouse. The proposed Specific Aims are: 1) To characterize the functional status of BFCNs and document age-related dysfunction of these neurons in Ts65Dn mice. Using unbiased stereology, biochemical and behavioral studies we will document the time of onset of BFCN dysfunction in Ts65Dn mice. 2) To determine if NGF signaling is defective in BFCNs in Ts65Dn and, if so, to determine whether the abnormality predate degeneration of BFCNs. Abnormal NGF retrograde transport will be used to document the existence of a signaling defect and biochemical studies will define its nature and time of onset. 3) To determine whether disrupting NGF signaling reproduces the cholinergic abnormalities seen in Ts65Dn. If the NGF signaling defect demonstrated in Aim 2 is sufficient to produce the degeneration of
64 Down Syndrome
BFCNs in Ts65Dn, animals defective for NGF signaling should show the same degenerative events. We will examine mice treated with NGF antibodies to sequester endogenous NGF, mice in which one copy of the NGF gene has been disrupted, and mice in which both copies of the gene for the NGF TrkA receptor has been knocked-out. 4) To define NGF actions on degenerating BFCNs in Ts65Dn. Current data suggest that NGF may be capable of reversing other aspects of BFCN degeneration. In this Aim, we will determine whether NGF reverses the degenerative phenotypes defined in Aim 1. 5) To determine whether BFCN degeneration is found in other genetic models of Ds and AD and, if so, whether failed NGF signaling is present. We will examine BFCNs in several models of AD. If BFCN atrophy is detected, we will determine whether there is an abnormality of NGF signaling. We will also examine Ts65Dn animals expressing either human Apo E3 or E4 to determine whether, as expected, BFCN degeneration is worse in ApoE4 expressing mice. Evidence that abnormal NGF signaling is responsible for BFCN degeneration in models of AD and DS will give important new insights into pathogenesis and may suggest novel approaches to prevent or reverse dementia in these patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NONDISJUNCTION AND PHENOTYPES IN DOWN SYNDROME Principal Investigator & Institution: Hassold, Terry J. Professor of Genetics; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001 Summary: Trisomy 21, the chromosome abnormality associated with over 95% of Down syndrome (DS), is the most important genetic cause of mental retardation, with an estimated incidence of 1/600 livebirths. Despite its high rate of occurrence and obvious clinical importance, we still know surprisingly little about the mechanism of origin of trisomy 21 or about factors which may predispose to non-disjunction of chromosome 21. In the proposed studies, we intend to combine cytogenetic, molecular and epidemiological approaches to address these questions. In one set of investigations we will focus on the genesis of trisomy 21, conducting studies to determine the effect of aberrant recombination and paternal non-disjunction, with particular emphasis on examining the association between maternal age and trisomy 21. In companion studies, we will investigates the hypothesis that specific environmental exposures may influence the frequency of trisomy 21, and confirm or refute preliminary observations that two such factors-smoking and oral contraceptive use-are risk factors for trisomy 21. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: OBSESSIONS & COMPULSIONS: PRADER-WILLI & OTHER SYNDROMES Principal Investigator & Institution: Dykens, Elisabeth M. Associate Professor; None; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 01-AUG-1997; Project End 31-MAR-2003 Summary: (adapted from the applicant's abstract): Prader-Willi syndrome (PWS) has long been characterized by hyperphagia, food obsessions, and increased risks of obesity in affected individuals. Although less well-described, many people with PWS show obsessions and compulsions not related to food, as well as significant behavioral dysfunction. The proposed study will examine these obsessions, compulsions, and other maladaptive features, filling a long-standing behavioral research void in this complex
Studies 65
developmental disorder. To this aim, the investigators propose to identify the onset, course, and phenomenology of obsessive-compulsive symptoms in PWS, and how these relate to children with obsessive-compulsive disorder (OCD). PWS is hypothesized to represent a specific clinical subtype of OCD, opening up possible roles for genomic imprinting or the PWS Critical Region in delineating these subtypes. It is hypothesized that compulsivity in PWS has an unusually early-onset, and that salient features of the PWS cognitive-behavioral phenotype may provide new clues into how compulsivity is expressed in young children. Early-onset compulsivity is also likely associated with aspects of hyperphagia and of normative development. The second aim is to identify possible mechanisms in PWS that mediate the expression of compulsivity. The proposed study hypothesizes that whole-blood serotonin will mediate symptom expression, and that subtle differences in symptoms may be seen across PWS subjects with paternallyderived deletions at 15q11-q13 versus those with maternal uniparental disomy of chromosome 15. Third, the investigators aim to determine the distinctiveness of compulsivity in PWS relative to children with Williams syndrome (WS), and Down syndrome (DS). WS is a particularly powerful contrast group as it is characterized by increased anxiety and obsessional thinking. The three aims will be addressed in two ways: 1) a longitudinal study of 60 children with PWS, WS, and DS aged 2 to 7 years who are tested twice, two years apart; and 2) a cross-sectional study of 35 children with PWS aged 10-14 years who are compared to subjects with WS, DS, and appropriately matched children with OCD. Findings will shed new light on treatment, on certain subtypes of OCD, and on the range and correlates of PWS' complex behavioral phenotype. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATHOLOGICAL SIGNIFICANCE OF ENDOCYTIC PATHWAY Principal Investigator & Institution: Cataldo, Anne M.; Nathan S. Kline Institute for Psych Res Psychiatric Research Orangeburg, NY 10962 Timing: Fiscal Year 2001 Summary: The endocytic pathway )EP) is central to the function of amyloid precursor protein (APP), Abeta, apolipoprotein E and other molecules etiologically linked to Alzheimer's disease (AD) pathogenesis. Recently, we identified abnormalities of early endosomes (EE), implying strong EP activation, in control and hippocampal neurons before beta-amyloid deposition in sporadic AD (SAD) and Down Syndrome (DS). The overall objective of this project is to define the consequences of EP abnormalities for Abeta production, Abeta clearance, and cell survival in SAD and the influence of APOE genotype and vascular risk factors on these interrelationships. In well-characterized AD brains at the APOE epsilon allele accentuates the onset and magnitude of EE abnormalities (Aim 1). Based on preliminary data, we will investigate the localization and increased context of Abeta in EE from SAD and early DS brain using ICC and confocal microscopy on tissues and on purified EE fractions using immunoblot assays (Aim 1). Based on preliminary data, we will investigate the localization and increased content of Abeta in EE from SAD and early DS brain using ICC and confocal microscopy on tissues and on purified EE fractions using immunoblot assays (Aim 1) and immunoEM. Changes in the protease composition of EE will also be analyzed based on our earlier findings of increased lysosomal hydrolase expression and trafficking to EE in AD. In Aim 2, we will model the abnormalities seen in SAD and DS by appropriate genetic manipulations that upregulate endocytosis and direct hydrolyases preferentially to EE in transfected cells and transgenic mice to test predicted effects of these SAD mechanisms on Abeta biology and cell survival. In Aim 3, the evolution of these EPO
66 Down Syndrome
abnormalities will be investigated in mice trisomic for a segment of the human homolog of chromosome 21 where we have seen EP disturbances, including Abeta accumulation in EE, which are similar to those in mice expressing human APOE alleles. In aim 4, neuron-vascular interrelationships suggested by the presence of EP and lysosomal system activation in cerebrovascular endothelia will be investigated by characterizing these abnormalities in SAD, inherited cerebral amyloid angiopathy (CAA), and animal and cultured human endothelial cell models of CAA and ischemia. This project will clarify the hypothesized role of EP abnormalities, the earliest known cellular response in SAD, in accelerating amyloidogenesis as well as generate novel models of SAD-relevant pathology and identify new targets for possible therapeutic intervention at stages of disease well before clinical onset. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PERCEPTUAL AND MOTOR BEHAVIOR IN DOWN SYNDROME Principal Investigator & Institution: Elliott, Digby; Mc Master University Hamilton L8s 4L8, Canada Hamilton, Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 30-JUN-2002 Summary: As well as general intellectual difficulties, children and adults with Down syndrome exhibit a number of specific information processing problems, some of which are associated with an atypical pattern of brain organization in these individuals. For example, compared to other children and adults of a similar mental age, persons with Down syndrome have difficulty performing sequential limb and oral movements on the basis of verbal direction. The position taken in this research program is that this problem is due to the functional dissociation of the cerebral areas responsible for speech perception and those responsible for movement organization. This research program has four interrelated objectives. The first is to develop a neurobehavioral index of cerebral organization in persons with Down syndrome that will reliably predict individual differences in verbal-motor performance. The protocol, which involves performing rapid limb and oral movements following the dichotic presentation of verbal stimuli, will be validated using the latest in brain-imaging technology. The second objective is to use the brain- imaging technology to extend the understanding of cerebral organization in persons with Down syndrome to visual-spatial function, visuallanguage function and visual and auditory attentional processes. The third objective involves studies to extend research on sequential oral and limb movements to movements involving the coordination of effectors with each other and with information from the environment. The final objective involves experiments conducted to determine if verbal-motor performance findings involving children and adults with Down syndrome generalize to perceptual-motor skill acquisition. Of interest is whether or not the neurobehavioral and neurophysiological indices of cerebral organization associated with the first two research objectives predict skill acquisition in different instructional and rehabilitation contexts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PROBING CELLULAR FUNCTIONS OF THE MINIBRAIN KINASE Principal Investigator & Institution: Hwang, Yu-Wen; Institute for Basic Res in Dev Disabil Developmental Disabilities New York, NY 10314 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2005 Summary: The Minibrain (Mnb) gene is mapped to the Down syndrome critical region of human chromosome 21. Evidence suggests that an elevated Mnb gene dosage, as in
Studies 67
trisomy 21, contributes to Down syndrome phenotypes. The Mnb encodes a dual specificity protein kinase whose cellular function has yet to be determined. Our preliminary results suggest that MnB kinase is involved in controlling the activity of dynamin-1, while its enzymatic activity is in turn regulated by rabaptin-5 and a novel cysteine-rich protein. Since both dynamin-1 and rabaptin-5 are part of endocytosis machinery, it also suggests that the Mnb kinase must play an essential role in regulating endocytic membrane trafficking. We plan to pursue the following specific aims in this study: 1. To establish the Mnb kinase as the enzyme responsible for regulating dynamin1 physiological activity through phosphorylation. 2. To determine the mechanisms of regulating the enzymatic activity of Mnb kinase by rabaptin-5 and the cysteine-rich protein. 3. To characterize the biochemical properties of dynamin-12 phosphorylated by Mnb kinase. 4. To study the effects of Mnb kinase over-expression on endocytic membrane trafficking. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROCESSING PREGNANCIES
OF
HCG
IN
NORMAL
AND
ABNORMAL
Principal Investigator & Institution: Cole, Laurence A. Obstetrics and Gynecology; University of New Mexico Albuquerque Controller's Office Albuquerque, NM 87131 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: Preliminary studies in our laboratory are consistent with a relationship between hyperglycosylation (additional antennae and fucose residues on N-linked oligosaccharides) and nicking or cleavage of hCG. Other preliminary studies indicate the structural instability and diminished biological activity of hyperglycosylated and of nicked hCG molecules, and how they may be the source of free beta-subunit in the circulation and beta-core fragment in urine samples. Papers have been published showing raised hCG levels, and raised proportions of free beta-subunit and beta-core fragment levels in serum or urine samples from patients with trophoblast disease, hyperemesis gravidarum, or Down syndrome pregnancies. It is our hypothesis these raised levels arise from the hyperglycosylation of hCG, through pathways involving nicking, ineffectual autocrine control of hCG production, and dissociation to nicked free beta-subunit, and degradation to beta-core fragment. Other pathways raise levels of hCG and lower the proportions of hyperglycosylated hCG in patients with preeclampsia. Four sets of experiments are proposed to test this hypothesis and investigate the clinical ramification of the observations in normal and abnormal pregnancies. Studies are proposed to confirm and compare the levels of hCG, free betasubunit and beta-core fragment in 1140 sets of parallel serum and urine samples from normal and abnormal pregnancies (Aim 1A); and to use the parallel serum and urine samples to investigate the clinical use of two new immunoassays that specifically measure hyperglycosylated hCG and nicked hCG, and their potential uses in screening for Down syndrome and preeclampsia (Aim 1B). Basic science studies are proposed to purify hCG from normal first, second and third trimester pregnancy urine samples, and preeclampsia, hyperemesis trophoblast disease and Down syndrome pregnancy urine samples (3 each) and compare the extents and sites of nicking, and the type, amounts and locations of hyperglycosylated N-linked oligosaccharides (Aim 2). Further studies are planned to investigate the hyperglycosylation- nicking relationship by comparing normal and hyperglycosylated hCG as substrates for nicking enzymes (Aim 3); and to examine the biological activities of the 21 purified normal and abnormal pregnancy molecules, and to determine their ability abilities to feedback through to the placenta and control hCG synthesis (Aim 4).
68 Down Syndrome
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF ARGININE-NITRIC OXIDE CYCLE IN BRAIN Principal Investigator & Institution: Jackson, Marian J.; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2001 Summary: Regulated synthesis of nitric oxide (NO) from arginine plays a key role in normal neural development, signalling, and response of the brain to trauma and infections. However, excessive NO production (as may result from trauma or inflammatory stress) can cause cell injury and/or death resulting in impaired brain function. Our data show that arginine synthesis is coordinately regulated with nitric oxide synthase (iNOS) induction in bacterial lipopolysaccharide-or S100B-treated astrocytes. Augmentation of argininosuccinate synthetase (AS), which catalyzes the ratelimiting step in arginine synthases, facilitates recycling of citrulline to support ongoing NO production under conditions of arginine depletion. We hypothesize that an arginine-nitric oxide cycle functions in neural tissue to insure that arginine availability does not limit NO synthesis. Several lines of evidence suggest that altered brain metabolism in response to these mediators may play a role in the development of mental retardation. Epidemiological studies have shown an association between intrauterine or perinatal infectious and development of mental retardation in some nongenetic causes of mental retardation. For patients with inborn efforts of metabolism, hyperammonemia during intercurrent infections is though to be causative in generating neural damage. S100B (which has been shown to induce neurotoxic levels of NO) maps to the Down syndrome region of chromosome 21. Its expression is elevated throughout development in Down Syndrome patients. In the proposed studies we will perturb brain cells with lipopolysaccharide (LPS, to mimic infection) or with S100B and we will determine the mechanisms which influence the capacity of brain cells to synthesize arginine under steady-state and stress conditions. We will evaluate the possible compartmentation of arginine and nitric oxide metabolism in cerebral cortex and cerebellum, two regions of the brain which differ in their content of nitrergic neurons. In addition, we will determine the effects of LPS-stimulated inflammatory stress on the flux of nitrogen metabolism through arginine versus glutamine synthesis. The molecular mechanism(s) by which LPS and S100B coordinately up-regulate argininosuccinate synthetase and inducible nitric oxide synthase in astrocytes will be determined using biochemical and molecular genetic techniques. We will examine AS enzyme kinetics, synthesis and gene expression. These studies will provide insight into alterations of brain nitrogen metabolism which occur in response to infection or trauma and will lay the groundwork for designing therapeutic strategies to limit their neurological consequences. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RESEARCH ON COGNITION AND BEHAVIOR IN DOWN SYNDROME Principal Investigator & Institution: Nadel, Lynn; Professor; National Down Syndrome Society 666 Broadway, 8Th Fl New York, NY 10012 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2004 Summary: (provided by applicant): The Research Conference on Cognition and Behavior in Down Syndrome will be held in the United States under the auspices of the National Down Syndrome Society (New York, NY) and the Down Syndrome Research
Studies 69
Foundation (Vancouver, BC). The conference will be convened under the direction of the NDSS and DSRF Science Advisory Boards, in collaboration with a conference organizing committee. The meeting will review and document the current status of research on cognitive function and behavior in Down syndrome, including an overview of current neuroscientific research and the use of mouse models. It will also review current knowledge about applying research findings to early stimulation and education programs that aim to optimize the functioning and status of individuals with Down syndrome. Finally, it will explore the directions that future research on this genetic condition should take. Plenary sessions will focus on the link between Down syndromespecific and non-Down syndrome-specific research, the state of the art in research on cognition and behavior, motor skill development, functional MRI imaging, and dementia and memory across the lifespan. Paper presentations and working groups will address the current status of research in the areas of imaging, sleep and memory, mental health, mouse models, speech and language and positive behavioral support. Research priorities and potential areas of collaboration in these key areas will be determined by working groups and shared with the entire audience. There will also be a poster session for scientists to present work on specific related topics, as well as on more broad-based Down syndrome research. The conference will provide several opportunities for participants to interact with colleagues, synthesize and share knowledge, develop new collaborations and generate ideas about practical applications. The ultimate goal is for this conference to facilitate progress in research and practice on cognition and behavior in Down syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RETT SYNDROME: DETERMINANTS OF OUTCOME AND BURDEN Principal Investigator & Institution: Leonard, Helen M.; University of Western Australia Crawley, Wa, 6009 Timing: Fiscal Year 2003; Project Start 18-SEP-2003; Project End 31-JUL-2008 Summary: (provided by applicant): This population-based study will follow the current cohort of live (n=225) cases with Rett syndrome in Australia for a further five years. New cases ascertained during the study period will also be included. It will describe the natural history of Rett syndrome and assess its impact on resource utilization and the economic and social burden on families and community in comparison with Down syndrome and a normal comparison group. Baseline data on communication, mobility, symptoms and classification have been gathered on the cohort since 1993. In 2000 data were collected on functional ability in daily living, behavior, hand function, medical conditions, and use of health and education services. Mutation data, collected on 80 percent of cases will be continued. A questionnaire has been developed, piloted and will be used to collect data on function, health and well-being of the Rett syndrome subjects and family in 2002, 2004 and 2006. Data will be gathered for the Down syndrome comparison group in 2003. Participants will respond via paper-based or through secure on-line formats. Optical scanning or on-line data capture will be used for data entry. In 2003 and 2005 clinical assessments or clinical file review will provide EEG, ECG, blood parameters, bone densitometry and autonomic nervous system data. A video protocol developed in 2001 to record functional ability will be extended to include gross motor and oral motor function, hand apraxia, gait assessment and language function. Serial videos collected in 2003 and again in 2005 will enable us to monitor changes over time and the effect of therapy or surgery. Yearly telephone interviews to families will record anthropometric data, current medication usage and update previously collected family tree data. Every two years a validated questionnaire to identify epilepsy type will be
70 Down Syndrome
included. Resource data to determine the direct, indirect and opportunity costs associated with Rett syndrome will be compared with a normal and Down syndrome comparison group. Data analysis will use multiple regression models to examine effects of different variables on child and family level outcomes and discriminant analysis, recursive partitioning and machine learning to identify genotype/phenotype associations at the individual child level. Feedback to families on study progress will be given through the study Web site. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE FOR FIBROBLAST GROWTH FACTOR IN ALZHEIMER'S DISEASE Principal Investigator & Institution: Barnea, Ayalla; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2001 Summary: Our long-term objective is to gain insight into the cellular and molecular mechanisms underlying the initiation and progression of neuronal death in the brain, particularly in brains of Alzheimer patients. The goal of this pilot study is to establish a culture study of fetal brain cells derived from "normal" human abortuses and from Down Syndrome (DS). These cultures will serve as models for the study of processes leading to neuronal death in Alzheimer disease. The rational for choosing the DS brain is based on the consistent findings that DS patients develop Alzheimer neuropathology at a much earlier age than "normal" aging people and on the hypothesis that processes leading to Alzheimer neuropathology at a much earlier age than "normal" aging people and on the hypothesis that processes leading to Alzheimer neuropathology are operative at an earlier age, possibly already even in the fetus. S.A.1. Establish a human model system for the study of the regulation of neuronal survival Aggregate cultures comprised of neurons and glial cells will be established from dissociated brain cells obtained from the cortex of "normal" human abortuses and of DS brains, using our previous experience with this culture system derived from rat fetal brains as a guideline. Two population of peptidergic neurons, neuropeptide Y (NPY) and somatostain (SRIF), will serve as model neurons. The morphological and functional differentiation of these neurons and the topographical arrangement of the cells will be defined. S.A.2. Test our "ping pong" hypothesis of basic fibroblast growth factor (bFGF) - Beta-amyloid interactions. Neurite sprouting has been implicated in the early stages of senile plaque formation in Alzheimer disease. Our working "ping pong" hypothesis is that bFGF stimulates expression of the gene encoding Beta-amyloid precursor protein (APP), a product(s) of which, in turn, stimulates more bFGF production. Thus, each round of bFGF - Beta-amyloid interaction results in greater extracellular levels of agents capable of promoting neurite sprouting, of which Beta-amyloid may be a substantial component. We will initiate this study by assessing the effect of bFGF on neurite sprouting and survival of NPY/SRIF neurons in our human model systems. These results will serve as the basis for a full-scale research proposal to elucidate the cellular and intracellular mechanisms underlying bFGF - Beta-amyloid interactions in processes leading to neuronal death. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 71
•
Project Title: ROLE NEUROPATHOLOGY
OF
ETS-2
AND
SOD-1
IN
DOWN
SYNDROME
Principal Investigator & Institution: Busciglio, Jorge A. Assistant Professor; Pharmacology; University of Connecticut Sch of Med/Dnt Bb20, Mc 2806 Farmington, CT 060302806 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2004 Summary: Down's syndrome (DS) or trisomy 21 is the most frequent genetic cause of mental retardation. It occurs in about 1 in 800 to 1 in 1000 live births. Mental retardation and development of Alzheimer's disease (AD) by middle age are hallmarks of DS neuropathology. Previous studies demonstrated that DS neurons in culture exhibit elevated intracellular free radicals and lipid peroxidation leading to increased neuronal death. This increase in oxidative stress and neurodegeneration may contribute to mental retardation and the development of AD in DS patient. The goal of our research is to characterize the molecular mechanisms involved in neuronal oxidative stress and degeneration in DS. This project will study the role of Ets-2 and Cu/Zn superoxide dismutase (SOD-1) over- expression in DS neurodegeneration. The following hypotheses will be tested: 1. Over-expression of the transcription factor Ets-2 in DS neurons compromises neuronal viability by altering the expression of genes that control neuronal survival and death. More specifically, the possibility that Ets-2 down-regulates Bcl-2 and up-regulates Bax and p53 protein levels will be tested. 2. Increased activity of Cu/Zn superoxide dismutase (SOD- 1) may contribute to oxidative stress and DS neuronal degeneration. The research will focus on: 1) the functional analysis of Ets-2 and SOD-1 in DS and Ets-2 transgenic neurons in culture; and 2) the association of Ets- 2 and SOD-1 with neurodegenerative changes in the brains of DS and AD patients and Ets-2 transgenic mice. The specific aims are: 1: to determine the role of Ets-2 over-expression in DS neuronal degeneration in culture and in the brains of DS and AD patients. 2: To characterize the role of Ets-2 during normal neuronal development. 3: To determine the role of SOD-1 in DS neuronal degeneration. These experiments will provide valuable information towards understanding the molecular basis of neuronal dysfunction and death in DS and AD. In addition, the results of this investigation may identify new molecular targets for the design of neuroprotective therapies for the treatment of mental retardation and the prevention of AD in DS patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SISTER CHROMATID LINKAGE AND SEPARATION Principal Investigator & Institution: Murray, Andrew W. Professor; Molecular and Cellular Biology; Harvard University Holyoke Center 727 Cambridge, MA 02138 Timing: Fiscal Year 2001; Project Start 01-MAY-1997; Project End 31-MAY-2005 Summary: (APPLICANT'S ABSTRACT): Accurate chromosome segregation is essential for the faithful transmission of genetic information. The linkage between sister chromatids directs them to attach to opposite poles of the mitotic spindle, and the prompt dissolution of this linkage allows chromosomes to segregate to the poles at anaphase. Mitotic chromosome movements depend on kinetochores, which also act as signaling centers to delay anaphase until all the chromosomes have been correctly aligned on the spindle. This proposal describes experiments to investigate kinetochore assembly and function, the nature of the linkage between sister chromatids, and the mechanisms that regulate this linkage during the eukaryotic cell cycle. Frog egg extracts will be used to investigate how the Xenopus homolog of the conserved CENP-A, B, and C proteins contribute to the assembly and function of the kinetochore. Antibodies to
72 Down Syndrome
CENP-A will be used to enrich kinetochore-containing chromosome fragments, making it possible to screen large pools ol expressed cDNAs for novel kinetochore-binding proteins. Sister chromatid separation will be studied in budding yeast using green fluorescent protein (GFP) marked chromosomes. This technique will be used to, 1) investigate the length, DNA sequence, and topological features of chromosomes that are needed to establish and maintain sister chromatid linkage, 2) test the role of proximity in establishing the linkage between sisters, and 3) investigate the relationship between topological and cohesin-dependent mechanisms of sister linkage. DNA microarrays will be used to determine why topoisomerase II activity is required during anaphase to resolve sister chromatid linkage. These experiments will combine the genetic tractability of yeast and the complex in vitro reactions that are possible in frog extracts in an integrated approach to understanding mitotic chromosome behavior. This information will be directly relevant to understanding how aneuploidy is generated in Down syndrome and tumor progression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SOMATIC CELL GENETIC STUDIES OF DOWN SYNDROME Principal Investigator & Institution: Patterson, David; President and Senior Fellow; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001; Project Start 01-JAN-1993; Project End 31-DEC-2002 Summary: Affecting one in 700 live births, Down Syndrome is the major recognized genetic cause of mental retardation. It is, and expected to remain, a significant medical and social problem. While the neurological and behavioral phenotype of Down Syndrome and its genetic basis is complex, recent advances in technology, resources and knowledge mean that renal and effective progress in understanding Down Syndrome is now attainable. The immediate goal of this program project is the identification and characterization of the genes involved in the neurological, neurophysiological and behavioral phenotype of Down Syndrome. The long term goal is to apply this knowledge to the development of therapeutic interventions to ameliorate the cognitive deficits seen in Down Syndrome. The accomplishment of goals of this nature requires application of a broad spectrum of approaches, spanning molecular biology, mouse genetics and human behavior. Accordingly, this proposal will build upon the large body of information regarding Down Syndrome and human chromosome 21 compiled by this Program over the last fifteen years, and will extend its research focus in a clinically relevant direction. The specific aims of this program include: i)systematic identification and preliminary characterization of essentially all genes on chromosome 21 to determine best candidates for causation of the neurological and cognitive deficits of Down Syndrome; ii) construction and analysis of mouse models, both single gene transgenics and segmental trisomies, to test the roles of specific genes; iii) dissection of the cognitive deficits seen in individuals with Down Syndrome; iv) analysis of the behavior and physiology of relevant mouse mutants to refine understanding of the deficits seen in individuals with Down Syndrome and to define the limits of utility of mouse models; and v) design and testing in mice of new hypotheses and treatment approaches based on information obtained from the molecular, human behavior and mouse genetic data. Building on the past accomplishments and expertise of members of this program project and adding new directions and new areas of expertise makes attainment of these goals eminently feasible. Their success will add greatly to our understanding of neurological development in general and of mental retardation in Down syndrome in particular. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 73
•
Project Title: SPEECH OF YOUNG MALES WITH FRAGILE X SYNDROME Principal Investigator & Institution: Roberts, Joanne E. Senior Scientist and Professor; F.P. Graham Child Devel Ctr; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2003; Project Start 07-JUL-2003; Project End 30-APR-2008 Summary: (provided by applicant): Fragile X syndrome is the most common inherited cause of mental retardation, and unintelligible speech is a very common characteristics of young males with fragile X syndrome (FXS). It is unclear what aspects of speech (e.g., rate, prosody, oral structure/function, articulation, phonological processes) cause poor intelligibility. Furthermore, it has not been determined what is the role of motor speech/FMR1 protein (FMRP) levels, cognitive/linguistic factors, and the communicative context in affecting intelligibility of conversational speech of males with FXS. Identifying these factors is important because the ability to be understood is critical for effective communication, and poor speech intelligibility compromises all aspects of daily verbal interactions. The proposed study builds on a currently funded R0-3 pilot study Hearing and Speech of Young with Males with Fragile X Syndrome, funded by the RFA "Neurobiology and Genetics of Fragile X Syndrome" in April of 2001, which examined at one point in time the speech and hearing skills of young males with fragile X syndrome. The proposed research will expand this research by examining longitudinally over a five year period the factors that affect changes in the speech intelligibility of 8 to 12 year old males with FXS in comparison to developmental age matched males with Down syndrome (DS) and males who are typically developing (TD). It will identify if motor speech/FMRP levels, cognitive/linguistic factors, and the social demands of the communicative context affect speech intelligibility. The specific objectives of this study are to: a) compare the development of phonological, prosodic, and segmental factors in the speech of males with FXS, males with DS, and TD males; b) identify the phonological, prosodic, and segmental factors affecting the speech intelligibility in conversational speech of males with FXS and determine if similar patterns of association are observed among males with DS and TD males; and c) to identify the motor speech/FMRP, cognitive/linguistic, and communicative contextual factors associated with speech intelligibility in conversational speech among males with FXS, and determine if similar patterns of association are observed among males with DS and TD males. Sixty males with FXS between 8 and 12 years of age, 40 males with Down syndrome between 8 and 12 years of age and 40 typically developing males matched for nonverbal intelligence age will be followed for five years. Speech production in isolated words, imitated sentences, spontaneous conversational speech, and narratives will be examined for prosodic and segmental features, phonological processes, and speech intelligibility for the three groups. In addition, children's oral motor skills, phonological processing, and selective listening will be examined. Fragile X DNA testing and FMRP analysis from blood samples will be done only on males with FXS. Growth curve methods will be used to quantify patterns of change over time in the overall level and rate of speech development including speech intelligibility. Of particular interest will be longitudinal analyses of speech intelligibility designed to determine the degree to which motor speech/FMRP, cognitive/linguistic, and contextual factors predict speech intelligibility among males with FXS. Subsequent analyses will ask whether factors associated with intelligibility among males with FXS are also associated among males with DS and TD males. Findings will contribute to a better understanding of the factors that affect speech intelligibility in young males with FXS and provide an essential knowledge base for speech intervention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
74 Down Syndrome
•
Project Title: STEM CELL GENES IN LEUKEMIA PATHOGENESIS Principal Investigator & Institution: Horwitz, Marshall S. Associate Professor; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001 Summary: Leukemia is a leading cause of cancer death and requires a significant expenditure of the national healthcare budget to treat. There is substantial evidence that hereditary factors contribute to leukemia predisposition and the frequently observed familial clustering and racial variations in risk. In many families, affected individuals have developed leukemias of differing type and subtype, suggesting a defect in a gene responsible for hematopoietic stem cell differentiation. A unusual of familial leukemia is that it is inherited with "anticipation" in the form of a declining age of onset with each passing generation, and we hypothesize that a defect in a mitotic clock might be responsible for this phenomenon. A locus for familial AML in association with inherited platelet defects has been mapped to chromosome 21q. Preliminary evidence suggests a second locus for familial AML on chromosome 16q in families that do not have a platelet defect. The specific aims are the following: 1) Clone the locus for familial leukemia on chromosome 21: A. Collect new individuals with the familial platelet disorder/AML syndrome, B. Narrow the critical region on chromosome 21q by studying Down syndrome patients, C. Positionally clone the chromosome 21q locus from leukemia families by mutational analysis of candidate genes from the critical region; 2) Confirm and clone a locus for familial AML on chromosome 16q: A. Use leukemia families to narrow the critical region, B. Use sporadic cases of AML and myelodysplasia to refine the critical region, C. Positionally clone the chromosome 16q AML gene; and c) Characterize the role of familial leukemia genes in hematopoietic stem cell differentiation and leukemia pathogenesis: A. Functionally characterize the genes for familial leukemia, B. Develop animal models, C. Search for common but low penetrance alleles among sporadic leukemia cases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STUDIES ON CHILDREN WITH EARLY FOCAL BRAIN INJURY Principal Investigator & Institution: Bates, Elizabeth A. Professor; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2001; Project Start 16-SEP-1985; Project End 31-JUL-2006 Summary: Over the past 15 years, we have made significant progress in the study lf language and affective development in children with congenital injuries to one side of the brain (FL). In each behavioral , we have covered evidence of initial deficits, and specific effects of lesion side and site, but these initial deficits are followed by substantial recovery and development, providing strong evidence for behavioral and neural plasticity in this population. Furthermore, we have shown that trajectories of deficit and recovery differ across domains. In language, lesion- symptom correlations exist in the first years of life, but they do not resemble the patterns observed in adults; by 5-7 years of age, specific effects of lesion side and site seem to have disappeared altogether. In spatial cognition, lesion-symptom correlations persist across childhood and adolescence, albeit in a mild form, and continue to resemble the correlations observed in adults. These results are compatible with a large literature on plasticity and reorganization in animals, supporting the view that brain development is a dynamic, responsive and selforganizing system. But they also offer a unique perspective on plasticity and brain organization in humans. We are now well-positioned to take a historic new steps, with convergent use of functional magnetic resonance imaging (fMRI), event-related brain
Studies 75
potentials(ERP), combined with analogous "on-line" (timed" behavioral studies of language, spatial cognition and spatial attention. These convergent methods will yield unprecedented information about the "alternative brain plans" that have emerged across the course of development in children with FL. E will also continue to chart language and cognitive development into adolescence, using benchmark "off-line" (untimed" measures of language (including aspects of discourse that re critical to success in school and work), visual-spatial cognition, memory and executive function. On all measures, results for children with FL will be compared systematically to findings for children in other populations, including Specific Language Impairment, Williams Syndrome, Down Syndrome, and new project studying other forms of FL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDY ON A NOVEL ALZHEIMER APP REGULATORY FACTOR Principal Investigator & Institution: Quitschke, Wolfgang W. Psychiatry and Behavioral Scis; State University New York Stony Brook Stony Brook, NY 11794 Timing: Fiscal Year 2002; Project Start 01-JUL-1992; Project End 30-NOV-2006 Summary: (provided by the applicant): An important neuropathological manifestation of Alzheimer's disease is the presence of amyloid depositions in brains and leptomeninges of afflicted individuals. However, amyloid depositions are not unique to Alzheimer's disease. They also occur in Down syndrome and hereditary cerebral hemorrhage with amyloidosis of the Dutch type and to a lesser degree in the normal aging brain. A major component of the amyloid plaque is the amyloid f3-protein (AB). This peptide is derived from a larger protein termed the amyloid precursor protein (APP) through proteolytic processing. Several lines of genetic evidence indicate that the pathological manifestations of Alzheimer's disease are a direct consequence of the deposition of AB. In addition, increased or altered APP expression, such as in Down syndrome, may be an important factor in a multistep process leading to the formation of amyloid deposits. This suggests that the progression of the disease might be delayed or arrested by reducing or eliminating APP expression and it emphasizes the importance of elucidating the mechanism of APP gene regulation. A sequence element in the proximal promoter region was found to be essential for high levels of expression. This element binds the multivalent and multifunctional transcription factor CTCF, which acts as a transcriptional activator. The precise region within the CTCF protein that mediates transcriptional activation will be identified by deletion and mutation analysis. The coactivator(s) that interacts with CTCF will be identified. In addition, further essential factors that encompass the transcription complex of the APP promoter will be identified. These include the components of the transcriptional initiation complex and other as yet uncharacterized APP promoter binding factors. Finally, the nucleosomal organization of the APP promoter will be examined for a better understanding of APP gene regulation in vivo. One ultimate goal of this research is to control APP gene expression in vivo by altering the interaction of activating factors with the APP promoter. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SYNAPTIC PLASTICITY IN MOUSE MODELS FOR DOWN SYNDROME Principal Investigator & Institution: Costa, Alberto C.; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2003
76 Down Syndrome
Summary: (adapted from applicant's abstract) Down syndrome is the most common genetically defined cause of mental retardation in human beings. There are about 250 thousand people with DS in the US and this number is likely to continue rising due to the current trend towards an increased life expectancy. In general, the cells of individuals with DS have one extra chromosome 21. This genetic condition affects the nervous system in many different ways besides producing different degrees of mental retardation. Individuals with DS have an increased incidence of seizure disorders and exhibit abnormalities of neuromuscular tone, audiovestibular function, ocular movements and visual acuity. They also develop a neuropathology indistinguishable from Alzheimer's disease after the third decade of life. Currently, Ts65Dn mice are the prime animal model for the mental deficit in DS. These mice are trisomic for a chromosomal segment homologous to a large portion of human chromosome 21. In behavioral tests, Ts65Dn mice display significant learning deficits. More recently, another partially trisomic mouse model for DS, called Ts1Cje, has been described. It has a trisomic segment only slightly shorter than the Ts65Dn segment and a comparatively milder learning deficit. The overall hypothesis is that the region of difference between the trisomic segments of these two mouse strains may contain genes responsible for a significant portion of the learning deficit seen in Ts65Dn mice, and possibly in persons with DS. The identification of such genes may provide targets for a rational pharmacotherapy for DS. This proposal has three specific aims: 1) Test the hypothesis that some forms of synaptic plasticity are selectively altered in aneuploid mouse models for DS; 2) Test the hypothesis that dendritic morphology is altered in mouse models for DS; 3) Test the hypothesis that three copies of specific single genes are necessary for the expression of part of the learning deficit seen in Ts65Dn mice by analyzing the phenotype of crosses between Ts65Dn and knockout mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE BIOLOGY OF CHROMOSOME 21 GENES: R13 EXPERT WORKSHOP Principal Investigator & Institution: Gardiner, Katheleen; Senior Scientist; Eleanor Roosevelt Inst for Cancer Res 1899 Gaylord St Denver, CO 80206 Timing: Fiscal Year 2003; Project Start 18-SEP-2003; Project End 31-MAY-2004 Summary: [Provided by Applicant]: To c